{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "%matplotlib inline\n",
    "\n",
    "from snorkel import SnorkelSession\n",
    "\n",
    "session = SnorkelSession()\n",
    "\n",
    "from snorkel.models import candidate_subclass\n",
    "\n",
    "ChemicalDisease = candidate_subclass('ChemicalDisease', ['chemical', 'disease'])\n",
    "\n",
    "train_cands = session.query(ChemicalDisease).filter(ChemicalDisease.split == 0).all()\n",
    "dev_cands = session.query(ChemicalDisease).filter(ChemicalDisease.split == 1).all()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "from gensim.parsing.preprocessing import STOPWORDS\n",
    "import gensim.matutils as gm\n",
    "\n",
    "from gensim.models.keyedvectors import KeyedVectors\n",
    "\n",
    "# Load pretrained model (since intermediate data is not included, the model cannot be refined with additional data)\n",
    "model = KeyedVectors.load_word2vec_format('../glove_w2v.txt', binary=False)  # C binary format\n",
    "\n",
    "\n",
    "wordvec_unavailable= set()\n",
    "def write_to_file(wordvec_unavailable):\n",
    "    with open(\"wordvec_unavailable.txt\",\"w\") as f:\n",
    "        for word in wordvec_unavailable:\n",
    "            f.write(word+\"\\n\")\n",
    "\n",
    "def preprocess(tokens):\n",
    "    btw_words = [word for word in tokens if word not in STOPWORDS]\n",
    "    btw_words = [word for word in btw_words if word.isalpha()]\n",
    "    return btw_words\n",
    "\n",
    "def get_word_vectors(btw_words): # returns vector of embeddings of words\n",
    "    word_vectors= []\n",
    "    for word in btw_words:\n",
    "        try:\n",
    "            word_v = np.array(model[word])\n",
    "            word_v = word_v.reshape(len(word_v),1)\n",
    "            #print(word_v.shape)\n",
    "            word_vectors.append(model[word])\n",
    "        except:\n",
    "            wordvec_unavailable.add(word)\n",
    "    return word_vectors\n",
    "\n",
    "def get_similarity(word_vectors,target_word): # sent(list of word vecs) to word similarity\n",
    "    similarity = 0\n",
    "    target_word_vector = 0\n",
    "    try:\n",
    "        target_word_vector = model[target_word]\n",
    "    except:\n",
    "        wordvec_unavailable.add(target_word+\" t\")\n",
    "        return similarity\n",
    "    target_word_sparse = gm.any2sparse(target_word_vector,eps=1e-09)\n",
    "    for wv in word_vectors:\n",
    "        wv_sparse = gm.any2sparse(wv, eps=1e-09)\n",
    "        similarity = max(similarity,gm.cossim(wv_sparse,target_word_sparse))\n",
    "    return similarity\n",
    "\n",
    "import bz2\n",
    "from six.moves.cPickle import load\n",
    "\n",
    "with bz2.BZ2File('data/ctd.pkl.bz2', 'rb') as ctd_f:\n",
    "    ctd_unspecified, ctd_therapy, ctd_marker = load(ctd_f)\n",
    " "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "\n",
    "def distanceCDfar(c):\n",
    "    dist = 0\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    return dist/5000\n",
    "\n",
    "def distanceCD(c):\n",
    "    dist = 0\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    return (5000 - dist)/5000\n",
    "\n",
    "def distanceCD_(c,l):\n",
    "    dist = []\n",
    "    for w in l:\n",
    "        pattern = r'({{A}})(.*)('+w+r')(.*)({{B}})'\n",
    "        matchObj = re.search(pattern, get_tagged_text(c), flags=re.I)\n",
    "        if(matchObj):\n",
    "            match_groups = matchObj.group(2,4)\n",
    "            dist.append(max([len(mg) for mg in match_groups]))\n",
    "    if(len(dist)>0):\n",
    "        return (5000-min(dist))/5000\n",
    "    return 0\n",
    "\n",
    "def distanceDC_(c,l):\n",
    "    dist = []\n",
    "    for w in l:\n",
    "        pattern = r'({{B}})(.*)('+w+r')(.*)({{A}})'\n",
    "        matchObj = re.search(pattern, get_tagged_text(c), flags=re.I)\n",
    "        if(matchObj):\n",
    "            match_groups = matchObj.group(2,4)\n",
    "            dist.append(max([len(mg) for mg in match_groups]))\n",
    "    if(len(dist)>0):\n",
    "        return (5000-min(dist))/5000\n",
    "    return 0\n",
    "\n",
    "def distanceDevFol(c):\n",
    "    dist = 1000\n",
    "    matchObj = re.search(r'(develop)(.*)({{B}})(.*)(following)(.*)({{A}})', get_tagged_text(c), flags=re.I)\n",
    "    if(matchObj):\n",
    "        match_groups = matchObj.group(2,4,6)\n",
    "        dist = max([len(mg) for mg in match_groups])\n",
    "    return (5000-dist)/5000\n",
    "    \n",
    "\n",
    "def levenshtein(source, target):\n",
    "    if len(source) < len(target):\n",
    "        return levenshtein(target, source)\n",
    "\n",
    "    # So now we have len(source) >= len(target).\n",
    "    if len(target) == 0:\n",
    "        return len(source)\n",
    "\n",
    "    # We call tuple() to force strings to be used as sequences\n",
    "    # ('c', 'a', 't', 's') - numpy uses them as values by default.\n",
    "    source = np.array(tuple(source))\n",
    "    target = np.array(tuple(target))\n",
    "\n",
    "    # We use a dynamic programming algorithm, but with the\n",
    "    # added optimization that we only need the last two rows\n",
    "    # of the matrix.\n",
    "    previous_row = np.arange(target.size + 1)\n",
    "    for s in source:\n",
    "        # Insertion (target grows longer than source):\n",
    "        current_row = previous_row + 1\n",
    "\n",
    "        # Substitution or matching:\n",
    "        # Target and source items are aligned, and either\n",
    "        # are different (cost of 1), or are the same (cost of 0).\n",
    "        current_row[1:] = np.minimum(\n",
    "                current_row[1:],\n",
    "                np.add(previous_row[:-1], target != s))\n",
    "\n",
    "        # Deletion (target grows shorter than source):\n",
    "        current_row[1:] = np.minimum(\n",
    "                current_row[1:],\n",
    "                current_row[0:-1] + 1)\n",
    "\n",
    "        previous_row = current_row\n",
    "\n",
    "    return previous_row[-1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# import bz2\n",
    "# from six.moves.cPickle import load\n",
    "\n",
    "# with bz2.BZ2File('data/ctd.pkl.bz2', 'rb') as ctd_f:\n",
    "#     ctd_unspecified, ctd_therapy, ctd_marker = load(ctd_f)\n",
    "    \n",
    "    \n",
    "def cand_in_ctd_unspecified(c):\n",
    "    return 1 if c.get_cids() in ctd_unspecified else 0\n",
    "\n",
    "def cand_in_ctd_therapy(c):\n",
    "    return 1 if c.get_cids() in ctd_therapy else 0\n",
    "\n",
    "def cand_in_ctd_marker(c):\n",
    "    return 1 if c.get_cids() in ctd_marker else 0\n",
    "\n",
    "def LF_in_ctd_unspecified(c):\n",
    "    if(cand_in_ctd_unspecified(c)==1):\n",
    "        return (-1,1)\n",
    "    else:\n",
    "        return (0,0)\n",
    "\n",
    "def LF_in_ctd_therapy(c):\n",
    "    if(cand_in_ctd_therapy(c)==1):\n",
    "        return (-1,1)\n",
    "    else:\n",
    "        return (0,0)\n",
    "\n",
    "def LF_in_ctd_marker(c):\n",
    "    if(cand_in_ctd_marker(c)==1):\n",
    "        return (1,1)\n",
    "    else:\n",
    "        return (0,0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "from __future__ import division\n",
    "\n",
    "def LF_closer_chem(c):\n",
    "    # Get distance between chemical and disease\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    # Try to find chemical closer than @dist/2 in either direction\n",
    "    sent = c.get_parent()\n",
    "    closest_other_chem = float('inf')\n",
    "    #print(\"LF_CHEM\",len(sent.words),dis_end + dist // 2)\n",
    "    for i in range(dis_end, min(len(sent.words), dis_end + dist // 2)):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Chemical' and cid != sent.entity_cids[chem_start]:\n",
    "            return (-1,1)\n",
    "    for i in range(max(0, dis_start - dist // 2), dis_start):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Chemical' and cid != sent.entity_cids[chem_start]:\n",
    "            return (-1,1)\n",
    "    return (0,0)\n",
    "\n",
    "def LF_closer_dis(c):\n",
    "    # Get distance between chemical and disease\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    # Try to find chemical disease than @dist/8 in either direction\n",
    "    sent = c.get_parent()\n",
    "    for i in range(chem_end, min(len(sent.words), chem_end + dist // 8)):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Disease' and cid != sent.entity_cids[dis_start]:\n",
    "            return (-1,1)\n",
    "    for i in range(max(0, chem_start - dist // 8), chem_start):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Disease' and cid != sent.entity_cids[dis_start]:\n",
    "            return (-1,1)\n",
    "    return (0,0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AnnotatorLabels created: 0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<888x1 sparse matrix of type '<type 'numpy.int64'>'\n",
       "\twith 888 stored elements in Compressed Sparse Row format>"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from load_external_annotations import load_external_labels\n",
    "load_external_labels(session, ChemicalDisease, split=1, annotator='gold')\n",
    "\n",
    "from snorkel.annotations import load_gold_labels\n",
    "L_gold_dev = load_gold_labels(session, annotator_name='gold', split=1)\n",
    "L_gold_dev"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "888\n",
      "(296, 592)\n"
     ]
    }
   ],
   "source": [
    "#gold_labels_dev = [x[0,0] for x in L_gold_dev.todense()]\n",
    "#for i,L in enumerate(gold_labels_dev):\n",
    "#    print(i,gold_labels_dev[i])\n",
    "\n",
    "gold_labels_dev = []\n",
    "for i,L in enumerate(L_gold_dev):\n",
    "    gold_labels_dev.append(L[0,0])\n",
    "    \n",
    "    \n",
    "print(len(gold_labels_dev))\n",
    "print(gold_labels_dev.count(1),gold_labels_dev.count(-1))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def LF_ctd_marker_c_d(c):\n",
    "    l,s = LF_c_d(c)\n",
    "    return (l*cand_in_ctd_marker(c),s)\n",
    "\n",
    "def LF_ctd_marker_induce(c):\n",
    "    l1,s1 = LF_c_induced_d(c)\n",
    "    l2,s2 = LF_d_induced_by_c_tight(c)\n",
    "    return ((l1 or l2) * cand_in_ctd_marker(c),(s1*s2))\n",
    "\n",
    "def LF_ctd_therapy_treat(c):\n",
    "    l,s = LF_c_treat_d_wide(c)\n",
    "    return (l* cand_in_ctd_therapy(c),s)\n",
    "\n",
    "def LF_ctd_unspecified_treat(c):\n",
    "    l,s = LF_c_treat_d_wide(c)\n",
    "    return (l* cand_in_ctd_unspecified(c),s)\n",
    "\n",
    "def LF_ctd_unspecified_induce(c):\n",
    "    l1,s1 = LF_c_induced_d(c)\n",
    "    l2,s2 = LF_d_induced_by_c_tight(c)\n",
    "    return ((l1 or l2) * cand_in_ctd_unspecified(c),(s1*s2))\n",
    "\n",
    "import re\n",
    "from snorkel.lf_helpers import (\n",
    "    get_tagged_text,\n",
    "    rule_regex_search_tagged_text,\n",
    "    rule_regex_search_btw_AB,\n",
    "    rule_regex_search_btw_BA,\n",
    "    rule_regex_search_before_A,\n",
    "    rule_regex_search_before_B,\n",
    ")\n",
    "\n",
    "from snorkel.lf_helpers import (\n",
    "    get_left_tokens, get_right_tokens, get_between_tokens,\n",
    "    get_text_between, get_tagged_text,\n",
    ")\n",
    "\n",
    "# List to parenthetical\n",
    "def ltp(x):\n",
    "    return '(' + '|'.join(x) + ')'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# def LF_induce(c):\n",
    "#     return (1,1) if re.search(r'{{A}}.{0,20}induc.{0,20}{{B}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "\n",
    "def LF_induce(c):\n",
    "    return (1,distanceCD_(c,['induc'])) if re.search(r'{{A}}.*induc.*{{B}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "causal_past = ['induced', 'caused', 'due']\n",
    "# def LF_d_induced_by_c(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.{0,50}' + ltp(causal_past) + '.{0,9}(by|to).{0,50}', 1),1)\n",
    "\n",
    "def LF_d_induced_by_c(c):\n",
    "    sc = 0\n",
    "    word_vectors = get_word_vectors(get_between_tokens(c))\n",
    "    for w in causal_past:\n",
    "        sc=max(sc,get_similarity(word_vectors,w))\n",
    "    return (1,sc)\n",
    "\n",
    "# def LF_d_induced_by_c_tight(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.{0,50}' + ltp(causal_past) + ' (by|to) ', 1),1)\n",
    "\n",
    "def LF_d_induced_by_c_tight(c):\n",
    "    return (rule_regex_search_btw_BA(c, '.*' + ltp(causal_past) + ' (by|to) ', 1),distanceCD_(c,causal_past))\n",
    "\n",
    "def LF_induce_name(c):\n",
    "    return (1,1) if 'induc' in c.chemical.get_span().lower() else (0,0)     \n",
    "\n",
    "causal = ['cause[sd]?', 'induce[sd]?', 'associated with']\n",
    "# def LF_c_cause_d(c):\n",
    "#     return (1,1) if (\n",
    "#         re.search(r'{{A}}.{0,50} ' + ltp(causal) + '.{0,50}{{B}}', get_tagged_text(c), re.I)\n",
    "#         and not re.search('{{A}}.{0,50}(not|no).{0,20}' + ltp(causal) + '.{0,50}{{B}}', get_tagged_text(c), re.I)\n",
    "#     ) else (0,0)\n",
    "\n",
    "def LF_c_cause_d(c):\n",
    "    return (1,distanceCD_(c,causal)) if (\n",
    "        re.search(r'{{A}}.* ' + ltp(causal) + '.*{{B}}', get_tagged_text(c), re.I)\n",
    "        and not re.search('{{A}}.{0,50}(not|no).{0,20}' + ltp(causal) + '.{0,50}{{B}}', get_tagged_text(c), re.I)\n",
    "    ) else (0,0)\n",
    "\n",
    "\n",
    "treat = ['treat', 'effective', 'prevent', 'resistant', 'slow', 'promise', 'therap']\n",
    "\n",
    "# def LF_d_treat_c(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.*' + ltp(treat) + '.*', -1),distanceDC_(c,treat))\n",
    "\n",
    "def LF_d_treat_c(c):\n",
    "    return (rule_regex_search_btw_BA(c, '.{0,50}' + ltp(treat) + '.{0,50}', -1),distanceDC_(c,treat))\n",
    "\n",
    "\n",
    "# def LF_d_treat_c(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.*' + ltp(treat) + '.*', -1),1)\n",
    "\n",
    "# def LF_c_treat_d(c):\n",
    "#     return (rule_regex_search_btw_AB(c, '.*' + ltp(treat) + '.*', -1),distanceCD_(c,treat))\n",
    "\n",
    "def LF_c_treat_d(c):\n",
    "    return (rule_regex_search_btw_AB(c, '.{0,50}' + ltp(treat) + '.{0,50}', -1),distanceCD_(c,treat))\n",
    "\n",
    "\n",
    "# def LF_treat_d(c):\n",
    "#     return (rule_regex_search_before_B(c, ltp(treat) + '.{0,50}', -1),1)\n",
    "\n",
    "\n",
    "def LF_treat_d(c):\n",
    "    sc = 0\n",
    "    word_vectors = get_word_vectors(get_left_tokens(c[1],5))\n",
    "    for w in treat:\n",
    "        sc=max(sc,get_similarity(word_vectors,w))\n",
    "    if(re.search('(not|no|none) .* {{B}}', get_tagged_text(c), re.I)):\n",
    "        return (0,0)\n",
    "    else:\n",
    "        return (-1,sc)\n",
    "    \n",
    "# def LF_c_treat_d_wide(c):\n",
    "#     return (rule_regex_search_btw_AB(c, '.*' + ltp(treat) + '.*', -1),1)\n",
    "\n",
    "def LF_c_treat_d_wide(c):\n",
    "    return (rule_regex_search_btw_AB(c, '.{0,200}' + ltp(treat) + '.{0,200}', -1),distanceCD_(c,treat))\n",
    "\n",
    "# def LF_c_treat_d_wide(c):\n",
    "#     return (rule_regex_search_btw_AB(c, '.*' + ltp(treat) + '.*', -1),distanceCD_(c,treat))\n",
    "\n",
    "\n",
    "def LF_c_d(c):\n",
    "    return (1,1) if ('{{A}} {{B}}' in get_tagged_text(c)) else (0,0)\n",
    "\n",
    "def LF_c_induced_d(c):\n",
    "    return (1,1) if (\n",
    "        ('{{A}} {{B}}' in get_tagged_text(c)) and \n",
    "        (('-induc' in c[0].get_span().lower()) or ('-assoc' in c[0].get_span().lower()))\n",
    "        ) else (0,0)\n",
    "\n",
    "\n",
    "def distanceImproveBeforeDisease(c):\n",
    "    m=re.search(r'(improv)(.*)({{B}}.*{{A}})', get_tagged_text(c), flags=re.I)\n",
    "    if(m):\n",
    "        return (5000-len(m.group(2)))/5000\n",
    "    return 0\n",
    "\n",
    "def LF_improve_before_disease(c):\n",
    "    return (rule_regex_search_before_B(c, 'improv.*', -1), distanceImproveBeforeDisease(c))\n",
    "\n",
    "pat_terms = ['in a patient with ', 'in patients with']\n",
    "def LF_in_patient_with(c):\n",
    "    return (-1,1) if re.search(ltp(pat_terms) + '{{B}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "uncertain = ['combin', 'possible', 'unlikely']\n",
    "# def LF_uncertain(c):\n",
    "#     return (rule_regex_search_before_A(c, ltp(uncertain) + '.*', -1),1)\n",
    "\n",
    "def LF_uncertain(c):\n",
    "    sc = 0\n",
    "    word_vectors = get_word_vectors(get_left_tokens(c[1],5))\n",
    "    for w in uncertain:\n",
    "        sc=max(sc,get_similarity(word_vectors,w))\n",
    "    if(re.search('(not|no|none) .* {{B}}', get_tagged_text(c), re.I)):\n",
    "        return (0,0)\n",
    "    else:\n",
    "        return (-1,sc)\n",
    "    \n",
    "# def LF_induced_other(c):\n",
    "#     return (rule_regex_search_tagged_text(c, '{{A}}.*-induced {{B}}', -1),distanceCD(c))\n",
    "\n",
    "def LF_induced_other(c):\n",
    "    return (rule_regex_search_tagged_text(c, '{{A}}.{20,1000}-induced {{B}}', -1),distanceCDfar(c))\n",
    "\n",
    "# def LF_induced_other(c):\n",
    "#     return (rule_regex_search_tagged_text(c, '{{A}}.*-induced {{B}}', -1),1)\n",
    "\n",
    "def LF_far_c_d(c):\n",
    "    return (rule_regex_search_btw_AB(c, '.{100,5000}', -1),distanceCDfar(c))\n",
    "\n",
    "# def LF_far_c_d(c):\n",
    "#     return (rule_regex_search_btw_AB(c, '.*', -1),distanceCD(c))\n",
    "\n",
    "# def LF_far_d_c(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.{100,5000}', -1),1)\n",
    "\n",
    "def LF_far_d_c(c):\n",
    "    return (rule_regex_search_btw_BA(c, '.{100,5000}', -1),distanceCDfar(c))\n",
    "\n",
    "# def LF_far_d_c(c):\n",
    "#     return (rule_regex_search_btw_BA(c, '.*', -1),distanceCD(c))\n",
    "\n",
    "# def LF_risk_d(c):\n",
    "#     return (rule_regex_search_before_B(c, 'risk of ', 1),1)\n",
    "\n",
    "\n",
    "def LF_risk_d(c):\n",
    "    sc = 0\n",
    "    word_vectors = get_word_vectors(get_left_tokens(c[1],5))\n",
    "    sc=max(sc,get_similarity(word_vectors,'risk'))\n",
    "    return (1,sc)\n",
    "\n",
    "# def LF_develop_d_following_c(c):\n",
    "#     return (1,1) if re.search(r'develop.{0,25}{{B}}.{0,25}following.{0,25}{{A}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def LF_develop_d_following_c(c):\n",
    "    return (1,distanceDevFol(c)) if re.search(r'develop.*{{B}}.*following.*{{A}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "procedure, following = ['inject', 'administrat'], ['following']\n",
    "# def LF_d_following_c(c):\n",
    "#     return (1,1) if re.search('{{B}}.{0,50}' + ltp(following) + '.{0,20}{{A}}.{0,50}' + ltp(procedure), get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def LF_d_following_c(c):\n",
    "    return (1,distanceDC_(c,following)) if re.search('{{B}}.*' + ltp(following) + '.*{{A}}.*' + ltp(procedure), get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "# def LF_measure(c):\n",
    "#     return (-1,1) if re.search('measur.{0,75}{{A}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def distanceMeasureA(c):\n",
    "    m = re.search('(measur)(.*)({{A}})', get_tagged_text(c), flags=re.I) \n",
    "    if(m):\n",
    "        return (5000-len(m.group(2)))/5000\n",
    "    return 0\n",
    "\n",
    "def LF_measure(c):\n",
    "    return (-1,distanceMeasureA(c)) if re.search('measur.*{{A}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "# def LF_level(c):\n",
    "#     return (-1,1) if re.search('{{A}}.{0,25} level', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def distanceLevel(c):\n",
    "    m = re.search('({{A}})(.*)(level)', get_tagged_text(c), flags=re.I)\n",
    "    if(m):\n",
    "        return (5000-len(m.group(2)))/5000\n",
    "    return 0\n",
    "\n",
    "def LF_level(c):\n",
    "    return (-1,distanceLevel(c)) if re.search('{{A}}.* level', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def distanceNeg(c):\n",
    "    m = re.search('(none|not|no)(.*)({{B}})', get_tagged_text(c), flags=re.I)\n",
    "    if(m):\n",
    "        return (5000-len(m.group(2)))/5000\n",
    "    return 0\n",
    "\n",
    "# def LF_neg_d(c):\n",
    "#     return (-1,1) if re.search('(none|not|no) .{0,25}{{B}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "def LF_neg_d(c):\n",
    "    return (-1,distanceNeg(c)) if re.search('(none|not|no) .*{{B}}', get_tagged_text(c), flags=re.I) else (0,0)\n",
    "\n",
    "\n",
    "WEAK_PHRASES = ['none', 'although', 'was carried out', 'was conducted',\n",
    "                'seems', 'suggests', 'risk', 'implicated',\n",
    "               'the aim', 'to (investigate|assess|study)']\n",
    "\n",
    "WEAK_RGX = r'|'.join(WEAK_PHRASES)\n",
    "\n",
    "def LF_weak_assertions(c):\n",
    "    return (-1,1) if re.search(WEAK_RGX, get_tagged_text(c), flags=re.I) else (0,0)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# original\n",
    "from __future__ import absolute_import\n",
    "from __future__ import division\n",
    "from __future__ import print_function\n",
    "import tensorflow as tf\n",
    "from tensorflow.contrib.tensorboard.plugins import projector\n",
    "\n",
    "def train_NN():\n",
    "    print()\n",
    "    result_dir = \"./\"\n",
    "    config = projector.ProjectorConfig()\n",
    "    tf.logging.set_verbosity(tf.logging.INFO)\n",
    "    summary_writer = tf.summary.FileWriter(result_dir)\n",
    "\n",
    "    tf.reset_default_graph()\n",
    "\n",
    "    dim = 2 #(labels,scores)\n",
    "\n",
    "    _x = tf.placeholder(tf.float64,shape=(dim,len(LFs)))\n",
    "\n",
    "    alphas = tf.get_variable('alpha', _x.get_shape()[-1],initializer=tf.truncated_normal_initializer(1,0.1,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    thetas = tf.get_variable('theta', _x.get_shape()[-1],initializer=tf.truncated_normal_initializer(2,0.2,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    l,s = tf.unstack(_x)\n",
    "\n",
    "    prelu_out_s = tf.maximum(tf.subtract(s,alphas), tf.zeros(shape=(len(LFs)),dtype=tf.float64))        \n",
    "\n",
    "    mul_L_S = tf.multiply(l,prelu_out_s)\n",
    "\n",
    "    phi_p1 = tf.reduce_sum(tf.multiply(mul_L_S,thetas))\n",
    "\n",
    "    phi_n1 = tf.reduce_sum(tf.multiply(tf.negative(mul_L_S),thetas))\n",
    "\n",
    "    phi_out = tf.stack([phi_n1,phi_p1])\n",
    "    \n",
    "    predict = tf.argmax(tf.nn.softmax(phi_out))\n",
    "\n",
    "    loss = tf.negative(tf.reduce_logsumexp(phi_out))\n",
    "\n",
    "    train_step = tf.train.GradientDescentOptimizer(0.0001).minimize(loss) \n",
    "\n",
    "\n",
    "    check_op = tf.add_check_numerics_ops()\n",
    "\n",
    "    sess = tf.Session()\n",
    "    init = tf.global_variables_initializer()\n",
    "    sess.run(init)\n",
    "\n",
    "    for i in range(1):\n",
    "        c = 0\n",
    "        te_prev=1\n",
    "        total_te = 0\n",
    "        for L_S_i in train_L_S:\n",
    "\n",
    "            a,t,te_curr,_ = sess.run([alphas,thetas,loss,train_step],feed_dict={_x:L_S_i})\n",
    "            total_te+=te_curr\n",
    "\n",
    "            if(abs(te_curr-te_prev)<1e-200):\n",
    "                print(\"too low\")\n",
    "                break\n",
    "\n",
    "            if(c%100==0):\n",
    "                pl = []\n",
    "                t_de=0\n",
    "                for L_S_i in dev_L_S:\n",
    "                    a,t,de_curr,p = sess.run([alphas,thetas,loss,predict],feed_dict={_x:L_S_i})\n",
    "                    pl.append(p)\n",
    "                    t_de+=de_curr\n",
    "                predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "                print(\"dev err:\",t_de/888)\n",
    "                print(total_te/100)\n",
    "                total_te=0\n",
    "#                 print(a)\n",
    "#                 print(t)\n",
    "                print()\n",
    "                print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "                print(c,\" d \",precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))\n",
    "            c+=1\n",
    "            te_prev = te_curr\n",
    "        pl = []\n",
    "        \n",
    "        for L_S_i in dev_L_S:\n",
    "            p = sess.run(predict,feed_dict={_x:L_S_i})\n",
    "            pl.append(p)\n",
    "        predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "        print(i,total_te)\n",
    "#         a,t = sess.run([alphas,thetas],feed_dict={_x:dev_L_S[0]})\n",
    "        a,t = sess.run([alphas,thetas])\n",
    "        print(a)\n",
    "        print(t)\n",
    "        print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "        print(precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average=None))\n",
    "        print()\n",
    "        print(precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import math\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "LFs = [\n",
    "    LF_c_cause_d,\n",
    "    LF_c_d,\n",
    "    LF_c_induced_d,\n",
    "    LF_c_treat_d,\n",
    "    LF_c_treat_d_wide,\n",
    "    LF_closer_chem,\n",
    "    LF_closer_dis,\n",
    "    LF_ctd_marker_c_d,\n",
    "    LF_ctd_marker_induce,\n",
    "    LF_ctd_therapy_treat,\n",
    "    LF_ctd_unspecified_treat,\n",
    "    LF_ctd_unspecified_induce,\n",
    "    LF_d_following_c,\n",
    "    LF_d_induced_by_c,\n",
    "    LF_d_induced_by_c_tight,\n",
    "    LF_d_treat_c,\n",
    "    LF_develop_d_following_c,\n",
    "    LF_far_c_d,\n",
    "    LF_far_d_c,\n",
    "    LF_improve_before_disease,\n",
    "    LF_in_ctd_therapy,\n",
    "    LF_in_ctd_marker,\n",
    "    LF_in_patient_with,\n",
    "    LF_induce,\n",
    "    LF_induce_name,\n",
    "    LF_induced_other,\n",
    "    LF_level,\n",
    "    LF_measure,\n",
    "    LF_neg_d,\n",
    "    LF_risk_d,\n",
    "    LF_treat_d,\n",
    "    LF_uncertain,\n",
    "    LF_weak_assertions\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "''' output:\n",
    "\n",
    "    [[[L_x1],[S_x1]],\n",
    "     [[L_x2],[S_x2]],\n",
    "     ......\n",
    "     ......\n",
    "    ]\n",
    "\n",
    "'''\n",
    "def get_L_S_Tensor(cands): \n",
    "    \n",
    "    L_S = []\n",
    "    for ci in cands:\n",
    "        L_S_ci=[]\n",
    "        L=[]\n",
    "        S=[]\n",
    "        P_ik = []\n",
    "        for LF in LFs:\n",
    "            #print LF.__name__\n",
    "            l,s = LF(ci)\n",
    "            L.append(l)\n",
    "            S.append((s+1)/2)  #to scale scores in [0,1] \n",
    "        L_S_ci.append(L)\n",
    "        L_S_ci.append(S)\n",
    "        L_S.append(L_S_ci) \n",
    "    return L_S"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# import matplotlib.pyplot as plt\n",
    "   \n",
    "from sklearn.metrics import precision_recall_fscore_support\n",
    "\n",
    "import cPickle as pkl\n",
    "\n",
    "dev_L_S = get_L_S_Tensor(dev_cands)\n",
    "train_L_S = get_L_S_Tensor(train_cands)\n",
    "# test_L_S = get_L_S_Tensor(test_cands)\n",
    "\n",
    "import cPickle as pkl\n",
    "from sklearn.metrics import precision_recall_fscore_support\n",
    "\n",
    "pkl.dump(dev_L_S,open(\"dev_L_S.p\",\"wb\"))\n",
    "pkl.dump(train_L_S,open(\"train_L_S.p\",\"wb\"))\n",
    "# pkl.dump(test_L_S,open(\"test_L_S.p\",\"wb\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# with an extra layer\n",
    "from __future__ import absolute_import\n",
    "from __future__ import division\n",
    "from __future__ import print_function\n",
    "import tensorflow as tf\n",
    "from tensorflow.contrib.tensorboard.plugins import projector\n",
    "\n",
    "def train_NN_EL():\n",
    "    print()\n",
    "    result_dir = \"./\"\n",
    "    config = projector.ProjectorConfig()\n",
    "    tf.logging.set_verbosity(tf.logging.INFO)\n",
    "    summary_writer = tf.summary.FileWriter(result_dir)\n",
    "\n",
    "    tf.reset_default_graph()\n",
    "\n",
    "    dim = 2 #(labels,scores)\n",
    "\n",
    "    _x = tf.placeholder(tf.float64,shape=(dim,len(LFs)))\n",
    "\n",
    "    alphas = tf.get_variable('alpha', _x.get_shape()[-1],initializer=tf.truncated_normal_initializer(1,0.1,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    layer12_out_dim = _x.get_shape()[-1]\n",
    "    \n",
    "    layer12 = tf.get_variable('layer12',[_x.get_shape()[-1], layer12_out_dim ],initializer=tf.truncated_normal_initializer(2,0.2,12),\n",
    "                            dtype=tf.float64)\n",
    "    \n",
    "    layer2b = tf.get_variable('layer2b',layer12_out_dim,initializer=tf.truncated_normal_initializer(2,0.2,12),\n",
    "                            dtype=tf.float64)\n",
    "    \n",
    "    thetas = tf.get_variable('theta', layer12.get_shape()[-1],initializer=tf.truncated_normal_initializer(2,0.2,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    l,s = tf.unstack(_x)\n",
    "\n",
    "    prelu_out_s = tf.maximum(tf.subtract(s,alphas), tf.zeros(shape=(len(LFs)),dtype=tf.float64))        \n",
    "\n",
    "    \n",
    "    mul_L_S = tf.multiply(l,prelu_out_s)\n",
    "    \n",
    "    layer12_out = tf.nn.relu(tf.matmul(tf.expand_dims(prelu_out_s,0)+layer2b,layer12))\n",
    "\n",
    "#     phi_p1 = tf.reduce_sum(tf.multiply(mul_L_S,thetas))\n",
    "\n",
    "    phi_p1 = tf.reduce_sum(tf.multiply(layer12_out,thetas))\n",
    "\n",
    "\n",
    "#     phi_n1 = tf.reduce_sum(tf.multiply(tf.negative(mul_L_S),thetas))\n",
    "\n",
    "    phi_n1 = tf.reduce_sum(tf.multiply(tf.negative(layer12_out),thetas))\n",
    "\n",
    "    phi_out = tf.stack([phi_n1,phi_p1])\n",
    "    \n",
    "    predict = tf.argmax(tf.nn.softmax(phi_out))\n",
    "\n",
    "    loss = tf.negative(tf.reduce_logsumexp(phi_out))\n",
    "\n",
    "    train_step = tf.train.GradientDescentOptimizer(0.01).minimize(loss) \n",
    "\n",
    "\n",
    "    check_op = tf.add_check_numerics_ops()\n",
    "\n",
    "    sess = tf.Session()\n",
    "    init = tf.global_variables_initializer()\n",
    "    sess.run(init)\n",
    "\n",
    "    for i in range(1):\n",
    "        c = 0\n",
    "        te_prev=1\n",
    "        total_te = 0\n",
    "        for L_S_i in train_L_S:\n",
    "\n",
    "            a,t,te_curr,_ = sess.run([alphas,thetas,loss,train_step],feed_dict={_x:L_S_i})\n",
    "            total_te+=te_curr\n",
    "\n",
    "            if(abs(te_curr-te_prev)<1e-200):\n",
    "                print(\"too low\")\n",
    "                break\n",
    "\n",
    "            if(c%1000==0):\n",
    "                pl = []\n",
    "                t_de=0\n",
    "                for L_S_i in dev_L_S:\n",
    "                    a,t,de_curr,p = sess.run([alphas,thetas,loss,predict],feed_dict={_x:L_S_i})\n",
    "                    pl.append(p)\n",
    "                    t_de+=de_curr\n",
    "                predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "                print(\"dev err:\",t_de/888)\n",
    "                print(total_te/1000)\n",
    "                total_te=0\n",
    "                print(a)\n",
    "                print(t)\n",
    "                print()\n",
    "                print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "                print(c,\" d \",precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))\n",
    "            c+=1\n",
    "            te_prev = te_curr\n",
    "        pl = []\n",
    "        \n",
    "        for L_S_i in dev_L_S:\n",
    "            p = sess.run(predict,feed_dict={_x:L_S_i})\n",
    "            pl.append(p)\n",
    "        predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "        print(i,total_te)\n",
    "#         a,t = sess.run([alphas,thetas],feed_dict={_x:dev_L_S[0]})\n",
    "        a,t = sess.run([alphas,thetas])\n",
    "        print(a)\n",
    "        print(t)\n",
    "        print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "        print(precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average=None))\n",
    "        print()\n",
    "        print(precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709887445754\n",
      "-0.00699214594392\n",
      "\n",
      "350 538\n",
      "0  d  (0.76801911842804038, 0.7880067567567568, 0.71968412531121595, None)\n",
      "too low\n",
      "0 -6.53739772714\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98357064  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116148  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82205496  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714129  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287928  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398282  1.67675493  1.92430086]\n",
      "350 538\n",
      "(array([ 0.99142857,  0.54460967]), array([ 0.58614865,  0.98986486]), array([ 0.73673036,  0.70263789]), array([592, 296]))\n",
      "\n",
      "(0.76801911842804038, 0.7880067567567568, 0.71968412531121595, None)\n"
     ]
    }
   ],
   "source": [
    "# distances changed\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709871351813\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53481099834\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358419  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116723  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204994  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.8828791   1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398284  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, tight ranges for -1 but used distancefarCD , exp22\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 212,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.705421228101\n",
      "-0.00693703542313\n",
      "\n",
      "563 325\n",
      "0  d  (0.69574258778521658, 0.70439189189189189, 0.69915302089215137, None)\n",
      "too low\n",
      "0 -14.8749292717\n",
      "[ 1.11754463  0.81414095  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98355774  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91991171\n",
      "  1.05962482  0.83641602  1.03537624  0.94116747  0.99621468  1.16301113\n",
      "  0.87350344  1.17747756  1.06808572  1.06850778  1.05747627  0.99037652\n",
      "  0.82194712  0.83837747  0.96207502]\n",
      "[ 2.23508926  1.62843746  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714137  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986962\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.7474835   2.35495511  2.13617144  2.13701556  2.11495255  1.98068728\n",
      "  1.64398348  1.67675493  1.92430256]\n",
      "563 325\n",
      "(array([ 0.80994671,  0.58153846]), array([ 0.77027027,  0.63851351]), array([ 0.78961039,  0.60869565]), array([592, 296]))\n",
      "\n",
      "(0.69574258778521658, 0.70439189189189189, 0.69915302089215137, None)\n"
     ]
    }
   ],
   "source": [
    "# All non tight with distance score exp21\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.710106593062\n",
      "-0.00699214594392\n",
      "\n",
      "419 469\n",
      "0  d  (0.74778256687920774, 0.77787162162162171, 0.73247997517503549, None)\n",
      "too low\n",
      "0 -6.54534869958\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358541  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91990846\n",
      "  1.05962482  0.83641602  1.03537624  0.94116606  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82202947  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714119  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83987009\n",
      "  2.11924965  1.67283205  2.07075248  1.88287914  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398293  1.67675493  1.92430086]\n",
      "419 469\n",
      "(array([ 0.92840095,  0.56716418]), array([ 0.65709459,  0.89864865]), array([ 0.76953511,  0.69542484]), array([592, 296]))\n",
      "\n",
      "(0.74778256687920774, 0.77787162162162171, 0.73247997517503549, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, tight ranges for -1 but used distance, \n",
    "#also changed imporveBeforeB exp20\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.710242046373\n",
      "-0.00699214594392\n",
      "\n",
      "423 465\n",
      "0  d  (0.74830321055441162, 0.77871621621621623, 0.73443291494857033, None)\n",
      "too low\n",
      "0 -6.54534869958\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358541  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91990846\n",
      "  1.05962482  0.83641602  1.03537624  0.94116606  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82202947  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714119  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83987009\n",
      "  2.11924965  1.67283205  2.07075248  1.88287914  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398293  1.67675493  1.92430086]\n",
      "423 465\n",
      "(array([ 0.92671395,  0.56989247]), array([ 0.66216216,  0.89527027]), array([ 0.77241379,  0.69645204]), array([592, 296]))\n",
      "\n",
      "(0.74830321055441162, 0.77871621621621623, 0.73443291494857033, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, tight ranges for -1 but used distance, exp19\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.71029466018\n",
      "-0.00699214594392\n",
      "\n",
      "424 464\n",
      "0  d  (0.74674690956408596, 0.77702702702702697, 0.73319519270617484, None)\n",
      "too low\n",
      "0 -6.54478867599\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358387  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91990846\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82202818  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83987009\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398293  1.67675493  1.92430086]\n",
      "424 464\n",
      "(array([ 0.9245283 ,  0.56896552]), array([ 0.66216216,  0.89189189]), array([ 0.77165354,  0.69473684]), array([592, 296]))\n",
      "\n",
      "(0.74674690956408596, 0.77702702702702697, 0.73319519270617484, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, tight ranges for -1 but used distance, all -1 exp18\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.710624123218\n",
      "-0.00699214594392\n",
      "\n",
      "426 462\n",
      "0  d  (0.74589964026583744, 0.77618243243243246, 0.73301677975854151, None)\n",
      "too low\n",
      "0 -6.5471247757\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358387  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91990565\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82202566  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83987034\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398294  1.67675493  1.92430086]\n",
      "426 462\n",
      "(array([ 0.92253521,  0.56926407]), array([ 0.66385135,  0.88851351]), array([ 0.77210216,  0.6939314 ]), array([592, 296]))\n",
      "\n",
      "(0.74589964026583744, 0.77618243243243246, 0.73301677975854151, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, tight ranges for -1 but used distance  LF_far_d_c exp17\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709880393687\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53470386686\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358388  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204968  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398285  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d distanceCDn1, LF_far_d_c ,LF_measure  \n",
    "# LF_level, LF_neg_d exp16 old\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709880393687\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53470386686\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358388  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204968  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398285  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d distanceCDn1, LF_far_d_c ,LF_measure  \n",
    "# LF_level exp15\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709880393687\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53470386686\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358388  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204968  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398285  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d distanceCDn1, LF_far_d_c ,LF_measure  exp14\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709880393687\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53470386686\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358388  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204968  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398285  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d distanceCDn1, LF_far_d_c   exp13\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.709880393687\n",
      "-0.00699214594392\n",
      "\n",
      "352 536\n",
      "0  d  (0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n",
      "too low\n",
      "0 -6.53470386686\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358388  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91993454\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82204968  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83986908\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398285  1.67675493  1.92430086]\n",
      "352 536\n",
      "(array([ 0.98579545,  0.54291045]), array([ 0.58614865,  0.98310811]), array([ 0.73516949,  0.69951923]), array([592, 296]))\n",
      "\n",
      "(0.76435295115332424, 0.7846283783783784, 0.71734436114732725, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d distanceCDn1   exp12\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-88-ec976bdd65d9>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[0;31m# distanceCD_ ,LF_d_following_c,LF_far_c_d, 1/distanceCD  exp11\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 4\u001b[0;31m \u001b[0mtrain_NN\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m<ipython-input-79-95af70978dc7>\u001b[0m in \u001b[0;36mtrain_NN\u001b[0;34m()\u001b[0m\n\u001b[1;32m     67\u001b[0m                 \u001b[0mt_de\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     68\u001b[0m                 \u001b[0;32mfor\u001b[0m \u001b[0mL_S_i\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdev_L_S\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 69\u001b[0;31m                     \u001b[0ma\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mt\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mde_curr\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mp\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msess\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrun\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0malphas\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mthetas\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mloss\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mpredict\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mfeed_dict\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m{\u001b[0m\u001b[0m_x\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0mL_S_i\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     70\u001b[0m                     \u001b[0mpl\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mp\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     71\u001b[0m                     \u001b[0mt_de\u001b[0m\u001b[0;34m+=\u001b[0m\u001b[0mde_curr\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/home/vinay/anaconda3/envs/en27/lib/python2.7/site-packages/tensorflow/python/client/session.pyc\u001b[0m in \u001b[0;36mrun\u001b[0;34m(self, fetches, feed_dict, options, run_metadata)\u001b[0m\n\u001b[1;32m    893\u001b[0m     \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    894\u001b[0m       result = self._run(None, fetches, feed_dict, options_ptr,\n\u001b[0;32m--> 895\u001b[0;31m                          run_metadata_ptr)\n\u001b[0m\u001b[1;32m    896\u001b[0m       \u001b[0;32mif\u001b[0m \u001b[0mrun_metadata\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    897\u001b[0m         \u001b[0mproto_data\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtf_session\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mTF_GetBuffer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mrun_metadata_ptr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/home/vinay/anaconda3/envs/en27/lib/python2.7/site-packages/tensorflow/python/client/session.pyc\u001b[0m in \u001b[0;36m_run\u001b[0;34m(self, handle, fetches, feed_dict, options, run_metadata)\u001b[0m\n\u001b[1;32m   1122\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mfinal_fetches\u001b[0m \u001b[0;32mor\u001b[0m \u001b[0mfinal_targets\u001b[0m \u001b[0;32mor\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mhandle\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mfeed_dict_tensor\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1123\u001b[0m       results = self._do_run(handle, final_targets, final_fetches,\n\u001b[0;32m-> 1124\u001b[0;31m                              feed_dict_tensor, options, run_metadata)\n\u001b[0m\u001b[1;32m   1125\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1126\u001b[0m       \u001b[0mresults\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/home/vinay/anaconda3/envs/en27/lib/python2.7/site-packages/tensorflow/python/client/session.pyc\u001b[0m in \u001b[0;36m_do_run\u001b[0;34m(self, handle, target_list, fetch_list, feed_dict, options, run_metadata)\u001b[0m\n\u001b[1;32m   1319\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mhandle\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1320\u001b[0m       return self._do_call(_run_fn, self._session, feeds, fetches, targets,\n\u001b[0;32m-> 1321\u001b[0;31m                            options, run_metadata)\n\u001b[0m\u001b[1;32m   1322\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1323\u001b[0m       \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_do_call\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0m_prun_fn\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_session\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhandle\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfeeds\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfetches\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/home/vinay/anaconda3/envs/en27/lib/python2.7/site-packages/tensorflow/python/client/session.pyc\u001b[0m in \u001b[0;36m_do_call\u001b[0;34m(self, fn, *args)\u001b[0m\n\u001b[1;32m   1325\u001b[0m   \u001b[0;32mdef\u001b[0m \u001b[0m_do_call\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfn\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1326\u001b[0m     \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1327\u001b[0;31m       \u001b[0;32mreturn\u001b[0m \u001b[0mfn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1328\u001b[0m     \u001b[0;32mexcept\u001b[0m \u001b[0merrors\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mOpError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1329\u001b[0m       \u001b[0mmessage\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mcompat\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mas_text\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0me\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmessage\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/home/vinay/anaconda3/envs/en27/lib/python2.7/site-packages/tensorflow/python/client/session.pyc\u001b[0m in \u001b[0;36m_run_fn\u001b[0;34m(session, feed_dict, fetch_list, target_list, options, run_metadata)\u001b[0m\n\u001b[1;32m   1304\u001b[0m           return tf_session.TF_Run(session, options,\n\u001b[1;32m   1305\u001b[0m                                    \u001b[0mfeed_dict\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfetch_list\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtarget_list\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1306\u001b[0;31m                                    status, run_metadata)\n\u001b[0m\u001b[1;32m   1307\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1308\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_prun_fn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msession\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhandle\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfeed_dict\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfetch_list\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c,LF_far_c_d, 1/distanceCD  exp11\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "dev err: -0.710624123218\n",
      "-0.00699214594392\n",
      "\n",
      "426 462\n",
      "0  d  (0.74589964026583744, 0.77618243243243246, 0.73301677975854151, None)\n",
      "too low\n",
      "0 -6.5471247757\n",
      "[ 1.11754463  0.81412327  1.00955965  1.00062431  1.10637787  1.04133855\n",
      "  1.169206    1.03120785  1.14633471  1.0647233   0.98358387  1.06661405\n",
      "  0.98238184  1.07858159  1.04081247  1.04223612  0.85334134  0.91990565\n",
      "  1.05962482  0.83641602  1.03537624  0.94116753  0.99621468  1.16301113\n",
      "  0.87352575  1.17747756  1.06808572  1.06850778  1.05747627  0.99033244\n",
      "  0.82202566  0.83837747  0.9621615 ]\n",
      "[ 2.23508926  1.62843948  2.01911931  2.00124861  2.21275574  2.0826771\n",
      "  2.33841199  2.0624157   2.29266943  2.12944659  1.96714118  2.13322809\n",
      "  1.96476369  2.15716318  2.08162495  2.08447223  1.70668268  1.83987034\n",
      "  2.11924965  1.67283205  2.07075248  1.88287909  1.99242937  2.32602226\n",
      "  1.74748188  2.35495511  2.13617144  2.13701556  2.11495255  1.9806875\n",
      "  1.64398294  1.67675493  1.92430086]\n",
      "426 462\n",
      "(array([ 0.92253521,  0.56926407]), array([ 0.66385135,  0.88851351]), array([ 0.77210216,  0.6939314 ]), array([592, 296]))\n",
      "\n",
      "(0.74589964026583744, 0.77618243243243246, 0.73301677975854151, None)\n"
     ]
    }
   ],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, exp10\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ ,LF_d_following_c, exp10\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, LF_develop_d_following_c,\n",
    "# distanceCD_ , exp9\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, F_induce, distanceCD_ , exp8\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * ,LF_c_cause_d, distanceCD_ , exp7\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * , distanceCD_ , exp6\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    " #LF_d_induced_by_c_tight, LF_far_c_d made *, distance (500-dist)/500 exp5\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    " #LF_d_induced_by_c_tight, LF_far_c_d made *, distance (5000-dist)/5000 exp4\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    " #LF_d_induced_by_c_tight, LF_far_c_d made *, distance (100-dist)/100 exp3\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight, LF_far_c_d made *,  exp2\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "#LF_d_induced_by_c_tight made * , exp1\n",
    "\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# baseline reproduce\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# new baseline\n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# for reference\n",
    "from __future__ import absolute_import\n",
    "from __future__ import division\n",
    "from __future__ import print_function\n",
    "import tensorflow as tf\n",
    "from tensorflow.contrib.tensorboard.plugins import projector\n",
    "\n",
    "def train_NN():\n",
    "    print()\n",
    "    result_dir = \"./\"\n",
    "    config = projector.ProjectorConfig()\n",
    "    tf.logging.set_verbosity(tf.logging.INFO)\n",
    "    summary_writer = tf.summary.FileWriter(result_dir)\n",
    "\n",
    "    tf.reset_default_graph()\n",
    "\n",
    "    dim = 2 #(labels,scores)\n",
    "\n",
    "    _x = tf.placeholder(tf.float64,shape=(dim,len(LFs)))\n",
    "\n",
    "    alphas = tf.get_variable('alpha', _x.get_shape()[-1],initializer=tf.truncated_normal_initializer(1,0.1,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    thetas = tf.get_variable('theta', _x.get_shape()[-1],initializer=tf.truncated_normal_initializer(2,0.2,12),\n",
    "                            dtype=tf.float64)\n",
    "\n",
    "    l,s = tf.unstack(_x)\n",
    "\n",
    "    prelu_out_s = tf.maximum(tf.subtract(s,alphas), tf.zeros(shape=(len(LFs)),dtype=tf.float64))        \n",
    "\n",
    "    mul_L_S = tf.multiply(l,prelu_out_s)\n",
    "\n",
    "    phi_p1 = tf.reduce_sum(tf.multiply(mul_L_S,thetas))\n",
    "\n",
    "    phi_n1 = tf.reduce_sum(tf.multiply(tf.negative(mul_L_S),thetas))\n",
    "\n",
    "    phi_out = tf.stack([phi_n1,phi_p1])\n",
    "    \n",
    "    predict = tf.argmax(tf.nn.softmax(phi_out))\n",
    "\n",
    "    loss = tf.negative(tf.reduce_logsumexp(phi_out))\n",
    "\n",
    "    train_step = tf.train.GradientDescentOptimizer(0.0001).minimize(loss) \n",
    "\n",
    "\n",
    "    check_op = tf.add_check_numerics_ops()\n",
    "\n",
    "    sess = tf.Session()\n",
    "    init = tf.global_variables_initializer()\n",
    "    sess.run(init)\n",
    "\n",
    "    for i in range(1):\n",
    "        c = 0\n",
    "        te_prev=1\n",
    "        total_te = 0\n",
    "        for L_S_i in train_L_S:\n",
    "\n",
    "            a,t,te_curr,_ = sess.run([alphas,thetas,loss,train_step],feed_dict={_x:L_S_i})\n",
    "            total_te+=te_curr\n",
    "\n",
    "            if(abs(te_curr-te_prev)<1e-200):\n",
    "                print(\"too low\")\n",
    "                break\n",
    "\n",
    "            if(c%100==0):\n",
    "                pl = []\n",
    "                t_de=0\n",
    "                for L_S_i in dev_L_S:\n",
    "                    a,t,de_curr,p = sess.run([alphas,thetas,loss,predict],feed_dict={_x:L_S_i})\n",
    "                    pl.append(p)\n",
    "                    t_de+=de_curr\n",
    "                predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "                print(\"dev err:\",t_de/888)\n",
    "                print(total_te/100)\n",
    "                total_te=0\n",
    "                print(a)\n",
    "                print(t)\n",
    "                print()\n",
    "                print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "                print(c,\" d \",precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))\n",
    "            c+=1\n",
    "            te_prev = te_curr\n",
    "        pl = []\n",
    "        for L_S_i in dev_L_S:\n",
    "            p = sess.run(predict,feed_dict={_x:L_S_i})\n",
    "            pl.append(p)\n",
    "        predicted_labels = [-1 if x==0 else x for x in pl]\n",
    "        print(i,total_te)\n",
    "        print(predicted_labels.count(-1),predicted_labels.count(1))\n",
    "        print(precision_recall_fscore_support(np.array(gold_labels_dev),np.array(predicted_labels),average='macro'))\n",
    "    \n",
    "train_NN()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 228,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence(Document 7234705,7,In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.)\n",
      "In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of {{A}} therapy, polymorphous {{B}} did not reoccur.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2 Estrogens protect ovariectomized rats from hippocampal injury induced by {{A}} {{B}} (SE).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3 Estrogens protect ovariectomized rats from hippocampal injury induced by {{A}} status epilepticus ({{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4 Estrogens protect ovariectomized rats from {{B}} induced by {{A}} status epilepticus (SE).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "9 NRA0160 and {{A}} antagonized locomotor {{B}} induced by methamphetamine (MAP) in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "10 {{A}} and clozapine antagonized locomotor {{B}} induced by methamphetamine (MAP) in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "11 NRA0160 and clozapine antagonized locomotor {{B}} induced by {{A}} (MAP) in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "12 NRA0160 and clozapine antagonized locomotor {{B}} induced by methamphetamine ({{A}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "19 The yield of severe {{B}} (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of {{A}} given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "20 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, {{B}} greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of {{A}} given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "21 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and {{B}} approximately half normal weight) after 12 doses of {{A}} given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "22 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, {{B}} 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of {{A}} given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "23 The yield of severe {{B}} (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of {{A}} at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "24 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, {{B}} greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of {{A}} at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "25 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and {{B}} approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of {{A}} at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "26 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, {{B}} 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of {{A}} at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "27 The yield of severe {{B}} (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the {{A}} rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "28 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, {{B}} greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the {{A}} rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "29 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and {{B}} approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the {{A}} rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "30 The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, {{B}} 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the {{A}} rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "35 Warfarin-induced {{B}} is accelerated by growth and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "37 NRA0160 and {{A}} significantly induced {{B}} in rats, although their effects did not exceed 50% induction even at the highest dose given.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly ', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} significantly induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  significantly \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "38 {{A}} and clozapine significantly induced {{B}} in rats, although their effects did not exceed 50% induction even at the highest dose given.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and clozapine significantly ', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} and clozapine significantly induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  and clozapine significantly \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "40 We compared the effects of {{A}} in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in adult male and ovariectomized female rats subjected to lithium-pilocarpine-', u'ed ')\n",
      "[79, 3]\n",
      "3\n",
      "0 97 {{A}} in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 79  in adult male and ovariectomized female rats subjected to lithium-pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "43 Cerebral blood flow and cerebral metabolic rate for {{A}} were measured during isoflurane-induced {{B}} in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' were measured during isoflurane-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} were measured during isoflurane-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  were measured during isoflurane-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "44 Cerebral blood flow and cerebral metabolic rate for {{A}} were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' were measured during isoflurane-', u'ed hypotension in 10 patients subjected to craniotomy for clipping of a ')\n",
      "[33, 72]\n",
      "33\n",
      "0 120 {{A}} were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  were measured during isoflurane-\n",
      "3 5 induc\n",
      "4 72 ed hypotension in 10 patients subjected to craniotomy for clipping of a \n",
      "5 5 {{B}}\n",
      "47 {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "59 {{A}} reduces seizure-induced {{B}} in ovariectomized female but not in male rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reduces seizure-', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}} reduces seizure-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  reduces seizure-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "66 {{A}} (10 micro g) was injected into the masseter muscle to induce {{B}} in 11 healthy volunteers.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (10 micro g) was injected into the masseter muscle to ', u'e ')\n",
      "[55, 2]\n",
      "2\n",
      "0 72 {{A}} (10 micro g) was injected into the masseter muscle to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  (10 micro g) was injected into the masseter muscle to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "79 RESULTS: The results of this paper confirm that inhibition of {{A}} receptors and inducible NO synthase but not neuronal NO synthase activity reduces {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors and ', u'ible NO synthase but not neuronal NO synthase activity reduces ')\n",
      "[15, 63]\n",
      "15\n",
      "0 93 {{A}} receptors and inducible NO synthase but not neuronal NO synthase activity reduces {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  receptors and \n",
      "3 5 induc\n",
      "4 63 ible NO synthase but not neuronal NO synthase activity reduces \n",
      "5 5 {{B}}\n",
      "80 Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1) in arteritis induced in rats by {{A}} and theophylline, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "81 Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in {{B}} induced in rats by {{A}} and theophylline, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "82 Immunohistochemical study on inducible type of {{A}} (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "83 Immunohistochemical study on inducible type of {{A}} (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in {{B}} induced in rats by fenoldopam and theophylline, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "84 Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and {{A}}, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "85 Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in {{B}} induced in rats by fenoldopam and {{A}}, vasodilators.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "105 To clarify the mechanisms of FK 506-induced {{B}}, we studied the chronic effects of {{A}} on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "106 To clarify the mechanisms of FK 506-induced {{B}}, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial {{A}} synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "107 In addition, the effect of the specific endothelin type A receptor antagonist {{A}} on FK 506-induced {{B}} in rats was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on FK 506-', u'ed ')\n",
      "[11, 3]\n",
      "3\n",
      "0 29 {{A}} on FK 506-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  on FK 506-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "112 Arteritis induced in rats by vasodilators, {{A}} and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and theophylline, was examined immunohistochemically for expressions of ', u'ible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and ')\n",
      "[73, 85]\n",
      "73\n",
      "0 173 {{A}} and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  and theophylline, was examined immunohistochemically for expressions of \n",
      "3 5 induc\n",
      "4 85 ible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and \n",
      "5 5 {{B}}\n",
      "113 {{B}} induced in rats by vasodilators, {{A}} and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "114 Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of {{A}} synthase (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "115 {{B}} induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of {{A}} synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "116 Arteritis induced in rats by vasodilators, fenoldopam and {{A}}, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and {{B}} growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', was examined immunohistochemically for expressions of ', u'ible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and ')\n",
      "[56, 85]\n",
      "56\n",
      "0 156 {{A}}, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and {{B}}\n",
      "1 5 {{A}}\n",
      "2 56 , was examined immunohistochemically for expressions of \n",
      "3 5 induc\n",
      "4 85 ible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and \n",
      "5 5 {{B}}\n",
      "117 {{B}} induced in rats by vasodilators, fenoldopam and {{A}}, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "123 {{A}} (1 mg/kg ip) induced parkinsonian-like {{B}}, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (1 mg/kg ip) ', u'ed parkinsonian-like ')\n",
      "[14, 21]\n",
      "14\n",
      "0 50 {{A}} (1 mg/kg ip) induced parkinsonian-like {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  (1 mg/kg ip) \n",
      "3 5 induc\n",
      "4 21 ed parkinsonian-like \n",
      "5 5 {{B}}\n",
      "124 {{A}} (1 mg/kg ip) induced {{B}} muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (1 mg/kg ip) ', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} (1 mg/kg ip) induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  (1 mg/kg ip) \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "146 Phenobarbitone-induced enlargement of the liver in the rat: its relationship to {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "147 Phenobarbitone-induced {{B}} in the rat: its relationship to {{A}} cirrhosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "148 {{A}} enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' enlargement of the liver in the rat: its relationship to carbon tetrachloride-', u'ed ')\n",
      "[79, 3]\n",
      "3\n",
      "0 97 {{A}} enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 79  enlargement of the liver in the rat: its relationship to carbon tetrachloride-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "149 {{A}} {{B}} in the rat: its relationship to carbon tetrachloride-induced cirrhosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "168 Following unilateral {{A}} induced SN lesion, a transient period of {{B}} has been reported to precede the predominant ipsilateral circling.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed SN lesion, a transient period of ')\n",
      "[1, 36]\n",
      "1\n",
      "0 52 {{A}} induced SN lesion, a transient period of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 36 ed SN lesion, a transient period of \n",
      "5 5 {{B}}\n",
      "178 Such {{B}} may result from either degeneration-induced breakdown of the {{A}} pool, or lesion-induced increase of DA turnover in the spared neurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "179 Such {{B}} may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of {{A}} turnover in the spared neurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "187 {{A}} cardiomyopathy-induced {{B}} and apoptosis are attenuated by gene deletion of the kinin B1 receptor.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' cardiomyopathy-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} cardiomyopathy-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  cardiomyopathy-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "191 Clinical use of the anthracycline {{A}} (DOX) is limited by its {{B}} effects, which are attributed to the induction of apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "192 Clinical use of the anthracycline doxorubicin ({{A}} is limited by its {{B}} effects, which are attributed to the induction of apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "193 Clinical use of the {{A}} doxorubicin (DOX) is limited by its {{B}} effects, which are attributed to the induction of apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "232 Therefore, the effects of {{A}}, a beta-adrenoceptor antagonist, on haloperidol-induced {{B}} in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a beta-adrenoceptor antagonist, on haloperidol-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}}, a beta-adrenoceptor antagonist, on haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49 , a beta-adrenoceptor antagonist, on haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "234 Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced {{B}} in rats were behaviorally studied and compared with those of propranolol and {{A}}, a muscarinic receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "235 Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced {{B}} in rats were behaviorally studied and compared with those of {{A}} and biperiden, a muscarinic receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "240 The memory-enhancing effects of {{A}} and its analogs were tested in the passive avoidance task using the model of scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and its analogs were tested in the passive avoidance task using the model of scopolamine-', u'ed ')\n",
      "[90, 3]\n",
      "3\n",
      "0 108 {{A}} and its analogs were tested in the passive avoidance task using the model of scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 90  and its analogs were tested in the passive avoidance task using the model of scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "263 Pentoxifylline (Trental) does not inhibit dipyridamole-induced {{B}}: implications for {{A}} myocardial imaging.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "264 {{A}} (Trental) does not inhibit dipyridamole-induced {{B}}: implications for dipyridamole-thallium-201 myocardial imaging.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Trental) does not inhibit dipyridamole-', u'ed ')\n",
      "[41, 3]\n",
      "3\n",
      "0 59 {{A}} (Trental) does not inhibit dipyridamole-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 41  (Trental) does not inhibit dipyridamole-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "275 Moreover, enantioselectivity was demonstrated by the ability of natural {{A}} to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-', u'ed ')\n",
      "[99, 3]\n",
      "3\n",
      "0 117 {{A}} to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 99  to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "280 Whether pentoxifylline inhibits dipyridamole-induced {{B}} like other {{A}} such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "282 Whether pentoxifylline inhibits dipyridamole-induced {{B}} like other methylxanthines such as theophylline and should be stopped prior to {{A}} imaging is unknown.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "283 Whether {{A}} inhibits dipyridamole-induced {{B}} like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' inhibits dipyridamole-', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} inhibits dipyridamole-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  inhibits dipyridamole-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "284 Whether pentoxifylline inhibits dipyridamole-induced {{B}} like other methylxanthines such as {{A}} and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "289 Heparin-induced {{B}} (HIT) is an adverse immune-mediated reaction to {{A}}, resulting in platelet count decreases of more than 50%.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "290 Heparin-induced thrombocytopenia ({{B}} is an adverse immune-mediated reaction to {{A}}, resulting in platelet count decreases of more than 50%.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "291 However, pilocarpine-induced {{B}} result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "292 However, pilocarpine-induced seizures result in a more widespread {{B}} in both WT and D2R -/- brains in comparison to {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "326 Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced {{B}} with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "333 Using a rat model of adriamycin-induced {{B}}, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in {{A}} cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "334 Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "350 Protective effect of a specific platelet-activating factor antagonist, {{A}}, on bupivacaine-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', on bupivacaine-', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}}, on bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17 , on bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "351 Reduction of {{B}} during induction with target-controlled {{A}} and remifentanil.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "352 Reduction of {{B}} during induction with target-controlled propofol and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "355 Early trials of cisplatin and {{A}} also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and {{B}} were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also suggested that the incidence and severity of cisplatin-', u'ed nephrotoxicity, ototoxicity, and ')\n",
      "[61, 36]\n",
      "36\n",
      "0 112 {{A}} also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 36 ed nephrotoxicity, ototoxicity, and \n",
      "5 5 {{B}}\n",
      "356 Early trials of cisplatin and {{A}} also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, {{B}}, and neuropathy were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also suggested that the incidence and severity of cisplatin-', u'ed nephrotoxicity, ')\n",
      "[61, 19]\n",
      "19\n",
      "0 95 {{A}} also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 19 ed nephrotoxicity, \n",
      "5 5 {{B}}\n",
      "357 Early trials of cisplatin and {{A}} also suggested that the incidence and severity of cisplatin-induced {{B}}, ototoxicity, and neuropathy were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also suggested that the incidence and severity of cisplatin-', u'ed ')\n",
      "[61, 3]\n",
      "3\n",
      "0 79 {{A}} also suggested that the incidence and severity of cisplatin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "358 Early trials of {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and {{B}} were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and amifostine also suggested that the incidence and severity of cisplatin-', u'ed nephrotoxicity, ototoxicity, and ')\n",
      "[76, 36]\n",
      "36\n",
      "0 127 {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and {{B}}\n",
      "1 5 {{A}}\n",
      "2 76  and amifostine also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 36 ed nephrotoxicity, ototoxicity, and \n",
      "5 5 {{B}}\n",
      "359 Early trials of {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, {{B}}, and neuropathy were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and amifostine also suggested that the incidence and severity of cisplatin-', u'ed nephrotoxicity, ')\n",
      "[76, 19]\n",
      "19\n",
      "0 110 {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, {{B}}\n",
      "1 5 {{A}}\n",
      "2 76  and amifostine also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 19 ed nephrotoxicity, \n",
      "5 5 {{B}}\n",
      "360 Early trials of {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced {{B}}, ototoxicity, and neuropathy were reduced.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and amifostine also suggested that the incidence and severity of cisplatin-', u'ed ')\n",
      "[76, 3]\n",
      "3\n",
      "0 94 {{A}} and amifostine also suggested that the incidence and severity of cisplatin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 76  and amifostine also suggested that the incidence and severity of cisplatin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "381 CONCLUSIONS: During induction of anaesthesia with TCI of {{A}} and remifentanil, a significant reduction in propofol infusion {{B}} was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "382 CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in {{A}} infusion {{B}} was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "383 CONCLUSIONS: During induction of anaesthesia with TCI of propofol and {{A}}, a significant reduction in propofol infusion {{B}} was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "384 CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion {{B}} was achieved without significant complications by prior administration of {{A}} at a target Ce of 4 ng ml(-1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "388 {{A}} produced a dose-dependent attenuation of isoproterenol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' produced a dose-dependent attenuation of isoproterenol-', u'ed ')\n",
      "[56, 3]\n",
      "3\n",
      "0 74 {{A}} produced a dose-dependent attenuation of isoproterenol-induced {{B}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1 5 {{A}}\n",
      "2 56  produced a dose-dependent attenuation of isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "393 {{A}} was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-', u'ed ')\n",
      "[107, 3]\n",
      "3\n",
      "0 125 {{A}} was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 107  was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "406 Pretreatment with the D2 agonist PHNO enhanced nicotine-induced {{B}}, whereas the D1 agonist {{A}} had no effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "425 METHODS: Three subjects with a history of {{A}} (EMB)-induced {{B}} of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (EMB)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (EMB)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (EMB)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "426 METHODS: Three subjects with a history of {{A}} (EMB)-induced optic neuropathy of short-, intermediate-, and long-term {{B}} were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (EMB)-', u'ed optic neuropathy of short-, intermediate-, and long-term ')\n",
      "[7, 60]\n",
      "7\n",
      "0 82 {{A}} (EMB)-induced optic neuropathy of short-, intermediate-, and long-term {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (EMB)-\n",
      "3 5 induc\n",
      "4 60 ed optic neuropathy of short-, intermediate-, and long-term \n",
      "5 5 {{B}}\n",
      "427 METHODS: Three subjects with a history of ethambutol ({{A}}-induced {{B}} of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "428 METHODS: Three subjects with a history of ethambutol ({{A}}-induced optic neuropathy of short-, intermediate-, and long-term {{B}} were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed optic neuropathy of short-, intermediate-, and long-term ')\n",
      "[1, 60]\n",
      "1\n",
      "0 76 {{A}}-induced optic neuropathy of short-, intermediate-, and long-term {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 60 ed optic neuropathy of short-, intermediate-, and long-term \n",
      "5 5 {{B}}\n",
      "437 {{A}} induced prolonged {{B}} in a patient receiving electroconvulsive therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed prolonged ')\n",
      "[1, 13]\n",
      "1\n",
      "0 29 {{A}} induced prolonged {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 13 ed prolonged \n",
      "5 5 {{B}}\n",
      "438 {{B}} associated with {{A}} administration during saline-induced abortion.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "439 Water intoxication associated with {{A}} administration during saline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during saline-', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} administration during saline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  administration during saline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "450 The protective effect of oral administration of the thiol compound {{A}} (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}} under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (MESNA) against urothelial toxicity ', u'ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable ')\n",
      "[37, 75]\n",
      "37\n",
      "0 127 {{A}} (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  (MESNA) against urothelial toxicity \n",
      "3 5 induc\n",
      "4 75 ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable \n",
      "5 5 {{B}}\n",
      "451 The protective effect of oral administration of the thiol compound {{A}} (MESNA) against {{B}} induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "452 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate ({{A}} against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}} under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' against urothelial toxicity ', u'ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable ')\n",
      "[29, 75]\n",
      "29\n",
      "0 119 {{A}} against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  against urothelial toxicity \n",
      "3 5 induc\n",
      "4 75 ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable \n",
      "5 5 {{B}}\n",
      "453 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate ({{A}} against {{B}} induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "454 The protective effect of oral administration of the {{A}} compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}} under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity ', u'ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable ')\n",
      "[81, 75]\n",
      "75\n",
      "0 171 {{A}} compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}}\n",
      "1 5 {{A}}\n",
      "2 81  compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity \n",
      "3 5 induc\n",
      "4 75 ed by ifosfamide (IF) was tested in a group of 45 patients with inoperable \n",
      "5 5 {{B}}\n",
      "455 The protective effect of oral administration of the {{A}} compound sodium 2-mercaptoethane sulphonate (MESNA) against {{B}} induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "456 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by {{A}} (IF) was tested in a group of 45 patients with inoperable {{B}} under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "457 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against {{B}} induced by {{A}} (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "458 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide ({{A}} was tested in a group of 45 patients with inoperable {{B}} under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "459 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against {{B}} induced by ifosfamide ({{A}} was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "460 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable {{B}} under treatment with {{A}} (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "461 The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against {{B}} induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with {{A}} (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "490 Effect of {{A}} treatment on collagenase-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment on collagenase-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} treatment on collagenase-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  treatment on collagenase-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "510 {{B}} induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "511 {{B}} induced by antithyroid drugs: four cases including one with cross-reactivity between {{A}} and benzylthiouracil.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "517 Remission induction of {{B}} with high-dose intravenous {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "531 Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on {{A}}- and carbamazepine-induced {{B}} and oxidative stress in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and carbamazepine-', u'ed ')\n",
      "[20, 3]\n",
      "3\n",
      "0 38 {{A}}- and carbamazepine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 20 - and carbamazepine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "532 Therefore, the present study was carried out to investigate the effect of chronic {{A}} administration on phenobarbitone- and carbamazepine-induced {{B}} and oxidative stress in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration on phenobarbitone- and carbamazepine-', u'ed ')\n",
      "[53, 3]\n",
      "3\n",
      "0 71 {{A}} administration on phenobarbitone- and carbamazepine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 53  administration on phenobarbitone- and carbamazepine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "542 Their ester prodrugs 6 and 8 were orally active in three models of {{B}}: reversal of formalin-induced paw licking, {{A}} thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "543 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, {{A}} {{B}}, and capsaicin-induced mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "544 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, {{A}} thermal hyperalgesia, and capsaicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' thermal hyperalgesia, and capsaicin-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} thermal hyperalgesia, and capsaicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  thermal hyperalgesia, and capsaicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "545 Their ester prodrugs 6 and 8 were orally active in three models of {{B}}: reversal of {{A}} paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "546 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of {{A}} paw licking, carrageenan-induced {{B}}, and capsaicin-induced mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' paw licking, carrageenan-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} paw licking, carrageenan-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  paw licking, carrageenan-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "547 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of {{A}} paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-', u'ed ')\n",
      "[70, 3]\n",
      "3\n",
      "0 88 {{A}} paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 70  paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "548 Their ester prodrugs 6 and 8 were orally active in three models of {{B}}: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and {{A}} mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "549 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced {{B}}, and {{A}} mechanical hyperalgesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "550 Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "553 Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of {{A}} therapy may be involved in the development of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "554 Using macaque monkeys with different types of MPTP-induced {{B}}, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of {{A}} therapy may be involved in the development of LIDs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "565 Effects of {{A}} channel blockers on bupivacaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blockers on bupivacaine-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} channel blockers on bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  channel blockers on bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "583 {{A}} (AZT)-induced {{B}} in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AZT)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (AZT)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (AZT)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "584 Azidothymidine ({{A}}-induced {{B}} in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "608 {{A}} in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "613 Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by {{A}} (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced {{B}}, and raised spontaneous nocturnal activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "614 Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field {{B}} caused by {{A}} (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "635 In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-{{A}} significantly attenuated cocaine-induced {{B}} and locomotor activity, but not lethality.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly attenuated cocaine-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} significantly attenuated cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  significantly attenuated cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "637 In behavioral studies, pretreatment of Swiss Webster mice with {{A}} or (+/-)-SM 21 significantly attenuated cocaine-induced {{B}} and locomotor activity, but not lethality.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or (+/-)-SM 21 significantly attenuated cocaine-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}} or (+/-)-SM 21 significantly attenuated cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49  or (+/-)-SM 21 significantly attenuated cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "660 What is less well known is a phenomenon whereby {{A}} may induce a {{B}}, which persists or may progress after stopping the drug.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may ', u'e a ')\n",
      "[5, 4]\n",
      "4\n",
      "0 24 {{A}} may induce a {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  may \n",
      "3 5 induc\n",
      "4 4 e a \n",
      "5 5 {{B}}\n",
      "668 CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "669 CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of {{A}} in doxorubicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in doxorubicin-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} in doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  in doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "675 The {{B}} induced by {{A}} antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "676 The catalepsy induced by {{A}} antagonists has been tested and the possible dopamine subtypes involved in {{B}} was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "677 The {{B}} induced by dopamine antagonists has been tested and the possible {{A}} subtypes involved in catalepsy was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "678 The catalepsy induced by dopamine antagonists has been tested and the possible {{A}} subtypes involved in {{B}} was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "691 CONCLUSION: Patients with tamoxifen-induced {{B}} may be at increased risk for granulosa cell tumors because of alterations in {{A}} metabolism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "692 CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for {{B}} because of alterations in {{A}} metabolism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "693 {{A}} (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}} when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, ', u'es ')\n",
      "[81, 3]\n",
      "3\n",
      "0 99 {{A}} (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 81  (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "694 Aspirin ({{A}} [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}} when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, ', u'es ')\n",
      "[59, 3]\n",
      "3\n",
      "0 77 {{A}} [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 59  [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "695 Aspirin (acetylsalicylic acid [{{A}}), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}} when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'), an irreversible cyclooxygenase 1 and 2 inhibitor, ', u'es ')\n",
      "[53, 3]\n",
      "3\n",
      "0 71 {{A}}), an irreversible cyclooxygenase 1 and 2 inhibitor, induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 53 ), an irreversible cyclooxygenase 1 and 2 inhibitor, \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "713 The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor {{B}} induced by {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "762 OBJECTIVE: In this study the effect of {{A}} on the prostigmine-morphine-induced {{B}} was evaluated in nine female patients with sphincter of Oddi dyskinesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on the prostigmine-morphine-', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} on the prostigmine-morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  on the prostigmine-morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "763 OBJECTIVE: In this study the effect of {{A}} on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on the prostigmine-morphine-', u'ed sphincter of Oddi spasm was evaluated in nine female patients with ')\n",
      "[29, 70]\n",
      "29\n",
      "0 114 {{A}} on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  on the prostigmine-morphine-\n",
      "3 5 induc\n",
      "4 70 ed sphincter of Oddi spasm was evaluated in nine female patients with \n",
      "5 5 {{B}}\n",
      "788 Drug-induced {{B}}, although common, has been reported only infrequently with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "791 Twenty-four patients were anaesthetized for middle-ear surgery with deliberate {{B}} induced by labetalol with {{A}} (hypotensive group).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "792 Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with {{A}} ({{B}} group).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "793 Twenty-four patients were anaesthetized for middle-ear surgery with deliberate {{B}} induced by {{A}} with isoflurane (hypotensive group).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "794 Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by {{A}} with isoflurane ({{B}} group).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "802 Effect of nondopaminergic drugs on L-dopa-induced {{B}} in {{A}} monkeys.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "841 {{A}} induced {{B}} without concomitant use of QT interval-prolonging drug.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "855 We postulate that by virtue of its direct blocking action on IKr, {{A}} alone may prolong QT interval and induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' alone may prolong QT interval and ', u'e ')\n",
      "[35, 2]\n",
      "2\n",
      "0 52 {{A}} alone may prolong QT interval and induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  alone may prolong QT interval and \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "856 Thus, the {{B}} induced by {{A}} has a different pathogenetic mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "859 Dose-related beneficial and adverse effects of dietary {{A}} on organophosphorus-induced delayed {{B}} in chickens.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on organophosphorus-', u'ed delayed ')\n",
      "[21, 11]\n",
      "11\n",
      "0 47 {{A}} on organophosphorus-induced delayed {{B}}\n",
      "1 5 {{A}}\n",
      "2 21  on organophosphorus-\n",
      "3 5 induc\n",
      "4 11 ed delayed \n",
      "5 5 {{B}}\n",
      "866 Calcitonin injection resulted in a potentiation of {{A}} catalepsy and a partial prevention of apomorphine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' catalepsy and a partial prevention of apomorphine-', u'ed ')\n",
      "[51, 3]\n",
      "3\n",
      "0 69 {{A}} catalepsy and a partial prevention of apomorphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 51  catalepsy and a partial prevention of apomorphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "867 Calcitonin injection resulted in a potentiation of {{A}} {{B}} and a partial prevention of apomorphine-induced hyperactivity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "868 Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "869 Calcitonin injection resulted in a potentiation of haloperidol-induced {{B}} and a partial prevention of {{A}} hyperactivity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "873 {{A}} has been shown to reduce ST-segment elevation during acute {{B}}, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "874 {{A}} has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-', u'ed ')\n",
      "[153, 3]\n",
      "3\n",
      "0 171 {{A}} has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 153  has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "890 The results indicate that {{B}} induced by labetalol with {{A}} has no significant harmful effects on mental functions compared to normotensive anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "891 The results indicate that {{B}} induced by {{A}} with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "900 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with {{B}} induced by coadministration of {{A}} and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "901 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating {{B}} and ulcer in rats with atherosclerosis induced by coadministration of {{A}} and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "902 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and {{B}} in rats with atherosclerosis induced by coadministration of {{A}} and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "903 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell {{A}} release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with {{B}} induced by coadministration of vitamin D2 and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "904 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell {{A}} release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating {{B}} and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "905 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell {{A}} release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and {{B}} in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "906 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with {{B}} induced by coadministration of vitamin D2 and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "907 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating {{B}} and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "908 The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and {{B}} in rats with atherosclerosis induced by coadministration of vitamin D2 and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "919 Since the administration of {{A}}, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-', u'ed ')\n",
      "[197, 3]\n",
      "3\n",
      "0 215 {{A}}, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 197 , at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "920 Since the administration of {{A}}, at all doses studied, did not alter MBP and {{B}} at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "921 Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of {{A}}, a specific antagonist of PAF, against bupivacaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a specific antagonist of PAF, against bupivacaine-', u'ed ')\n",
      "[52, 3]\n",
      "3\n",
      "0 70 {{A}}, a specific antagonist of PAF, against bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 52 , a specific antagonist of PAF, against bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "922 Since the administration of BN 52021, at all doses studied, did not alter MBP and {{B}} at the doses used, the bulk of these results clearly demonstrate a protective action of {{A}}, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "956 In conclusion, {{A}} induced {{B}} are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "957 In conclusion, {{A}} induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous {{B}}, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous ')\n",
      "[1, 104]\n",
      "1\n",
      "0 120 {{A}} induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 104 ed gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous \n",
      "5 5 {{B}}\n",
      "958 In conclusion, {{A}} induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some {{B}} containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some ')\n",
      "[1, 195]\n",
      "1\n",
      "0 211 {{A}} induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 195 ed gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some \n",
      "5 5 {{B}}\n",
      "959 In conclusion, octreotide induced {{B}} are generally small, multiple, and {{A}} rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "960 In conclusion, octreotide induced gall stones are generally small, multiple, and {{A}} rich although, in common with spontaneous {{B}}, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "961 In conclusion, octreotide induced gall stones are generally small, multiple, and {{A}} rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some {{B}} containing calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "962 In conclusion, octreotide induced {{B}} are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "963 In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous {{B}}, at presentation some patients will have a blocked cystic duct and some gall stones containing {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "964 In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some {{B}} containing {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "975 {{A}} (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-', u'ed ')\n",
      "[114, 3]\n",
      "3\n",
      "0 132 {{A}} (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 114  (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "976 UM-272 ({{A}}, a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-', u'ed ')\n",
      "[88, 3]\n",
      "3\n",
      "0 106 {{A}}, a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 88 , a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "982 Four cases of {{B}} in connection with {{A}} administration during saline-induced abortions are described.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "983 Four cases of water intoxication in connection with {{A}} administration during saline-induced {{B}} are described.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during saline-', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} administration during saline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  administration during saline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "986 We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced {{B}} in patients with acute leukemia treated with a {{A}} (DNR)-containing regimen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "987 We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with {{B}} treated with a {{A}} (DNR)-containing regimen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "988 We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced {{B}} in patients with acute leukemia treated with a daunorubicin ({{A}}-containing regimen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "989 We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with {{B}} treated with a daunorubicin ({{A}}-containing regimen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1005 Improvement of levodopa-induced dyskinesia by {{A}} in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1006 Improvement of levodopa-induced {{B}} by {{A}} in Parkinson's disease.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1027 {{A}}-, scopolamine- and ageing-induced {{B}} served as the interoceptive behavioral models.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, scopolamine- and ageing-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}}-, scopolamine- and ageing-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27 -, scopolamine- and ageing-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1028 Diazepam-, {{A}}- and ageing-induced {{B}} served as the interoceptive behavioral models.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and ageing-', u'ed ')\n",
      "[13, 3]\n",
      "3\n",
      "0 31 {{A}}- and ageing-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 13 - and ageing-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1061 Physicians who use {{A}} to treat patients with {{B}} should be aware of the signs of sulfasalazine-induced lupus syndrome.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1062 Physicians who use {{A}} to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-', u'ed ')\n",
      "[97, 3]\n",
      "3\n",
      "0 115 {{A}} to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 97  to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1097 In the course of developing this model, a common vehicle, {{A}}, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', by itself in high doses, was found to exhibit protective properties against ', u'ed seizures and inhibited ')\n",
      "[78, 26]\n",
      "26\n",
      "0 119 {{A}}, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited {{B}}\n",
      "1 5 {{A}}\n",
      "2 78 , by itself in high doses, was found to exhibit protective properties against \n",
      "3 5 induc\n",
      "4 26 ed seizures and inhibited \n",
      "5 5 {{B}}\n",
      "1098 In the course of developing this model, a common vehicle, {{A}}, by itself in high doses, was found to exhibit protective properties against induced {{B}} and inhibited weight gain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', by itself in high doses, was found to exhibit protective properties against ', u'ed ')\n",
      "[78, 3]\n",
      "3\n",
      "0 96 {{A}}, by itself in high doses, was found to exhibit protective properties against induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 78 , by itself in high doses, was found to exhibit protective properties against \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1099 STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with {{A}} 1 microg/kg and the effect of gender on the incidence of {{B}} after anesthesia induction with etomidate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1100 STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of {{B}} after anesthesia induction with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1142 A prospective study on the dose dependency of {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1143 CONCLUSION: Dexamethasone in combination with {{A}} was efficient in blocking IFS-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was efficient in blocking IFS-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} was efficient in blocking IFS-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  was efficient in blocking IFS-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1144 CONCLUSION: {{A}} in combination with mesna was efficient in blocking IFS-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in combination with mesna was efficient in blocking IFS-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} in combination with mesna was efficient in blocking IFS-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  in combination with mesna was efficient in blocking IFS-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1163 {{B}} induced by {{A}} on the second day of treatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1164 Postpartum {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1167 When coadministered with AZT from the onset of drug administration, {{A}} reduced AZT-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reduced AZT-', u'ed ')\n",
      "[13, 3]\n",
      "3\n",
      "0 31 {{A}} reduced AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 13  reduced AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1168 When coadministered with {{A}} from the onset of drug administration, BAU reduced AZT-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' from the onset of drug administration, BAU reduced AZT-', u'ed ')\n",
      "[56, 3]\n",
      "3\n",
      "0 74 {{A}} from the onset of drug administration, BAU reduced AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 56  from the onset of drug administration, BAU reduced AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1175 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of {{A}} {{B}}, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1176 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of {{A}} cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-', u'ed ')\n",
      "[132, 3]\n",
      "3\n",
      "0 150 {{A}} cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 132  cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1177 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of {{A}} cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac {{B}} and apoptosis after induction of DOX-induced cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1178 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX {{B}}, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of {{A}} cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1179 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1180 To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac {{B}} and apoptosis after induction of {{A}} cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1211 In a 12-week controlled study {{A}} was compared to benztropine in the treatment of {{B}} induced by fluphenazine enanthate in 60 schizophrenic outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1212 In a 12-week controlled study {{A}} was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 {{B}} outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was compared to benztropine in the treatment of parkinsonism ', u'ed by fluphenazine enanthate in 60 ')\n",
      "[62, 35]\n",
      "35\n",
      "0 112 {{A}} was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  was compared to benztropine in the treatment of parkinsonism \n",
      "3 5 induc\n",
      "4 35 ed by fluphenazine enanthate in 60 \n",
      "5 5 {{B}}\n",
      "1213 In a 12-week controlled study ethopropazine was compared to {{A}} in the treatment of {{B}} induced by fluphenazine enanthate in 60 schizophrenic outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1214 In a 12-week controlled study ethopropazine was compared to {{A}} in the treatment of parkinsonism induced by fluphenazine enanthate in 60 {{B}} outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in the treatment of parkinsonism ', u'ed by fluphenazine enanthate in 60 ')\n",
      "[34, 35]\n",
      "34\n",
      "0 84 {{A}} in the treatment of parkinsonism induced by fluphenazine enanthate in 60 {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  in the treatment of parkinsonism \n",
      "3 5 induc\n",
      "4 35 ed by fluphenazine enanthate in 60 \n",
      "5 5 {{B}}\n",
      "1215 In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of {{B}} induced by {{A}} in 60 schizophrenic outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1216 In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by {{A}} in 60 {{B}} outpatients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1247 No changes in haloperidol-induced {{B}} or {{A}} locomotion were seen following PD.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1248 No changes in {{A}} {{B}} or MK-801-induced locomotion were seen following PD.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1261 Transient platypnea-orthodeoxia-like syndrome induced by {{A}} {{B}} in a young woman with Ebstein's anomaly.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1262 Transient platypnea-orthodeoxia-like syndrome induced by {{A}} overdose in a young woman with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1284 Large doses of {{A}} repeatedly induced brief episodes of {{B}} in a depressed elderly woman.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' repeatedly ', u'ed brief episodes of ')\n",
      "[12, 21]\n",
      "12\n",
      "0 48 {{A}} repeatedly induced brief episodes of {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  repeatedly \n",
      "3 5 induc\n",
      "4 21 ed brief episodes of \n",
      "5 5 {{B}}\n",
      "1285 Large doses of {{A}} repeatedly induced brief episodes of mania in a {{B}} elderly woman.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' repeatedly ', u'ed brief episodes of mania in a ')\n",
      "[12, 32]\n",
      "12\n",
      "0 59 {{A}} repeatedly induced brief episodes of mania in a {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  repeatedly \n",
      "3 5 induc\n",
      "4 32 ed brief episodes of mania in a \n",
      "5 5 {{B}}\n",
      "1288 CONCLUSION: These results provide the first evidence of the effectiveness of {{A}} on the morphine-induced {{B}} in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on the morphine-', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}} on the morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  on the morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1327 CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and {{A}} induced {{B}} in patients with hepatitis C and we could not find any relation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1328 CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and {{A}} induced anemia in patients with {{B}} and we could not find any relation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed anemia in patients with ')\n",
      "[1, 27]\n",
      "1\n",
      "0 43 {{A}} induced anemia in patients with {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 27 ed anemia in patients with \n",
      "5 5 {{B}}\n",
      "1331 Drug-induced arterial {{B}} relieved by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1365 This suggests that {{A}} is not the anticholinergic drug of choice in the treatment of neuroleptic-induced {{B}}, because of its more toxic central and peripheral atropinic effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is not the anticholinergic drug of choice in the treatment of neuroleptic-', u'ed ')\n",
      "[75, 3]\n",
      "3\n",
      "0 93 {{A}} is not the anticholinergic drug of choice in the treatment of neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 75  is not the anticholinergic drug of choice in the treatment of neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1369 Based on a score of 8 on the Naranjo adverse drug reaction probability scale, {{A}} was the probable cause of acute {{B}} in this patient, and pathological findings suggested drug-induced toxic hepatitis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1370 Based on a score of 8 on the Naranjo adverse drug reaction probability scale, {{A}} was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-', u'ed ')\n",
      "[101, 3]\n",
      "3\n",
      "0 119 {{A}} was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 101  was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1376 The role of the renin--{{A}} system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced {{B}} was evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-', u'ed ')\n",
      "[104, 3]\n",
      "3\n",
      "0 122 {{A}} system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 104  system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1377 The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and {{A}} (SNP)-induced {{B}} was evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (SNP)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (SNP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (SNP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1378 The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ({{A}}-induced {{B}} was evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1379 The role of the renin--angiotensin system in the maintenance of blood pressure during {{A}} anesthesia and sodium nitroprusside (SNP)-induced {{B}} was evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' anesthesia and sodium nitroprusside (SNP)-', u'ed ')\n",
      "[43, 3]\n",
      "3\n",
      "0 61 {{A}} anesthesia and sodium nitroprusside (SNP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 43  anesthesia and sodium nitroprusside (SNP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1380 There are no previous reports of {{A}} {{B}} in a child undergoing induction of anesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1384 Two patients had a {{B}} induced by {{A}} (N  omercazole).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1385 Two patients had a {{B}} induced by carbimazole ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1397 {{A}} (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to ', u'e ')\n",
      "[135, 2]\n",
      "2\n",
      "0 152 {{A}} (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 135  (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1398 Cyclophosphamide ({{A}}, an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to ', u'e ')\n",
      "[130, 2]\n",
      "2\n",
      "0 147 {{A}}, an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 130 , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1399 Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite {{A}}, was used to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', was used to ', u'e ')\n",
      "[14, 2]\n",
      "2\n",
      "0 31 {{A}}, was used to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 , was used to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1401 Evidence for an involvement of D1 and D2 {{A}} receptors in mediating nicotine-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors in mediating nicotine-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} receptors in mediating nicotine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  receptors in mediating nicotine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1409 BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with {{A}}, {{B}} occurs frequently.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1444 Effects of the hippocampal deep brain stimulation on cortical {{B}} discharges in {{A}} - induced epilepsy model in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1445 Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in {{A}} - induced {{B}} model in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' - ', u'ed ')\n",
      "[3, 3]\n",
      "3\n",
      "0 21 {{A}} - induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 3  - \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1456 Changes in peroxisomes in preneoplastic liver and {{B}} of mice induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1458 BACKGROUND: {{A}} induces a self-perpetuating {{B}} characterized by early glomerular and late-onset tubular lesions in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es a self-perpetuating ')\n",
      "[1, 23]\n",
      "1\n",
      "0 39 {{A}} induces a self-perpetuating {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 23 es a self-perpetuating \n",
      "5 5 {{B}}\n",
      "1459 RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of {{B}} (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with {{A}} (mean dose 2.13 +/- 0.09 mg/week).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1460 RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) {{B}} or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with {{A}} (mean dose 2.13 +/- 0.09 mg/week).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1461 RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or {{B}}, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with {{A}} (mean dose 2.13 +/- 0.09 mg/week).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1465 DISCUSSION: Although there is increasing evidence of {{B}} induced by {{A}}, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1466 DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by {{A}}, this is the first case of fatality that could have resulted from {{B}} in a patient receiving bupropion while on concomitant treatment with carbimazole.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1467 DISCUSSION: Although there is increasing evidence of {{B}} induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving {{A}} while on concomitant treatment with carbimazole.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1468 DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from {{B}} in a patient receiving {{A}} while on concomitant treatment with carbimazole.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1469 DISCUSSION: Although there is increasing evidence of {{B}} induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1470 DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from {{B}} in a patient receiving bupropion while on concomitant treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1480 Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with {{A}} (CYP)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CYP)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (CYP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (CYP)-\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1481 Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide ({{A}}-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1482 {{A}} {{B}} (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1483 {{A}} paranoia ({{B}} remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1484 {{A}} paranoia (CIP) remains an important drug-induced model of {{B}} for which no psychophysiologic marker has yet emerged.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' paranoia (CIP) remains an important drug-', u'ed model of ')\n",
      "[42, 12]\n",
      "12\n",
      "0 69 {{A}} paranoia (CIP) remains an important drug-induced model of {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  paranoia (CIP) remains an important drug-\n",
      "3 5 induc\n",
      "4 12 ed model of \n",
      "5 5 {{B}}\n",
      "1500 Peroxisomes in hepatomas and {{B}} induced in mice by 500 ppm {{A}} were examined histochemically and electron microscopically.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1501 Peroxisomes in {{B}} and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm {{A}} were examined histochemically and electron microscopically.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1511 {{A}} prevents {{B}} caused by nitroglycerin-induced hypotension in adult mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1512 {{A}} prevents memory impairment caused by nitroglycerin-induced {{B}} in adult mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevents memory impairment caused by nitroglycerin-', u'ed ')\n",
      "[52, 3]\n",
      "3\n",
      "0 70 {{A}} prevents memory impairment caused by nitroglycerin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 52  prevents memory impairment caused by nitroglycerin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1522 Treatment of ifosfamide-induced urothelial toxicity by oral administration of {{A}} (MESNA) to patients with inoperable {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1523 Treatment of ifosfamide-induced {{B}} by oral administration of {{A}} (MESNA) to patients with inoperable lung cancer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1524 Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate ({{A}} to patients with inoperable {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1525 Treatment of ifosfamide-induced {{B}} by oral administration of sodium 2-mercaptoethane sulphonate ({{A}} to patients with inoperable lung cancer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1529 The nephroprotective effect of {{A}} was investigated in mice with {{B}} induced by a single i.p. injection of cisplatin (5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1530 The nephroprotective effect of coenzyme Q10 was investigated in mice with {{B}} induced by a single i.p. injection of {{A}} (5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1531 CONCLUSION: Pericarditis may be the initial manifestation of drug-induced {{B}} attributable to {{A}} therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1532 CONCLUSION: {{B}} may be the initial manifestation of drug-induced vasculitis attributable to {{A}} therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1551 Differential effects of {{A}} (lindane) on pharmacologically-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (lindane) on pharmacologically-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} (lindane) on pharmacologically-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  (lindane) on pharmacologically-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1552 Differential effects of gamma-hexachlorocyclohexane ({{A}} on pharmacologically-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on pharmacologically-', u'ed ')\n",
      "[22, 3]\n",
      "3\n",
      "0 40 {{A}} on pharmacologically-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  on pharmacologically-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1568 {{A}} (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease {{B}} threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1569 {{A}} (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-', u'ed ')\n",
      "[207, 3]\n",
      "3\n",
      "0 225 {{A}} (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 207  (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1570 Gamma-hexachlorocyclohexane ({{A}}, the active ingredient of the insecticide lindane, has been shown to decrease {{B}} threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1571 Gamma-hexachlorocyclohexane ({{A}}, the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-', u'ed ')\n",
      "[195, 3]\n",
      "3\n",
      "0 213 {{A}}, the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 195 , the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1572 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide {{A}}, has been shown to decrease {{B}} threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1573 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide {{A}}, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-', u'ed ')\n",
      "[145, 3]\n",
      "3\n",
      "0 163 {{A}}, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 145 , has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1574 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease {{B}} threshold to pentylenetrazol (PTZ) 3 h after exposure to {{A}} and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1575 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to {{A}} and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and conversely increase threshold to PTZ-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} and conversely increase threshold to PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  and conversely increase threshold to PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1576 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease {{B}} threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to {{A}} (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1577 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to {{A}} (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1578 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease {{B}} threshold to pentylenetrazol ({{A}} 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1579 Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol ({{A}} 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}} 24 h after exposure to gamma-HCH (Vohland et al. 1981).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-', u'ed ')\n",
      "[74, 3]\n",
      "3\n",
      "0 92 {{A}} 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 74  3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1612 In this study we postulated that during {{B}} induced by {{A}} the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1618 {{A}} induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but {{B}} persisted in this patient for ten years after lithium was stopped.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but ')\n",
      "[1, 93]\n",
      "1\n",
      "0 109 {{A}} induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 93 ed nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but \n",
      "5 5 {{B}}\n",
      "1619 {{A}} induced {{B}} is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1620 Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but {{B}} persisted in this patient for ten years after {{A}} was stopped.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1621 Lithium induced {{B}} is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after {{A}} was stopped.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1622 This is a case report of euphoria and {{B}} both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing {{A}} and cocaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1623 This is a case report of euphoria and {{B}} both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist {{A}} in an inpatient previously abusing heroine and cocaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1624 This is a case report of euphoria and {{B}} both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1625 We examined the abundance of ENaC subunit mRNAs and proteins in {{A}} (PAN)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PAN)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (PAN)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (PAN)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1626 We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ({{A}}-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1627 Interestingly, all the drugs, such as, AAP, {{A}} and DOX induced apoptotic {{B}} in addition to necrosis in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and DOX ', u'ed apoptotic ')\n",
      "[9, 13]\n",
      "9\n",
      "0 37 {{A}} and DOX induced apoptotic {{B}}\n",
      "1 5 {{A}}\n",
      "2 9  and DOX \n",
      "3 5 induc\n",
      "4 13 ed apoptotic \n",
      "5 5 {{B}}\n",
      "1628 Interestingly, all the drugs, such as, AAP, {{A}} and DOX induced apoptotic death in addition to {{B}} in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and DOX ', u'ed apoptotic death in addition to ')\n",
      "[9, 34]\n",
      "9\n",
      "0 58 {{A}} and DOX induced apoptotic death in addition to {{B}}\n",
      "1 5 {{A}}\n",
      "2 9  and DOX \n",
      "3 5 induc\n",
      "4 34 ed apoptotic death in addition to \n",
      "5 5 {{B}}\n",
      "1629 Interestingly, all the drugs, such as, {{A}}, AMI and DOX induced apoptotic {{B}} in addition to necrosis in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', AMI and DOX ', u'ed apoptotic ')\n",
      "[14, 13]\n",
      "13\n",
      "0 42 {{A}}, AMI and DOX induced apoptotic {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 , AMI and DOX \n",
      "3 5 induc\n",
      "4 13 ed apoptotic \n",
      "5 5 {{B}}\n",
      "1630 Interestingly, all the drugs, such as, {{A}}, AMI and DOX induced apoptotic death in addition to {{B}} in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', AMI and DOX ', u'ed apoptotic death in addition to ')\n",
      "[14, 34]\n",
      "14\n",
      "0 63 {{A}}, AMI and DOX induced apoptotic death in addition to {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 , AMI and DOX \n",
      "3 5 induc\n",
      "4 34 ed apoptotic death in addition to \n",
      "5 5 {{B}}\n",
      "1631 Interestingly, all the drugs, such as, AAP, AMI and {{A}} induced apoptotic {{B}} in addition to necrosis in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed apoptotic ')\n",
      "[1, 13]\n",
      "1\n",
      "0 29 {{A}} induced apoptotic {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 13 ed apoptotic \n",
      "5 5 {{B}}\n",
      "1632 Interestingly, all the drugs, such as, AAP, AMI and {{A}} induced apoptotic death in addition to {{B}} in the respective organs which was very effectively blocked by GSPE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed apoptotic death in addition to ')\n",
      "[1, 34]\n",
      "1\n",
      "0 50 {{A}} induced apoptotic death in addition to {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 34 ed apoptotic death in addition to \n",
      "5 5 {{B}}\n",
      "1633 Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic {{B}} in addition to necrosis in the respective organs which was very effectively blocked by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1634 Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to {{B}} in the respective organs which was very effectively blocked by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1640 In the present study, the possible enhancement by {{A}} of {{B}} induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1641 In the present study, the possible enhancement by isoniazid of {{B}} induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1693 {{B}} was induced by {{A}} (2.5 mg/kg i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1694 METHODS: We undertook a retrospective case review of four children with risperidone-induced {{B}} treated with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1700 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and {{B}} (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1701 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia ({{B}}, MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1702 RESULTS: The literature evaluation suggested that NSAIDs induce {{B}} (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1703 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects ({{B}} and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1704 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and {{B}} in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1705 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these {{B}}, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1706 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es several other low-incidence ')\n",
      "[1, 31]\n",
      "1\n",
      "0 47 {{A}} induces several other low-incidence {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 31 es several other low-incidence \n",
      "5 5 {{B}}\n",
      "1707 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and {{B}} (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1708 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects ({{B}} in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1709 RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), {{B}}, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though {{A}} induces several other low-incidence malformations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1718 Early onset {{B}} attacks were induced by {{A}} in seven out of 10 patients versus no patient in the placebo group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1721 Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the {{A}} modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-', u'ed secondary ')\n",
      "[109, 13]\n",
      "13\n",
      "0 137 {{A}} modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary {{B}}\n",
      "1 5 {{A}}\n",
      "2 109  modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-\n",
      "3 5 induc\n",
      "4 13 ed secondary \n",
      "5 5 {{B}}\n",
      "1722 Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and {{A}} secondary {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1723 {{A}} also reduced the {{B}} induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1724 KF17837 also reduced the {{B}} induced by {{A}} (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1725 KF17837 also reduced the {{B}} induced by haloperidol (1 mg/kg i.p.) and by {{A}} (5 mg/kg i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1743 Although the explanation for the association between {{B}} and growth status cannot be determined from the present study, there was a relationship between higher serum {{A}} and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1744 Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum {{A}} and susceptibility to {{B}}, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1745 Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum {{A}} and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced {{B}}, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-', u'ed ')\n",
      "[183, 3]\n",
      "3\n",
      "0 201 {{A}} and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 183  and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1746 Although the explanation for the association between {{B}} and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum {{A}} in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1747 Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to {{B}}, with 30% higher levels of serum {{A}} in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1748 Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum {{A}} in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced {{B}}, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-', u'ed ')\n",
      "[97, 3]\n",
      "3\n",
      "0 115 {{A}} in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 97  in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1756 Serotonergic drugs, {{A}} and baclofen block muscimol-induced {{B}} in a strain of mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and baclofen block muscimol-', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} and baclofen block muscimol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  and baclofen block muscimol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1757 Serotonergic drugs, benzodiazepines and {{A}} block muscimol-induced {{B}} in a strain of mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' block muscimol-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} block muscimol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  block muscimol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1760 Ten and 5 mg/kg i.v. (+)-{{A}} suppressed digitalis- and adrenaline-induced {{B}}, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' suppressed digitalis- and adrenaline-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} suppressed digitalis- and adrenaline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  suppressed digitalis- and adrenaline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1765 This observation suggests that increased susceptibility to Warfarin-induced {{B}} could be related to higher serum {{A}} levels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1770 We report a case of combined {{A}} treatment-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment-', u'ed ')\n",
      "[11, 3]\n",
      "3\n",
      "0 29 {{A}} treatment-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1771 Acute {{B}} induced by a high-dose infusion of {{A}} and folinic acid.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1772 Acute {{B}} induced by a high-dose infusion of 5-fluorouracil and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1775 Considering the fact that 5-HTP and the {{A}} have been found to be beneficial in the management of clinical {{B}}, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1776 Considering the fact that 5-HTP and the {{A}} have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced {{B}} seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' have been found to be beneficial in the management of clinical myoclonus, the muscimol-', u'ed ')\n",
      "[88, 3]\n",
      "3\n",
      "0 106 {{A}} have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 88  have been found to be beneficial in the management of clinical myoclonus, the muscimol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1781 Epithelial {{A}} channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-', u'ed ')\n",
      "[91, 3]\n",
      "3\n",
      "0 109 {{A}} channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1791 Prostaglandin E2-induced {{B}} in normal, conscious rats: involvement of {{A}}?\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1799 Similarly, pre-test scopolamine partially reversed the scopolamine-induced {{B}}, but not significantly; and pre-test {{A}} failed to reverse the cycloheximide-induced amnesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1800 Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test {{A}} failed to reverse the cycloheximide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' failed to reverse the cycloheximide-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} failed to reverse the cycloheximide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  failed to reverse the cycloheximide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1801 Similarly, pre-test scopolamine partially reversed the scopolamine-induced {{B}}, but not significantly; and pre-test cycloheximide failed to reverse the {{A}} amnesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1802 Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1803 Similarly, pre-test {{A}} partially reversed the scopolamine-induced {{B}}, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' partially reversed the scopolamine-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}} partially reversed the scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  partially reversed the scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1804 Similarly, pre-test {{A}} partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-', u'ed ')\n",
      "[139, 3]\n",
      "3\n",
      "0 157 {{A}} partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 139  partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1805 Similarly, pre-test scopolamine partially reversed the {{A}} {{B}}, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1806 Similarly, pre-test scopolamine partially reversed the {{A}} amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-', u'ed ')\n",
      "[96, 3]\n",
      "3\n",
      "0 114 {{A}} amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 96  amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1837 There was a close parallel between the effect of {{A}} dose on {{B}} and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1838 There was a close parallel between the effect of {{A}} dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce {{B}} through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may ', u'e ')\n",
      "[132, 2]\n",
      "2\n",
      "0 149 {{A}} dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 132  dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1839 There was a close parallel between the effect of vitamin D dose on {{B}} and the effect of {{A}} dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1840 There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of {{A}} dose on the elevation of serum calcium, which suggests that vitamin D may induce {{B}} through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' dose on the elevation of serum calcium, which suggests that vitamin D may ', u'e ')\n",
      "[75, 2]\n",
      "2\n",
      "0 92 {{A}} dose on the elevation of serum calcium, which suggests that vitamin D may induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 75  dose on the elevation of serum calcium, which suggests that vitamin D may \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1841 There was a close parallel between the effect of vitamin D dose on {{B}} and the effect of vitamin D dose on the elevation of serum calcium, which suggests that {{A}} may induce artery calcification through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1842 There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that {{A}} may induce {{B}} through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may ', u'e ')\n",
      "[5, 2]\n",
      "2\n",
      "0 22 {{A}} may induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  may \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1843 There was a close parallel between the effect of vitamin D dose on {{B}} and the effect of vitamin D dose on the elevation of serum {{A}}, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1844 There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum {{A}}, which suggests that vitamin D may induce {{B}} through its effect on serum calcium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', which suggests that vitamin D may ', u'e ')\n",
      "[36, 2]\n",
      "2\n",
      "0 53 {{A}}, which suggests that vitamin D may induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 36 , which suggests that vitamin D may \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "1845 There was a close parallel between the effect of vitamin D dose on {{B}} and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1846 There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce {{B}} through its effect on serum {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1847 {{A}} reversed dex-induced {{B}} (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reversed dex-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} reversed dex-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  reversed dex-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1848 Atorva reversed dex-induced {{B}} (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 {{A}} + dex, P < 0.0001).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1850 Atorva reversed dex-induced {{B}} (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 {{A}}, 1187 +/- 441.2 atorva + dex, P < 0.0001).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1851 Atorva reversed dex-induced {{B}} (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + {{A}}, P < 0.0001).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1852 Atorva reversed dex-induced {{B}} (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma {{A}} (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1853 {{A}} alleviates penile pain induced by intracavernous injections for {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' alleviates penile pain ', u'ed by intracavernous injections for ')\n",
      "[24, 36]\n",
      "24\n",
      "0 75 {{A}} alleviates penile pain induced by intracavernous injections for {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  alleviates penile pain \n",
      "3 5 induc\n",
      "4 36 ed by intracavernous injections for \n",
      "5 5 {{B}}\n",
      "1854 {{A}} alleviates {{B}} induced by intracavernous injections for erectile dysfunction.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1859 Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that {{A}} induces sympathetic withdrawal and {{B}}, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es sympathetic withdrawal and ')\n",
      "[1, 30]\n",
      "1\n",
      "0 46 {{A}} induces sympathetic withdrawal and {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 30 es sympathetic withdrawal and \n",
      "5 5 {{B}}\n",
      "1860 Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and {{B}}, we hypothesized that {{A}} developmental effects on cardiac rate and ultrasound production would mirror each other.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1868 Thus the migraine-inducing effect of {{A}} seems to depend on direct stimulation of the habitual site of {{B}}, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1870 Thus the migraine-inducing effect of {{A}} seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a {{B}} crisis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1880 PURPOSE: We present a case of a patient who developed {{B}} shortly after initiating treatment with {{A}} and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1881 PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with {{A}} and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-', u'ed ')\n",
      "[165, 3]\n",
      "3\n",
      "0 183 {{A}} and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 165  and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1899 TRI given repeatedly to rats {{B}} induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ({{A}} D2 and D3 effects).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1900 TRI given repeatedly to rats {{B}} induced by {{A}}, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1901 {{A}} given repeatedly to rats {{B}} induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1902 TRI given repeatedly to rats {{B}} induced by d-amphetamine, {{A}} and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1903 A prospective, randomized study was conducted to evaluate the role of {{A}} and folinic acid supplementation in preventing zidovudine (ZDV)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and folinic acid supplementation in preventing zidovudine (ZDV)-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} and folinic acid supplementation in preventing zidovudine (ZDV)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  and folinic acid supplementation in preventing zidovudine (ZDV)-\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1904 A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing {{A}} (ZDV)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (ZDV)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (ZDV)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (ZDV)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1905 A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ({{A}}-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1906 A prospective, randomized study was conducted to evaluate the role of vitamin B12 and {{A}} supplementation in preventing zidovudine (ZDV)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' supplementation in preventing zidovudine (ZDV)-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}} supplementation in preventing zidovudine (ZDV)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  supplementation in preventing zidovudine (ZDV)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1907 High doses of {{A}} increase hypotension induced by vasodilators and change the accompanying reflex {{B}} to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' increase hypotension ', u'ed by vasodilators and change the accompanying reflex ')\n",
      "[22, 54]\n",
      "22\n",
      "0 91 {{A}} increase hypotension induced by vasodilators and change the accompanying reflex {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  increase hypotension \n",
      "3 5 induc\n",
      "4 54 ed by vasodilators and change the accompanying reflex \n",
      "5 5 {{B}}\n",
      "1908 High doses of {{A}} increase {{B}} induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1909 High doses of {{A}} increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to {{B}}, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' increase hypotension ', u'ed by vasodilators and change the accompanying reflex tachycardia to ')\n",
      "[22, 69]\n",
      "22\n",
      "0 106 {{A}} increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  increase hypotension \n",
      "3 5 induc\n",
      "4 69 ed by vasodilators and change the accompanying reflex tachycardia to \n",
      "5 5 {{B}}\n",
      "1910 High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex {{B}} to bradycardia, an interaction attributed to decreased synthesis of brain {{A}} (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1911 High doses of isoniazid increase {{B}} induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain {{A}} (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1912 High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to {{B}}, an interaction attributed to decreased synthesis of brain {{A}} (GABA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1913 High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex {{B}} to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1914 High doses of isoniazid increase {{B}} induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1915 High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to {{B}}, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1916 {{A}} reverses azidothymidine-induced {{B}} without impairment of anti-human immunodeficiency virus activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reverses azidothymidine-', u'ed ')\n",
      "[25, 3]\n",
      "3\n",
      "0 43 {{A}} reverses azidothymidine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  reverses azidothymidine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1917 {{A}} reverses azidothymidine-induced marrow suppression without impairment of anti-human {{B}} activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reverses azidothymidine-', u'ed marrow suppression without impairment of anti-human ')\n",
      "[25, 55]\n",
      "25\n",
      "0 95 {{A}} reverses azidothymidine-induced marrow suppression without impairment of anti-human {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  reverses azidothymidine-\n",
      "3 5 induc\n",
      "4 55 ed marrow suppression without impairment of anti-human \n",
      "5 5 {{B}}\n",
      "1920 Increased extracellular concentrations of {{A}} (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}} (HIV) activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-', u'ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman ')\n",
      "[68, 99]\n",
      "68\n",
      "0 182 {{A}} (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}}\n",
      "1 5 {{A}}\n",
      "2 68  (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-\n",
      "3 5 induc\n",
      "4 99 ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman \n",
      "5 5 {{B}}\n",
      "1921 Increased extracellular concentrations of uridine ({{A}} have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}} (HIV) activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' have been reported to reduce, in vitro, azidothymidine (AZT)-', u'ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman ')\n",
      "[62, 99]\n",
      "62\n",
      "0 176 {{A}} have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  have been reported to reduce, in vitro, azidothymidine (AZT)-\n",
      "3 5 induc\n",
      "4 99 ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman \n",
      "5 5 {{B}}\n",
      "1922 Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, {{A}} (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}} (HIV) activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AZT)-', u'ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman ')\n",
      "[7, 99]\n",
      "7\n",
      "0 121 {{A}} (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (AZT)-\n",
      "3 5 induc\n",
      "4 99 ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman \n",
      "5 5 {{B}}\n",
      "1923 Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine ({{A}}-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}} (HIV) activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman ')\n",
      "[1, 99]\n",
      "1\n",
      "0 115 {{A}}-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 99 ed inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman \n",
      "5 5 {{B}}\n",
      "1924 Because of the clinical toxicities associated with chronic Urd administration, the ability of {{A}} (BAU) to effect, in vivo, AZT-induced {{B}} and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (BAU) to effect, in vivo, AZT-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} (BAU) to effect, in vivo, AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  (BAU) to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1925 Because of the clinical toxicities associated with chronic Urd administration, the ability of {{A}} (BAU) to effect, in vivo, AZT-induced anemia and {{B}} was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (BAU) to effect, in vivo, AZT-', u'ed anemia and ')\n",
      "[31, 14]\n",
      "14\n",
      "0 60 {{A}} (BAU) to effect, in vivo, AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  (BAU) to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "1926 Because of the clinical {{B}} associated with chronic Urd administration, the ability of {{A}} (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1927 Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine ({{A}} to effect, in vivo, AZT-induced {{B}} and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to effect, in vivo, AZT-', u'ed ')\n",
      "[25, 3]\n",
      "3\n",
      "0 43 {{A}} to effect, in vivo, AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1928 Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine ({{A}} to effect, in vivo, AZT-induced anemia and {{B}} was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to effect, in vivo, AZT-', u'ed anemia and ')\n",
      "[25, 14]\n",
      "14\n",
      "0 54 {{A}} to effect, in vivo, AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "1929 Because of the clinical {{B}} associated with chronic Urd administration, the ability of benzylacyclouridine ({{A}} to effect, in vivo, AZT-induced anemia and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1930 Because of the clinical toxicities associated with chronic {{A}} administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced {{B}} and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}} administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1931 Because of the clinical toxicities associated with chronic {{A}} administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and {{B}} was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-', u'ed anemia and ')\n",
      "[82, 14]\n",
      "14\n",
      "0 111 {{A}} administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "1932 Because of the clinical {{B}} associated with chronic {{A}} administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1936 Aging process of epithelial cells of the rat prostate lateral lobe in experimental {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1940 Epileptogenic activity of {{A}} after drug induces {{B}} (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' after drug ', u'es ')\n",
      "[12, 3]\n",
      "3\n",
      "0 30 {{A}} after drug induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  after drug \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "1941 Epileptogenic activity of {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural {{B}} and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' after drug ', u'es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural ')\n",
      "[12, 210]\n",
      "12\n",
      "0 237 {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  after drug \n",
      "3 5 induc\n",
      "4 210 es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural \n",
      "5 5 {{B}}\n",
      "1942 Epileptogenic activity of {{A}} after drug induces SLE (folic acid and {{B}} OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' after drug ', u'es SLE (folic acid and ')\n",
      "[12, 23]\n",
      "12\n",
      "0 50 {{A}} after drug induces SLE (folic acid and {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  after drug \n",
      "3 5 induc\n",
      "4 23 es SLE (folic acid and \n",
      "5 5 {{B}}\n",
      "1943 Epileptogenic activity of {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in {{B}} women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' after drug ', u'es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in ')\n",
      "[12, 121]\n",
      "12\n",
      "0 148 {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  after drug \n",
      "3 5 induc\n",
      "4 121 es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in \n",
      "5 5 {{B}}\n",
      "1944 Epileptogenic activity of {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and {{B}} side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' after drug ', u'es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and ')\n",
      "[12, 228]\n",
      "12\n",
      "0 255 {{A}} after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  after drug \n",
      "3 5 induc\n",
      "4 228 es SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and \n",
      "5 5 {{B}}\n",
      "1945 Epileptogenic activity of folic acid after drug induces {{B}} ({{A}} and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1946 Epileptogenic activity of folic acid after drug induces SLE ({{A}} and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural {{B}} and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1947 Epileptogenic activity of folic acid after drug induces SLE ({{A}} and {{B}} OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1948 Epileptogenic activity of folic acid after drug induces SLE ({{A}} and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in {{B}} women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1949 Epileptogenic activity of folic acid after drug induces SLE ({{A}} and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and {{B}} side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1950 Epileptogenic activity of folic acid after drug induces {{B}} (folic acid and epilepsy) OBJECTIVE: To study the effect of {{A}} multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1951 Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of {{A}} multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural {{B}} and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1952 Epileptogenic activity of folic acid after drug induces SLE (folic acid and {{B}} OBJECTIVE: To study the effect of {{A}} multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1953 Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of {{A}} multivitamin supplementation in {{B}} women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1954 Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of {{A}} multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and {{B}} side effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1956 Arterial thromboembolism in patients receiving systemic {{A}} therapy: a complication associated with heparin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy: a complication associated with heparin-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}} therapy: a complication associated with heparin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49  therapy: a complication associated with heparin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1957 Arterial {{B}} in patients receiving systemic {{A}} therapy: a complication associated with heparin-induced thrombocytopenia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1960 While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, {{B}} and behavior, asymmetry of cross-tolerance and a widely-different ID50 for {{A}} would argue against an action at a single opioid site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1961 While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced {{B}}, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for {{A}} would argue against an action at a single opioid site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1967 {{A}} (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}} (MMG) and the enhanced electromyographic activity (EMG).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-', u'ed ')\n",
      "[186, 3]\n",
      "3\n",
      "0 204 {{A}} (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 186  (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1968 5,7-dichlorokynurenic acid ({{A}}, a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}} (MMG) and the enhanced electromyographic activity (EMG).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-', u'ed ')\n",
      "[175, 3]\n",
      "3\n",
      "0 193 {{A}}, a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 175 , a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1969 5,7-dichlorokynurenic acid (5,7-DCKA), a selective {{A}} site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}} (MMG) and the enhanced electromyographic activity (EMG).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-', u'ed ')\n",
      "[154, 3]\n",
      "3\n",
      "0 172 {{A}} site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 154  site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "1983 RESULTS: {{A}} administration induced dose-dependent {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration ', u'ed dose-dependent ')\n",
      "[16, 18]\n",
      "16\n",
      "0 49 {{A}} administration induced dose-dependent {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  administration \n",
      "3 5 induc\n",
      "4 18 ed dose-dependent \n",
      "5 5 {{B}}\n",
      "1987 CONCLUSIONS: {{A}} is {{B}} in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1988 CONCLUSIONS: {{A}} is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that {{B}} is induced in the two drugs by the same mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is neurotoxic in our model, and the type of pathological changes it ', u'es are so closely similar to those caused by CDDP that it is probable that ')\n",
      "[69, 75]\n",
      "69\n",
      "0 159 {{A}} is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that {{B}}\n",
      "1 5 {{A}}\n",
      "2 69  is neurotoxic in our model, and the type of pathological changes it \n",
      "3 5 induc\n",
      "4 75 es are so closely similar to those caused by CDDP that it is probable that \n",
      "5 5 {{B}}\n",
      "1989 CONCLUSIONS: CBDCA is {{B}} in our model, and the type of pathological changes it induces are so closely similar to those caused by {{A}} that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "1990 CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by {{A}} that it is probable that {{B}} is induced in the two drugs by the same mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2020 Attenuation of methamphetamine-induced nigrostriatal dopaminergic {{B}} in mice by {{A}} pretreatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2023 In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2025 In this study, we examined the roles of {{A}}, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-', u'ed nigrostriatal dopamine ')\n",
      "[90, 26]\n",
      "26\n",
      "0 131 {{A}}, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine {{B}}\n",
      "1 5 {{A}}\n",
      "2 90 , a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-\n",
      "3 5 induc\n",
      "4 26 ed nigrostriatal dopamine \n",
      "5 5 {{B}}\n",
      "2026 Digitalis {{B}}, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in {{A}} dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2027 Digitalis {{B}}, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of {{A}} in pentobarbital-anesthetized dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2028 Digitalis {{B}}, which is suppressed by {{A}} channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2041 We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2043 We concluded a critical time window for systemic {{A}} pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment in exerting effective protection against methamphetamine-', u'ed nigrostriatal dopamine ')\n",
      "[71, 26]\n",
      "26\n",
      "0 112 {{A}} pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine {{B}}\n",
      "1 5 {{A}}\n",
      "2 71  pretreatment in exerting effective protection against methamphetamine-\n",
      "3 5 induc\n",
      "4 26 ed nigrostriatal dopamine \n",
      "5 5 {{B}}\n",
      "2078 Patterns of {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2087 Above mentioned {{A}} incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' incorporation may have ', u'ed an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the ')\n",
      "[24, 119]\n",
      "24\n",
      "0 158 {{A}} incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  incorporation may have \n",
      "3 5 induc\n",
      "4 119 ed an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the \n",
      "5 5 {{B}}\n",
      "2099 Anti-oxidant effects of {{A}} in dexamethasone-induced {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in dexamethasone-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} in dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  in dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2101 {{A}} (Dex)-induced {{B}} is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Dex)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (Dex)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (Dex)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2102 Dexamethasone ({{A}}-induced {{B}} is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2103 Dexamethasone (Dex)-induced {{B}} is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased {{A}} (O2-) production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2104 Dexamethasone (Dex)-induced {{B}} is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide ({{A}} production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2105 Dexamethasone (Dex)-induced {{B}} is characterized by endothelial dysfunction associated with {{A}} (NO) deficiency and increased superoxide (O2-) production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2106 Dexamethasone (Dex)-induced {{B}} is characterized by endothelial dysfunction associated with nitric oxide ({{A}} deficiency and increased superoxide (O2-) production.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2143 It was also evident that, by titrating the dose to achieve a maximum tolerated dose, {{B}} that normally occur at low incidence, as reported from previous single dose studies, could also be induced with {{A}} given at multiple doses.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2146 We assessed force coordination of the hand in {{B}} and its relationship to motor complications of {{A}} therapy, particularly to levodopa-induced dyskinesias (LID).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2147 We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of {{A}} therapy, particularly to levodopa-induced {{B}} (LID).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy, particularly to levodopa-', u'ed ')\n",
      "[35, 3]\n",
      "3\n",
      "0 53 {{A}} therapy, particularly to levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  therapy, particularly to levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2148 We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of {{A}} therapy, particularly to levodopa-induced dyskinesias ({{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy, particularly to levodopa-', u'ed dyskinesias (')\n",
      "[35, 16]\n",
      "16\n",
      "0 66 {{A}} therapy, particularly to levodopa-induced dyskinesias ({{B}}\n",
      "1 5 {{A}}\n",
      "2 35  therapy, particularly to levodopa-\n",
      "3 5 induc\n",
      "4 16 ed dyskinesias (\n",
      "5 5 {{B}}\n",
      "2162 We describe the effect of {{A}} and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-', u'ed ')\n",
      "[75, 3]\n",
      "3\n",
      "0 93 {{A}} and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 75  and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2163 We describe the effect of phenylephrine and {{A}} on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on frontal lobe oxygenation (S(c)O(2)) following anesthesia-', u'ed ')\n",
      "[61, 3]\n",
      "3\n",
      "0 79 {{A}} on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  on frontal lobe oxygenation (S(c)O(2)) following anesthesia-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2165 We report a case of a living donor renal transplant recipient who developed cyclosporine-induced {{B}} that responded to the withdrawal of {{A}} in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2168 CONCLUSIONS: The utilization of {{A}} to correct {{B}} induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2169 CONCLUSIONS: The utilization of phenylephrine to correct {{B}} induced by anesthesia has a negative impact on S(c)O(2) while {{A}} maintains frontal lobe oxygenation potentially related to an increase in CO.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2170 CONCLUSIONS: {{A}} is an effective treatment for male {{B}} induced by SSRIs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2171 CONCLUSIONS: Bupropion is an effective treatment for male {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2180 The {{B}} induced by {{A}} (AZT) is poorly understood.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2181 The {{B}} induced by 3'-azido-3'dideoxythymidine ({{A}} is poorly understood.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2184 As a result, switching to {{A}} has been reported to be a viable therapeutic option in the setting of cyclosporine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' has been reported to be a viable therapeutic option in the setting of cyclosporine-', u'ed ')\n",
      "[84, 3]\n",
      "3\n",
      "0 102 {{A}} has been reported to be a viable therapeutic option in the setting of cyclosporine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 84  has been reported to be a viable therapeutic option in the setting of cyclosporine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2186 In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous {{A}} infusions is associated with marked reductions of preexisting levodopa-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' infusions is associated with marked reductions of preexisting levodopa-', u'ed ')\n",
      "[72, 3]\n",
      "3\n",
      "0 90 {{A}} infusions is associated with marked reductions of preexisting levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 72  infusions is associated with marked reductions of preexisting levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2200 Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like {{A}} (known to induce {{B}} may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (known to ', u'e ')\n",
      "[11, 2]\n",
      "2\n",
      "0 28 {{A}} (known to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  (known to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "2201 Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce {{B}} may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as {{A}} (that blocks the adrenergic activity) may relieve it.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2211 Activation of {{A}} polymerase contributes to development of doxorubicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' polymerase contributes to development of doxorubicin-', u'ed ')\n",
      "[54, 3]\n",
      "3\n",
      "0 72 {{A}} polymerase contributes to development of doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 54  polymerase contributes to development of doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2216 Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2217 Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor {{A}}, we now demonstrate the role of PARP in the development of {{B}} induced by DOX.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2222 We postulate that the mechanism of the simvastatinezetimibe-induced {{B}} is the increased {{A}} exposure by ezetimibe inhibition of UGT enzymes.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2224 We postulate that the mechanism of the simvastatinezetimibe-induced {{B}} is the increased simvastatin exposure by {{A}} inhibition of UGT enzymes.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2227 METHODS: We investigated the effect of varying the intraperitoneal infusion rates of {{A}} 120 mg/kg, a known {{B}} dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2228 METHODS: We investigated the effect of varying the intraperitoneal infusion rates of {{A}} 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced {{B}} in the Swiss albino mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-', u'ed ')\n",
      "[90, 3]\n",
      "3\n",
      "0 108 {{A}} 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 90  120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2240 CONCLUSION: The administration of CaCl2 or {{A}} did not reverse tricyclic antidepressant-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' did not reverse tricyclic antidepressant-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} did not reverse tricyclic antidepressant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  did not reverse tricyclic antidepressant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2241 CONCLUSION: The administration of {{A}} or 4-aminopyridine did not reverse tricyclic antidepressant-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or 4-aminopyridine did not reverse tricyclic antidepressant-', u'ed ')\n",
      "[61, 3]\n",
      "3\n",
      "0 79 {{A}} or 4-aminopyridine did not reverse tricyclic antidepressant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  or 4-aminopyridine did not reverse tricyclic antidepressant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2242 In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of {{B}} induced by {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2245 These findings do not support a role for {{A}} channel inhibition in the pathogenesis of tricyclic antidepressant-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel inhibition in the pathogenesis of tricyclic antidepressant-', u'ed ')\n",
      "[68, 3]\n",
      "3\n",
      "0 86 {{A}} channel inhibition in the pathogenesis of tricyclic antidepressant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 68  channel inhibition in the pathogenesis of tricyclic antidepressant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2247 Drug-induced {{B}} was observed in subjects treated with risperidone (42%) and {{A}} (29%) and was observed at occupancy levels above 60%.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2248 Drug-induced {{B}} was observed in subjects treated with {{A}} (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2272 It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced {{B}} via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of {{A}}, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2273 It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the {{B}} action of {{A}}, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2274 It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced {{B}} via descending projections, the midline {{A}} B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2275 It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline {{A}} B3 cells in the medulla contribute to the {{B}} action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2289 Role of {{A}} oxidase in dexamethasone-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' oxidase in dexamethasone-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} oxidase in dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  oxidase in dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2292 Glucocorticoid-induced {{B}} (GC-HT) in the rat is associated with {{A}} imbalance.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2293 Glucocorticoid-induced hypertension ({{B}} in the rat is associated with {{A}} imbalance.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2297 We studied the role of {{A}} oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced {{B}} (dex-HT).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-', u'ed ')\n",
      "[98, 3]\n",
      "3\n",
      "0 116 {{A}} oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 98  oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2298 We studied the role of {{A}} oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT{{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-', u'ed hypertension (dex-HT')\n",
      "[98, 23]\n",
      "23\n",
      "0 136 {{A}} oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT{{B}}\n",
      "1 5 {{A}}\n",
      "2 98  oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-\n",
      "3 5 induc\n",
      "4 23 ed hypertension (dex-HT\n",
      "5 5 {{B}}\n",
      "2301 We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced {{B}} ({{A}}).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2302 We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension ({{A}}{{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2303 We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive {{A}} species, in dexamethasone-induced {{B}} (dex-HT).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species, in dexamethasone-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}} species, in dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  species, in dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2304 We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive {{A}} species, in dexamethasone-induced hypertension (dex-HT{{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species, in dexamethasone-', u'ed hypertension (dex-HT')\n",
      "[27, 23]\n",
      "23\n",
      "0 65 {{A}} species, in dexamethasone-induced hypertension (dex-HT{{B}}\n",
      "1 5 {{A}}\n",
      "2 27  species, in dexamethasone-\n",
      "3 5 induc\n",
      "4 23 ed hypertension (dex-HT\n",
      "5 5 {{B}}\n",
      "2316 {{A}} for detection of isoproterenol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for detection of isoproterenol-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} for detection of isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  for detection of isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2326 RESULTS: The results showed that IP administration of {{A}} 120 mg/kg by bolus injection induced {{B}} in 6 out of 10 mice (60% of convulsing mice) in group 1.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 120 mg/kg by bolus injection ', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} 120 mg/kg by bolus injection induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  120 mg/kg by bolus injection \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2330 Maximal {{B}} induced by 6 microM of {{A}} decreased after administration of ketoprofen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2331 Maximal {{B}} induced by 6 microM of adenosine diphosphate decreased after administration of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2345 The likelihood that {{A}} induced {{B}} in our patient was possible, based on the Naranjo probability scale.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2347 These findings indicate the synergistic protective effect of green tea and {{A}} during ISO induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' during ISO ', u'ed ')\n",
      "[12, 3]\n",
      "3\n",
      "0 30 {{A}} during ISO induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  during ISO \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2348 These findings indicate the synergistic protective effect of green tea and vitamin E during {{A}} induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2349 These findings indicate the synergistic protective effect of {{A}} and vitamin E during ISO induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "induc\n",
      "(u' and vitamin E during ISO ', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} and vitamin E during ISO induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  and vitamin E during ISO \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2369 The animal model used to produce {{B}} implies artery ligation but chemical induction can be easily obtained with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2381 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced {{B}} of {{A}} neurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2390 Thus, high {{A}} levels alone do not always induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' levels alone do not always ', u'e ')\n",
      "[28, 2]\n",
      "2\n",
      "0 45 {{A}} levels alone do not always induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 28  levels alone do not always \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "2411 {{B}} in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2412 Cardiac arrest in a child with {{B}} undergoing sevoflurane induction of anesthesia after preoperative {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2413 {{B}} in a child with cerebral palsy undergoing {{A}} induction of anesthesia after preoperative clonidine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2414 Cardiac arrest in a child with {{B}} undergoing {{A}} induction of anesthesia after preoperative clonidine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2422 Results showed that SSR103800 (10-30 mg/kg p.o.) blocked {{B}} induced by the non-competitive NMDA receptor antagonist, {{A}} and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2423 Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, {{A}} and partially reversed spontaneous {{B}} of NMDA Nr1(neo-/-) mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2425 In contrast, SSR103800 failed to affect {{B}} induced by amphetamine or naturally observed in {{A}} transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2426 In contrast, SSR103800 failed to affect {{B}} induced by {{A}} or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2434 243 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of {{B}} symptoms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' outpatients with cocaine-', u'ed mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of ')\n",
      "[26, 96]\n",
      "26\n",
      "0 137 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  outpatients with cocaine-\n",
      "3 5 induc\n",
      "4 96 ed mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of \n",
      "5 5 {{B}}\n",
      "2435 243 {{A}} outpatients with cocaine-induced mood disorder ({{B}}, other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' outpatients with cocaine-', u'ed mood disorder (')\n",
      "[26, 18]\n",
      "18\n",
      "0 59 {{A}} outpatients with cocaine-induced mood disorder ({{B}}\n",
      "1 5 {{A}}\n",
      "2 26  outpatients with cocaine-\n",
      "3 5 induc\n",
      "4 18 ed mood disorder (\n",
      "5 5 {{B}}\n",
      "2436 243 {{A}} outpatients with cocaine-induced {{B}} (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' outpatients with cocaine-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} outpatients with cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  outpatients with cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2437 243 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other {{B}}, or no mood disorder were compared on measures of psychiatric symptoms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' outpatients with cocaine-', u'ed mood disorder (CIMD), other ')\n",
      "[26, 31]\n",
      "26\n",
      "0 72 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  outpatients with cocaine-\n",
      "3 5 induc\n",
      "4 31 ed mood disorder (CIMD), other \n",
      "5 5 {{B}}\n",
      "2438 243 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no {{B}} were compared on measures of psychiatric symptoms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' outpatients with cocaine-', u'ed mood disorder (CIMD), other mood disorders, or no ')\n",
      "[26, 53]\n",
      "26\n",
      "0 94 {{A}} outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  outpatients with cocaine-\n",
      "3 5 induc\n",
      "4 53 ed mood disorder (CIMD), other mood disorders, or no \n",
      "5 5 {{B}}\n",
      "2454 Recurrent {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2457 {{A}} induces primary loss of dystrophin in rat hearts: correlation with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es primary loss of dystrophin in rat hearts: correlation with ')\n",
      "[1, 62]\n",
      "1\n",
      "0 78 {{A}} induces primary loss of dystrophin in rat hearts: correlation with {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 62 es primary loss of dystrophin in rat hearts: correlation with \n",
      "5 5 {{B}}\n",
      "2462 The mechanism of isoproterenol-induced {{B}} is unknown, but a mismatch of {{A}} supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2463 The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of {{A}} supply vs. demand following coronary hypotension and {{B}} is the best explanation for the complex morphological alterations observed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2464 The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of {{A}} supply vs. demand following coronary {{B}} and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2472 Investigation of mitochondrial involvement in the experimental model of {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2474 These changes, related to {{B}}, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2481 Protective effect of {{A}} on indomethacin induced {{B}} in elderly patients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on indomethacin ', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}} on indomethacin induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  on indomethacin \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2482 Protective effect of misoprostol on {{A}} induced {{B}} in elderly patients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2484 This study was conducted to examine whether prolonged pretreatment with {{A}} could abolish bromocriptine-induced {{B}} in conscious rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' could abolish bromocriptine-', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} could abolish bromocriptine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  could abolish bromocriptine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2489 In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces {{B}} in male Sprague-Dawley rats (250-275 g), sensitizes to {{A}} cardiotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2490 In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2491 In the current study, we investigated whether a physiological intervention by feeding 40% high {{A}} diet (HFD), which induces {{B}} in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' diet (HFD), which ', u'es ')\n",
      "[19, 3]\n",
      "3\n",
      "0 37 {{A}} diet (HFD), which induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  diet (HFD), which \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "2492 In the current study, we investigated whether a physiological intervention by feeding 40% high {{A}} diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-', u'ed ')\n",
      "[102, 3]\n",
      "3\n",
      "0 120 {{A}} diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 102  diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2502 These results show that 15-day {{A}} pretreatment not only abolished but reversed bromocriptine-induced {{B}} to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment not only abolished but reversed bromocriptine-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} pretreatment not only abolished but reversed bromocriptine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  pretreatment not only abolished but reversed bromocriptine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2503 These results show that 15-day {{A}} pretreatment not only abolished but reversed bromocriptine-induced tachycardia to {{B}}, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment not only abolished but reversed bromocriptine-', u'ed tachycardia to ')\n",
      "[60, 18]\n",
      "18\n",
      "0 93 {{A}} pretreatment not only abolished but reversed bromocriptine-induced tachycardia to {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  pretreatment not only abolished but reversed bromocriptine-\n",
      "3 5 induc\n",
      "4 18 ed tachycardia to \n",
      "5 5 {{B}}\n",
      "2520 In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced {{B}} behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist {{A}} had no effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2522 In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced {{B}} behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist {{A}} and the alpha(2) antagonist yohimbine had no effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2523 In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist {{A}} blocked cocaine-induced {{B}} behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' blocked cocaine-', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}} blocked cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  blocked cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2529 In control rats, intravenous {{A}} (150 microg/kg) induced significant hypotension and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (150 microg/kg) ', u'ed significant hypotension and ')\n",
      "[17, 31]\n",
      "17\n",
      "0 63 {{A}} (150 microg/kg) induced significant hypotension and {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  (150 microg/kg) \n",
      "3 5 induc\n",
      "4 31 ed significant hypotension and \n",
      "5 5 {{B}}\n",
      "2530 In control rats, intravenous {{A}} (150 microg/kg) induced significant {{B}} and tachycardia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (150 microg/kg) ', u'ed significant ')\n",
      "[17, 15]\n",
      "15\n",
      "0 47 {{A}} (150 microg/kg) induced significant {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  (150 microg/kg) \n",
      "3 5 induc\n",
      "4 15 ed significant \n",
      "5 5 {{B}}\n",
      "2534 It has been shown that bromocriptine-induced {{B}}, which persisted after adrenalectomy, is (i) mediated by central {{A}} D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2535 It has been shown that bromocriptine-induced {{B}}, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day {{A}} pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2536 In conclusion, HFD-induced {{B}} rats are highly sensitized to {{A}} cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2537 In conclusion, HFD-induced obese rats are highly sensitized to {{A}} {{B}} by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2538 In conclusion, {{A}} {{B}} rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2539 In conclusion, {{A}} obese rats are highly sensitized to doxorubicin-induced {{B}} by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' obese rats are highly sensitized to doxorubicin-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}} obese rats are highly sensitized to doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49  obese rats are highly sensitized to doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2540 In conclusion, HFD-induced {{B}} rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial {{A}} generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2541 In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced {{B}} by substantially downregulating cardiac mitochondrial {{A}} generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2554 Effects of long-term pretreatment with {{A}} on bromocriptine-induced {{B}} in conscious rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on bromocriptine-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} on bromocriptine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  on bromocriptine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2555 {{B}} induced by levetiracetam added to {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2556 {{B}} induced by {{A}} added to valproate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2558 Microinjection of {{A}} into the CA1 region of hippocampus improves scopolamine-induced {{B}} in adult male rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' into the CA1 region of hippocampus improves scopolamine-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} into the CA1 region of hippocampus improves scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  into the CA1 region of hippocampus improves scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2560 The effect of {{A}} (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced {{B}} in Morris water maze (MWM) was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-', u'ed ')\n",
      "[71, 3]\n",
      "3\n",
      "0 89 {{A}} (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 71  (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2561 The effect of ritanserin (5-HT2 antagonist) on {{A}} (muscarinic cholinergic antagonist)-induced {{B}} in Morris water maze (MWM) was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (muscarinic cholinergic antagonist)-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} (muscarinic cholinergic antagonist)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  (muscarinic cholinergic antagonist)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2572 Bromocriptine-induced hypotension was unaffected by {{A}} pretreatment, while {{B}} was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2573 Bromocriptine-induced {{B}} was unaffected by {{A}} pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2574 Bromocriptine-induced hypotension was unaffected by {{A}} pretreatment, while tachycardia was reversed to significant {{B}}, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2575 Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while {{B}} was reversed to significant bradycardia, an effect that was partly reduced by i.v. {{A}} (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2576 Bromocriptine-induced {{B}} was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. {{A}} (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2577 Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant {{B}}, an effect that was partly reduced by i.v. {{A}} (0.5 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2579 {{A}} prevents experimental gentamicin-induced {{B}} by a mitochondria-dependent pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevents experimental gentamicin-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} prevents experimental gentamicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  prevents experimental gentamicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2585 Verapamil-induced {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2609 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or {{A}} (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}} was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-', u'ed) ')\n",
      "[100, 4]\n",
      "4\n",
      "0 119 {{A}} (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}}\n",
      "1 5 {{A}}\n",
      "2 100  (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-\n",
      "3 5 induc\n",
      "4 4 ed) \n",
      "5 5 {{B}}\n",
      "2610 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or {{A}} (70 nmol/kg ip) respectively, in model of {{B}} (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2611 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin ({{A}}; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}} was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-', u'ed) ')\n",
      "[137, 4]\n",
      "4\n",
      "0 156 {{A}}; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}}\n",
      "1 5 {{A}}\n",
      "2 137 ; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-\n",
      "3 5 induc\n",
      "4 4 ed) \n",
      "5 5 {{B}}\n",
      "2612 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin ({{A}}; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of {{B}} (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2613 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic ({{A}}) {{B}} was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2614 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of {{B}} (streptozotocin-induced) and toxic ({{A}}) neuropathy was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2615 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic ({{A}}) and toxic (vincristine-induced) {{B}} was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u') and toxic (vincristine-', u'ed) ')\n",
      "[25, 4]\n",
      "4\n",
      "0 44 {{A}}) and toxic (vincristine-induced) {{B}}\n",
      "1 5 {{A}}\n",
      "2 25 ) and toxic (vincristine-\n",
      "3 5 induc\n",
      "4 4 ed) \n",
      "5 5 {{B}}\n",
      "2616 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of {{B}} ({{A}}) and toxic (vincristine-induced) neuropathy was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2617 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] {{A}} (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}} was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-', u'ed) ')\n",
      "[146, 4]\n",
      "4\n",
      "0 165 {{A}} (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) {{B}}\n",
      "1 5 {{A}}\n",
      "2 146  (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-\n",
      "3 5 induc\n",
      "4 4 ed) \n",
      "5 5 {{B}}\n",
      "2618 PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] {{A}} (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of {{B}} (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2640 It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in {{B}} produced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2641 It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as {{A}} are involved in {{B}} produced by vincristine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2644 In {{A}} {{B}}, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2645 In {{A}} hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced {{B}} bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-', u'ed ')\n",
      "[115, 3]\n",
      "3\n",
      "0 133 {{A}} hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 115  hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2646 In streptozotocin-induced {{B}}, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in {{A}} hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2647 In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in {{A}} {{B}} bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2648 In streptozotocin-induced {{B}}, inducible NO synthase participates in pronociceptive activity of {{A}}, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2649 In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of {{A}}, whereas in vincristine-induced {{B}} bradykinin seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', whereas in vincristine-', u'ed ')\n",
      "[25, 3]\n",
      "3\n",
      "0 43 {{A}}, whereas in vincristine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 25 , whereas in vincristine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2650 In streptozotocin-induced {{B}}, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia {{A}} seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2651 In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced {{B}} {{A}} seemed to activate neuronal NO synthase pathway.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2654 {{B}} were induced in F344 female rats by chronic treatment with {{A}} (DES, 8-10 mg) implanted subcutaneously in silastic capsules.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2655 {{B}} were induced in F344 female rats by chronic treatment with diethylstilbestrol ({{A}}, 8-10 mg) implanted subcutaneously in silastic capsules.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2658 Hyperbaric {{A}} therapy for control of intractable cyclophosphamide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy for control of intractable cyclophosphamide-', u'ed ')\n",
      "[53, 3]\n",
      "3\n",
      "0 71 {{A}} therapy for control of intractable cyclophosphamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 53  therapy for control of intractable cyclophosphamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2666 Nicotine-induced {{B}} was blocked by the selective D1 antagonist {{A}}, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2667 Nicotine-induced {{B}} was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2668 Nicotine-induced {{B}} was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist {{A}} and the D1/D2 antagonist fluphenazine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2681 This study was undertaken to determine the effect of {{A}} pretreatment on reduction of succinylcholine-induced {{B}} in patients undergoing general anesthesia for gynecological surgery.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment on reduction of succinylcholine-', u'ed ')\n",
      "[46, 3]\n",
      "3\n",
      "0 64 {{A}} pretreatment on reduction of succinylcholine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  pretreatment on reduction of succinylcholine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2685 The results indicate that acute {{A}} injection induces a pronounced {{B}} in rats habituated to the test environment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' injection ', u'es a pronounced ')\n",
      "[11, 16]\n",
      "11\n",
      "0 42 {{A}} injection induces a pronounced {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  injection \n",
      "3 5 induc\n",
      "4 16 es a pronounced \n",
      "5 5 {{B}}\n",
      "2688 Combined effects of prolonged {{A}} (PGE1)-induced {{B}} and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PGE1)-', u'ed ')\n",
      "[8, 3]\n",
      "3\n",
      "0 26 {{A}} (PGE1)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (PGE1)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2689 Combined effects of prolonged prostaglandin E1 ({{A}}-induced {{B}} and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2691 Can {{A}} reduce succinylcholine induced {{B}}?\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reduce succinylcholine ', u'ed ')\n",
      "[24, 3]\n",
      "3\n",
      "0 42 {{A}} reduce succinylcholine induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  reduce succinylcholine \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2692 Can lidocaine reduce {{A}} induced {{B}}?\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2693 Controlled {{B}} in groups A and C was induced with {{A}} to maintain mean arterial blood pressure at 55 mmHg for 180 min.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2712 We tested the sulfated polysaccharide {{A}}, which has been reported to reduce inflammatory {{B}}, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2713 We tested the sulfated polysaccharide {{A}}, which has been reported to reduce inflammatory brain damage, in a rat model of {{B}} induced by injection of bacterial collagenase into the caudate nucleus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2717 {{B}} induced by the cocaine metabolite {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2718 {{B}} induced by the {{A}} metabolite benzoylecgonine in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2719 Blockade of both D-1 and D-2 {{A}} receptors may induce {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors may ', u'e ')\n",
      "[15, 2]\n",
      "2\n",
      "0 32 {{A}} receptors may induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  receptors may \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "2736 Dopamine antagonist fluphenazine, D-1 antagonist {{A}} or D-2 antagonist sulpiride induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or D-2 antagonist sulpiride ', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} or D-2 antagonist sulpiride induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  or D-2 antagonist sulpiride \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2737 {{A}} antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride ', u'ed ')\n",
      "[79, 3]\n",
      "3\n",
      "0 97 {{A}} antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 79  antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2738 Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist {{A}} induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2739 Dopamine antagonist {{A}}, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', D-1 antagonist SCH 23390 or D-2 antagonist sulpiride ', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}}, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55 , D-1 antagonist SCH 23390 or D-2 antagonist sulpiride \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2740 Combination of {{A}} with sulpiride did not induce {{B}} potentiation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with sulpiride did not ', u'e ')\n",
      "[24, 2]\n",
      "2\n",
      "0 41 {{A}} with sulpiride did not induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  with sulpiride did not \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "2741 Combination of SCH 23390 with {{A}} did not induce {{B}} potentiation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' did not ', u'e ')\n",
      "[9, 2]\n",
      "2\n",
      "0 26 {{A}} did not induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 9  did not \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "2742 {{A}} {{B}} occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2743 BE-Induced {{B}} occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2744 Whereas cocaine-induced {{B}} were best characterized as brief, generalized, and tonic and resulted in death, those induced by {{A}} were prolonged, often multiple and mixed in type, and rarely resulted in death.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2745 Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in {{B}}, those induced by {{A}} were prolonged, often multiple and mixed in type, and rarely resulted in death.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2746 Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by {{A}} were prolonged, often multiple and mixed in type, and rarely resulted in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2747 Whereas {{A}} {{B}} were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2748 Whereas {{A}} seizures were best characterized as brief, generalized, and tonic and resulted in {{B}}, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2749 Whereas {{A}} seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' seizures were best characterized as brief, generalized, and tonic and resulted in death, those ', u'ed by BE were prolonged, often multiple and mixed in type, and rarely resulted in ')\n",
      "[96, 82]\n",
      "82\n",
      "0 193 {{A}} seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in {{B}}\n",
      "1 5 {{A}}\n",
      "2 96  seizures were best characterized as brief, generalized, and tonic and resulted in death, those \n",
      "3 5 induc\n",
      "4 82 ed by BE were prolonged, often multiple and mixed in type, and rarely resulted in \n",
      "5 5 {{B}}\n",
      "2750 D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the {{B}} induced by fluphenazine, {{A}} or sulpiride.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2751 D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the {{B}} induced by fluphenazine, SCH 23390 or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2752 D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the {{B}} induced by {{A}}, SCH 23390 or sulpiride.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2753 D-1 agonist {{A}} or D-2 agonist quinpirole decreased the {{B}} induced by fluphenazine, SCH 23390 or sulpiride.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2754 D-1 agonist SKF 38393 or D-2 agonist {{A}} decreased the {{B}} induced by fluphenazine, SCH 23390 or sulpiride.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2755 Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on {{B}} induced by {{A}} antagonists.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2756 Combination of {{A}} with quinpirole did not cause potentiated inhibitory effect on {{B}} induced by dopamine antagonists.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2757 Combination of SKF 38393 with {{A}} did not cause potentiated inhibitory effect on {{B}} induced by dopamine antagonists.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2758 The finding that cocaine- and {{A}} {{B}} differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2759 The finding that cocaine- and {{A}} seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}} and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' seizures differ in several respects suggests more than one mechanism for cocaine-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}} seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  seizures differ in several respects suggests more than one mechanism for cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2760 The finding that cocaine- and BE-induced {{B}} differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2761 The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}} and emphasizes the importance of a cocaine metabolite, {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2762 The finding that {{A}}- and BE-induced {{B}} differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and BE-', u'ed ')\n",
      "[9, 3]\n",
      "3\n",
      "0 27 {{A}}- and BE-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 9 - and BE-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2763 The finding that {{A}}- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}} and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-', u'ed ')\n",
      "[98, 3]\n",
      "3\n",
      "0 116 {{A}}- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 98 - and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2764 The finding that cocaine- and BE-induced {{B}} differ in several respects suggests more than one mechanism for {{A}} seizures and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2765 The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for {{A}} {{B}} and emphasizes the importance of a cocaine metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2766 The finding that cocaine- and BE-induced {{B}} differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a {{A}} metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2767 The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced {{B}} and emphasizes the importance of a {{A}} metabolite, BE.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2774 A murine model of adenomyosis: the effects of {{B}} induced by {{A}}, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2775 A murine model of {{B}}: the effects of hyperprolactinemia induced by {{A}}, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2776 A murine model of adenomyosis: the effects of hyperprolactinemia induced by {{A}}, a selective serotonin reuptake inhibitor, on {{B}} induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2777 A murine model of adenomyosis: the effects of {{B}} induced by fluoxetine hydrochloride, a selective {{A}} reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2778 A murine model of {{B}}: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective {{A}} reuptake inhibitor, on adenomyosis induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2779 A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective {{A}} reuptake inhibitor, on {{B}} induction in Wistar albino rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2787 Affinity profiles of (+/-)-{{A}} for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the {{B}} effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2788 Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the {{B}} effect induced by (+/-)-{{A}} through an increase in acetylcholine extracellular levels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2789 Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the {{B}} effect induced by (+/-)-PG-9 through an increase in {{A}} extracellular levels.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2811 Our findings indicate that cocaine induced {{B}} is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist ({{A}} and agonist (CP 93129), respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2812 Our findings indicate that cocaine induced {{B}} is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist ({{A}}, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2813 Our findings indicate that {{A}} induced {{B}} is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2816 A CD50 dose of local anesthetic (causing {{B}} in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the {{A}} group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2817 A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced {{B}}, in 57% of the chloroprocaine group, and in 6% of the {{A}} group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2820 A CD50 dose of local anesthetic (causing {{B}} in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the {{A}} group, and in 6% of the lidocaine group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2821 A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced {{B}}, in 57% of the {{A}} group, and in 6% of the lidocaine group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2838 Neither dose of {{A}} significantly decreased the dipyridamole-induced {{B}}, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly decreased the dipyridamole-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} significantly decreased the dipyridamole-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  significantly decreased the dipyridamole-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2839 Neither dose of pentoxifylline significantly decreased the dipyridamole-induced {{B}}, while peak coronary blood flow was significantly lower after {{A}} (p less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2844 In the study presented here, we investigated the use of dexamethasone in combination with {{A}} for the prevention of IFS-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for the prevention of IFS-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}} for the prevention of IFS-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  for the prevention of IFS-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2845 In the study presented here, we investigated the use of {{A}} in combination with mesna for the prevention of IFS-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in combination with mesna for the prevention of IFS-', u'ed ')\n",
      "[53, 3]\n",
      "3\n",
      "0 71 {{A}} in combination with mesna for the prevention of IFS-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 53  in combination with mesna for the prevention of IFS-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2852 Enhanced stimulus-induced neurotransmitter overflow in {{A}} {{B}} rats is not mediated by prejunctional beta-adrenoceptor activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2857 Use of dexamethasone with {{A}} for the prevention of ifosfamide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for the prevention of ifosfamide-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} for the prevention of ifosfamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  for the prevention of ifosfamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2858 Use of {{A}} with mesna for the prevention of ifosfamide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with mesna for the prevention of ifosfamide-', u'ed ')\n",
      "[45, 3]\n",
      "3\n",
      "0 63 {{A}} with mesna for the prevention of ifosfamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 45  with mesna for the prevention of ifosfamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2908 Oral administration of {{A}} (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the {{B}} responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2909 Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the {{B}} responses induced by intracerebroventricular administration of an {{A}} A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2910 Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the {{B}} responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, {{A}} (10 micrograms), in a dose-dependent manner.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2918 Use of {{A}} may be the optimal treatment of D-penicillamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may be the optimal treatment of D-penicillamine-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}} may be the optimal treatment of D-penicillamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49  may be the optimal treatment of D-penicillamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2930 Furthermore, {{A}} appeared to act on systems more closely involved with the induction of ketamine {{B}} rather than directly on the pituitary.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' appeared to act on systems more closely involved with the ', u'tion of ketamine ')\n",
      "[59, 17]\n",
      "17\n",
      "0 91 {{A}} appeared to act on systems more closely involved with the induction of ketamine {{B}}\n",
      "1 5 {{A}}\n",
      "2 59  appeared to act on systems more closely involved with the \n",
      "3 5 induc\n",
      "4 17 tion of ketamine \n",
      "5 5 {{B}}\n",
      "2931 Furthermore, dopamine appeared to act on systems more closely involved with the induction of {{A}} {{B}} rather than directly on the pituitary.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2940 To assess the antioxidant effects of {{A}} (atorva) on dexamethasone (dex)-induced {{B}}, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (atorva) on dexamethasone (dex)-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} (atorva) on dexamethasone (dex)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  (atorva) on dexamethasone (dex)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2941 To assess the antioxidant effects of atorvastatin ({{A}} on dexamethasone (dex)-induced {{B}}, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on dexamethasone (dex)-', u'ed ')\n",
      "[24, 3]\n",
      "3\n",
      "0 42 {{A}} on dexamethasone (dex)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  on dexamethasone (dex)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2942 To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced {{B}}, 60 male Sprague-Dawley rats were treated with {{A}} 30 mg/kg/day or tap water for 15 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2943 To assess the antioxidant effects of atorvastatin (atorva) on {{A}} (dex)-induced {{B}}, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (dex)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (dex)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (dex)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2944 To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone ({{A}}-induced {{B}}, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2947 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and {{A}} {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2948 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and {{A}} muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2949 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized {{A}} motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2950 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized {{A}} motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2951 Both verapamil (10 mg/kg i.p.) and {{A}} pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment enhanced morphine analgesia- and diazepam-', u'ed ')\n",
      "[56, 3]\n",
      "3\n",
      "0 74 {{A}} pretreatment enhanced morphine analgesia- and diazepam-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 56  pretreatment enhanced morphine analgesia- and diazepam-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2952 Both verapamil (10 mg/kg i.p.) and {{A}} pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2953 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor {{A}} affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2954 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor {{A}} affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2955 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced {{A}} analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' analgesia- and diazepam-', u'ed ')\n",
      "[25, 3]\n",
      "3\n",
      "0 43 {{A}} analgesia- and diazepam-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  analgesia- and diazepam-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2956 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced {{A}} {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2957 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2958 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2959 Both {{A}} (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}} (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "2960 Both {{A}} (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2961 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced {{B}} and antagonized amphetamine-induced motor activity, and neither {{A}} nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2962 Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine {{B}}- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither {{A}} nor NH4Ac affected the convulsant action of metrazol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2970 To investigate the relationship of {{A}} (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2971 To investigate the relationship of {{A}} (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PGs) to seizure ', u'tion, the effects of six PG synthetase inhibitors on ')\n",
      "[18, 53]\n",
      "18\n",
      "0 86 {{A}} (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  (PGs) to seizure \n",
      "3 5 induc\n",
      "4 53 tion, the effects of six PG synthetase inhibitors on \n",
      "5 5 {{B}}\n",
      "2972 To investigate the relationship of prostaglandins ({{A}} to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2973 To investigate the relationship of prostaglandins ({{A}} to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to seizure ', u'tion, the effects of six PG synthetase inhibitors on ')\n",
      "[12, 53]\n",
      "12\n",
      "0 80 {{A}} to seizure induction, the effects of six PG synthetase inhibitors on {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  to seizure \n",
      "3 5 induc\n",
      "4 53 tion, the effects of six PG synthetase inhibitors on \n",
      "5 5 {{B}}\n",
      "2974 To investigate the relationship of prostaglandins (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or {{A}} were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2975 To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or {{A}} were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2976 To investigate the relationship of prostaglandins (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, {{A}}, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2977 To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, {{A}}, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2978 To investigate the relationship of prostaglandins (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, {{A}} (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2979 To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, picrotoxin, {{A}} (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2980 To investigate the relationship of prostaglandins (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol ({{A}}, electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2981 To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by flurothyl, picrotoxin, pentetrazol ({{A}}, electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2982 To investigate the relationship of prostaglandins (PGs) to {{B}} induction, the effects of six PG synthetase inhibitors on convulsions induced by {{A}}, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "2983 To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on {{B}} induced by {{A}}, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3007 These results suggest that {{A}} are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced {{B}}, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' are involved in the mechanism(s) underlying fluorthyl- and PTZ-', u'ed ')\n",
      "[64, 3]\n",
      "3\n",
      "0 82 {{A}} are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 64  are involved in the mechanism(s) underlying fluorthyl- and PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3008 These results suggest that {{A}} are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-', u'ed ')\n",
      "[136, 3]\n",
      "3\n",
      "0 154 {{A}} are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 136  are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3009 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced {{B}}, but not picrotoxin-, electroshock-, or {{A}} convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3010 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3011 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced {{B}}, but not {{A}}-, electroshock-, or bicuculline-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3012 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not {{A}}-, electroshock-, or bicuculline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, electroshock-, or bicuculline-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}}-, electroshock-, or bicuculline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33 -, electroshock-, or bicuculline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3013 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and {{A}} {{B}}, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3014 These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and {{A}} convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' convulsions, but not picrotoxin-, electroshock-, or bicuculline-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  convulsions, but not picrotoxin-, electroshock-, or bicuculline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3015 These results suggest that PGs are involved in the mechanism(s) underlying {{A}}- and PTZ-induced {{B}}, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and PTZ-', u'ed ')\n",
      "[10, 3]\n",
      "3\n",
      "0 28 {{A}}- and PTZ-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 10 - and PTZ-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3016 These results suggest that PGs are involved in the mechanism(s) underlying {{A}}- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}}- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82 - and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3031 To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, {{A}}-, chloroform- and galactosamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, chloroform- and galactosamine-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}}-, chloroform- and galactosamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33 -, chloroform- and galactosamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3032 To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against {{A}}-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-', u'ed ')\n",
      "[69, 3]\n",
      "3\n",
      "0 87 {{A}}-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 69 -, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3033 To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, {{A}}- and galactosamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and galactosamine-', u'ed ')\n",
      "[20, 3]\n",
      "3\n",
      "0 38 {{A}}- and galactosamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 20 - and galactosamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3034 To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, {{A}}-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, carbon tetrachloride-, chloroform- and galactosamine-', u'ed ')\n",
      "[56, 3]\n",
      "3\n",
      "0 74 {{A}}-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 56 -, carbon tetrachloride-, chloroform- and galactosamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3035 To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, {{A}}, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-', u'ed ')\n",
      "[108, 3]\n",
      "3\n",
      "0 126 {{A}}, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 108 , tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3068 CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by {{A}} given concurrently with other {{B}} drugs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3069 CONCLUSIONS: Clinicians should be aware of the possibility of {{B}} induced by {{A}} given concurrently with other hepatotoxic drugs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3079 A deficient {{A}} system is implicated in cortisol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' system is implicated in cortisol-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} system is implicated in cortisol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  system is implicated in cortisol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3080 We report here the first case of {{A}} (PPA)-induced {{B}} in a young woman who was using it at recommended doses for weight control.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PPA)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (PPA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (PPA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3081 We report here the first case of Dexatrim ({{A}}-induced {{B}} in a young woman who was using it at recommended doses for weight control.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3102 In addition, we demonstrate that mice genetically engineered to have unilateral brain {{A}} deficits develop METH-induced {{B}} that are of comparable magnitude on both sides of the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' deficits develop METH-', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} deficits develop METH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  deficits develop METH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3104 Taken together, these findings demonstrate that {{A}} is not essential for the development of METH-induced dopaminergic {{B}} and suggest that mechanisms independent of DA warrant more intense investigation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is not essential for the development of METH-', u'ed dopaminergic ')\n",
      "[46, 16]\n",
      "16\n",
      "0 77 {{A}} is not essential for the development of METH-induced dopaminergic {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  is not essential for the development of METH-\n",
      "3 5 induc\n",
      "4 16 ed dopaminergic \n",
      "5 5 {{B}}\n",
      "3105 Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic {{B}} and suggest that mechanisms independent of {{A}} warrant more intense investigation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3171 Swallowing-induced {{B}} triggered by {{A}}: case report and review of the literature.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3180 {{A}} therapy-induced {{B}}: magnitude, profile, prognosis, and predictors of outcome.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy-', u'ed ')\n",
      "[9, 3]\n",
      "3\n",
      "0 27 {{A}} therapy-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 9  therapy-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3181 {{A}} therapy (ATT)-associated {{B}} (ATT-ALF) is the commonest drug-induced ALF in South Asia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3182 {{A}} therapy (ATT)-associated acute liver failure ({{B}} is the commonest drug-induced ALF in South Asia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3183 {{A}} therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced {{B}} in South Asia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-', u'ed ')\n",
      "[78, 3]\n",
      "3\n",
      "0 96 {{A}} therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 78  therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3197 After 7 days, {{A}} treatment induced significant proteinuria, {{B}}, decreased urinary sodium excretion, and extensive ascites.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment ', u'ed significant proteinuria, ')\n",
      "[11, 28]\n",
      "11\n",
      "0 54 {{A}} treatment induced significant proteinuria, {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment \n",
      "3 5 induc\n",
      "4 28 ed significant proteinuria, \n",
      "5 5 {{B}}\n",
      "3198 After 7 days, {{A}} treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment ', u'ed significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ')\n",
      "[11, 95]\n",
      "11\n",
      "0 121 {{A}} treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment \n",
      "3 5 induc\n",
      "4 95 ed significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive \n",
      "5 5 {{B}}\n",
      "3199 After 7 days, {{A}} treatment induced significant {{B}}, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment ', u'ed significant ')\n",
      "[11, 15]\n",
      "11\n",
      "0 41 {{A}} treatment induced significant {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment \n",
      "3 5 induc\n",
      "4 15 ed significant \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "5 5 {{B}}\n",
      "3200 After 7 days, PAN treatment induced significant proteinuria, {{B}}, decreased urinary {{A}} excretion, and extensive ascites.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3201 After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary {{A}} excretion, and extensive {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3202 After 7 days, PAN treatment induced significant {{B}}, hypoalbuminemia, decreased urinary {{A}} excretion, and extensive ascites.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3212 After a short period of basal activity recording, {{B}} focus was induced by injecting 400IU/2 microl {{A}} into the left lateral ventricle while the cortical activity was continuously recorded.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3214 IMPLICATIONS: Administration of dexamethasone before {{A}} was not effective in decreasing the incidence or the severity of succinylcholine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was not effective in decreasing the incidence or the severity of succinylcholine-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}} was not effective in decreasing the incidence or the severity of succinylcholine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  was not effective in decreasing the incidence or the severity of succinylcholine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3216 IMPLICATIONS: Administration of {{A}} before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-', u'ed ')\n",
      "[105, 3]\n",
      "3\n",
      "0 123 {{A}} before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 105  before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3227 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and {{A}} (1,2-DMH) (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3228 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine ({{A}} (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3229 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, {{A}} (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3230 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, 5-azacytidine ({{A}} (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3231 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, {{A}} (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3232 To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of {{B}}, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), {{A}} (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3234 Although {{A}} (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-', u'ed 5-HT ')\n",
      "[164, 8]\n",
      "8\n",
      "0 187 {{A}} (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}}\n",
      "1 5 {{A}}\n",
      "2 164  (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-\n",
      "3 5 induc\n",
      "4 8 ed 5-HT \n",
      "5 5 {{B}}\n",
      "3235 Although 3,4-methylenedioxymethamphetamine ({{A}} or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-', u'ed 5-HT ')\n",
      "[158, 8]\n",
      "8\n",
      "0 181 {{A}} or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}}\n",
      "1 5 {{A}}\n",
      "2 158  or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-\n",
      "3 5 induc\n",
      "4 8 ed 5-HT \n",
      "5 5 {{B}}\n",
      "3236 Although 3,4-methylenedioxymethamphetamine (MDMA or {{A}} has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-', u'ed 5-HT ')\n",
      "[146, 8]\n",
      "8\n",
      "0 169 {{A}} has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}}\n",
      "1 5 {{A}}\n",
      "2 146  has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-\n",
      "3 5 induc\n",
      "4 8 ed 5-HT \n",
      "5 5 {{B}}\n",
      "3238 Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain {{A}} (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-', u'ed 5-HT ')\n",
      "[105, 8]\n",
      "8\n",
      "0 128 {{A}} (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}}\n",
      "1 5 {{A}}\n",
      "2 105  (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-\n",
      "3 5 induc\n",
      "4 8 ed 5-HT \n",
      "5 5 {{B}}\n",
      "3239 Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin ({{A}} neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-', u'ed 5-HT ')\n",
      "[98, 8]\n",
      "8\n",
      "0 121 {{A}} neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}}\n",
      "1 5 {{A}}\n",
      "2 98  neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-\n",
      "3 5 induc\n",
      "4 8 ed 5-HT \n",
      "5 5 {{B}}\n",
      "3240 Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced {{A}} {{B}} on functions in which 5-HT is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3241 Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT {{B}} on functions in which {{A}} is involved, such as cognitive function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3242 This study addressed the potential role of {{A}} channel blockade in tricyclic antidepressant-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blockade in tricyclic antidepressant-', u'ed ')\n",
      "[46, 3]\n",
      "3\n",
      "0 64 {{A}} channel blockade in tricyclic antidepressant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  channel blockade in tricyclic antidepressant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3248 CONCLUSIONS: The rate of contrast-induced {{B}}, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or {{A}} to high-risk patients, with or without diabetes mellitus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3249 CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or {{A}} to high-risk patients, with or without {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3250 CONCLUSIONS: The rate of contrast-induced {{B}}, defined by multiple end points, is not statistically different after the intraarterial administration of {{A}} or iodixanol to high-risk patients, with or without diabetes mellitus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3251 CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of {{A}} or iodixanol to high-risk patients, with or without {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3275 High {{A}} diet-fed {{B}} rats are highly sensitive to doxorubicin-induced cardiotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3276 High {{A}} diet-fed obese rats are highly sensitive to doxorubicin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' diet-fed obese rats are highly sensitive to doxorubicin-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} diet-fed obese rats are highly sensitive to doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  diet-fed obese rats are highly sensitive to doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3279 OBJECTIVE: To assess lymphocyte reactivity to {{A}} and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-', u'ed ')\n",
      "[99, 3]\n",
      "3\n",
      "0 117 {{A}} and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 99  and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3280 OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo {{A}} antigens or metabolites in a case of dilevalol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' antigens or metabolites in a case of dilevalol-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}} antigens or metabolites in a case of dilevalol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  antigens or metabolites in a case of dilevalol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3284 Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to {{A}} nephrotoxicity and the {{B}} and thrombocytopenia to drug-induced bone marrow suppression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3285 Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to {{A}} nephrotoxicity and the anemia and {{B}} to drug-induced bone marrow suppression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3286 Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to {{A}} nephrotoxicity and the anemia and thrombocytopenia to drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' nephrotoxicity and the anemia and thrombocytopenia to drug-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} nephrotoxicity and the anemia and thrombocytopenia to drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  nephrotoxicity and the anemia and thrombocytopenia to drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3287 Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to {{A}} {{B}} and the anemia and thrombocytopenia to drug-induced bone marrow suppression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3288 Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because {{B}} may be ascribed to {{A}} nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3291 In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary {{A}} concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced {{B}} and is unable to absorb the drug.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-', u'ed ')\n",
      "[90, 3]\n",
      "3\n",
      "0 108 {{A}} concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 90  concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3292 In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral {{A}} who experiences severe ifosfamide-induced {{B}} and is unable to absorb the drug.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' who experiences severe ifosfamide-', u'ed ')\n",
      "[35, 3]\n",
      "3\n",
      "0 53 {{A}} who experiences severe ifosfamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  who experiences severe ifosfamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3300 {{B}} induced by the long-term use of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3307 Such an induced {{B}} by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3311 It is speculated that the induction of {{B}} by {{A}} may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3314 {{A}}, acting through central alpha-2 adrenoceptors, prevents opiate-induced {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', acting through central alpha-2 adrenoceptors, prevents opiate-', u'ed ')\n",
      "[64, 3]\n",
      "3\n",
      "0 82 {{A}}, acting through central alpha-2 adrenoceptors, prevents opiate-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 64 , acting through central alpha-2 adrenoceptors, prevents opiate-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3328 The highly-selective alpha-2 adrenergic agonist {{A}} (D-MED) is capable of inducing {{B}} and anesthesia in rats and dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (D-MED) is capable of ', u'ing ')\n",
      "[23, 4]\n",
      "4\n",
      "0 42 {{A}} (D-MED) is capable of inducing {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  (D-MED) is capable of \n",
      "3 5 induc\n",
      "4 4 ing \n",
      "5 5 {{B}}\n",
      "3329 The highly-selective alpha-2 adrenergic agonist dexmedetomidine ({{A}} is capable of inducing {{B}} and anesthesia in rats and dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is capable of ', u'ing ')\n",
      "[15, 4]\n",
      "4\n",
      "0 34 {{A}} is capable of inducing {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  is capable of \n",
      "3 5 induc\n",
      "4 4 ing \n",
      "5 5 {{B}}\n",
      "3337 {{A}} {{B}} was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3338 Puromycin aminonucleoside {{B}} was induced by single intraperitoneal injection of {{A}} (PAN, 20 mg/100g BW).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3339 Puromycin aminonucleoside {{B}} was induced by single intraperitoneal injection of puromycin aminonucleoside ({{A}}, 20 mg/100g BW).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3358 Furthermore, DCE reversed the {{B}} induced by scopolamine (0.4 mg/kg, i.p.) and {{A}} (1 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3359 Furthermore, {{A}} reversed the {{B}} induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3360 Furthermore, DCE reversed the {{B}} induced by {{A}} (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3389 To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,{{A}}-ATPase to NO-deficient {{B}} induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3390 To assess the molecular basis of disturbances in transmembraneous transport of {{A}}+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient {{B}} induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3391 To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac ({{A}},K)-ATPase to NO-deficient {{B}} induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3398 Anticoagulant-induced femoral nerve palsy represents the most common form of {{A}} peripheral neuropathy; it is characterized by severe {{B}} in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3399 Anticoagulant-induced femoral nerve palsy represents the most common form of {{A}} {{B}}; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3400 Anticoagulant-induced {{B}} represents the most common form of {{A}} peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3401 Anticoagulant-induced femoral nerve palsy represents the most common form of {{A}} peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and {{B}}, and flexure contracture of the involved extremity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3406 CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared {{A}} antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' antigens, suggesting the involvement of an immunologic mechanism in dilevalol-', u'ed ')\n",
      "[79, 3]\n",
      "3\n",
      "0 97 {{A}} antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 79  antigens, suggesting the involvement of an immunologic mechanism in dilevalol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3408 Serum- and glucocorticoid-inducible kinase 1 in {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3416 Doxorubicin-induced {{B}} leads to epithelial {{A}} channel (ENaC)-dependent volume retention and renal fibrosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3417 Doxorubicin-induced nephropathy leads to epithelial {{A}} channel (ENaC)-dependent {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3418 Inhibition of NO-synthase induced a reversible {{B}} accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,{{A}}-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3419 Inhibition of NO-synthase induced a reversible hypertension accompanied by {{B}} Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,{{A}}-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3420 Inhibition of NO-synthase induced a reversible {{B}} accompanied by depressed {{A}}+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3421 Inhibition of NO-synthase induced a reversible hypertension accompanied by {{B}} {{A}}+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3422 Inhibition of NO-synthase induced a reversible {{B}} accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated {{A}}+-binding properties of the (Na,K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3423 Inhibition of NO-synthase induced a reversible hypertension accompanied by {{B}} Na+-extrusion from cardiac cells as a consequence of deteriorated {{A}}+-binding properties of the (Na,K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3424 Inhibition of NO-synthase induced a reversible {{B}} accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the ({{A}},K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3425 Inhibition of NO-synthase induced a reversible hypertension accompanied by {{B}} Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the ({{A}},K)-ATPase.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3427 The {{A}} serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal {{B}} following mineralocorticoid and salt excess.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' serum- and glucocorticoid-', u'ible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal ')\n",
      "[27, 95]\n",
      "27\n",
      "0 137 {{A}} serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  serum- and glucocorticoid-\n",
      "3 5 induc\n",
      "4 95 ible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal \n",
      "5 5 {{B}}\n",
      "3464 Rats with {{A}} {{B}} were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3465 Rats with {{A}} nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to ', u'e glomerular hyperfiltration and further progression of ')\n",
      "[122, 56]\n",
      "56\n",
      "0 193 {{A}} nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of {{B}}\n",
      "1 5 {{A}}\n",
      "2 122  nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to \n",
      "3 5 induc\n",
      "4 56 e glomerular hyperfiltration and further progression of \n",
      "5 5 {{B}}\n",
      "3467 The morphine-induced {{B}} was potentiated by scopolamine and attenuated by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3468 The morphine-induced {{B}} was potentiated by {{A}} and attenuated by physostigmine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3483 Mechanisms of myocardial ischemia induced by {{A}}: comparison with exercise-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u': comparison with exercise-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}}: comparison with exercise-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27 : comparison with exercise-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3484 Mechanisms of {{B}} induced by {{A}}: comparison with exercise-induced ischemia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3493 {{A}} is not essential for the development of methamphetamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is not essential for the development of methamphetamine-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} is not essential for the development of methamphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  is not essential for the development of methamphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3497 In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by {{A}} that also causes increases in BP and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3504 It is widely believed that {{A}} (DA) mediates methamphetamine (METH)-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DA) mediates methamphetamine (METH)-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} (DA) mediates methamphetamine (METH)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  (DA) mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3505 It is widely believed that {{A}} (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DA) mediates methamphetamine (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease ')\n",
      "[38, 107]\n",
      "38\n",
      "0 160 {{A}} (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  (DA) mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 107 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease \n",
      "5 5 {{B}}\n",
      "3506 It is widely believed that {{A}} (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DA) mediates methamphetamine (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ')\n",
      "[38, 174]\n",
      "38\n",
      "0 227 {{A}} (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  (DA) mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 174 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance \n",
      "5 5 {{B}}\n",
      "3507 It is widely believed that dopamine ({{A}} mediates methamphetamine (METH)-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' mediates methamphetamine (METH)-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} mediates methamphetamine (METH)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3508 It is widely believed that dopamine ({{A}} mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' mediates methamphetamine (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease ')\n",
      "[33, 107]\n",
      "33\n",
      "0 155 {{A}} mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 107 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease \n",
      "5 5 {{B}}\n",
      "3509 It is widely believed that dopamine ({{A}} mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' mediates methamphetamine (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ')\n",
      "[33, 174]\n",
      "33\n",
      "0 222 {{A}} mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  mediates methamphetamine (METH)-\n",
      "3 5 induc\n",
      "4 174 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance \n",
      "5 5 {{B}}\n",
      "3510 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with {{A}} neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3511 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with {{A}} neurotransmission decrease {{B}}, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3512 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with {{A}} neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3513 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase {{A}} neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3514 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}, whereas drugs that increase {{A}} neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3515 It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase {{A}} neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3516 It is widely believed that dopamine (DA) mediates {{A}} (METH)-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (METH)-', u'ed ')\n",
      "[8, 3]\n",
      "3\n",
      "0 26 {{A}} (METH)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (METH)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3517 It is widely believed that dopamine (DA) mediates {{A}} (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease ')\n",
      "[8, 107]\n",
      "8\n",
      "0 130 {{A}} (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (METH)-\n",
      "3 5 induc\n",
      "4 107 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease \n",
      "5 5 {{B}}\n",
      "3518 It is widely believed that dopamine (DA) mediates {{A}} (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (METH)-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ')\n",
      "[8, 174]\n",
      "8\n",
      "0 197 {{A}} (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (METH)-\n",
      "3 5 induc\n",
      "4 174 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance \n",
      "5 5 {{B}}\n",
      "3519 It is widely believed that dopamine (DA) mediates methamphetamine ({{A}}-induced {{B}} to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3520 It is widely believed that dopamine (DA) mediates methamphetamine ({{A}}-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}, whereas drugs that increase DA neurotransmission enhance toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease ')\n",
      "[1, 107]\n",
      "1\n",
      "0 123 {{A}}-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 107 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease \n",
      "5 5 {{B}}\n",
      "3521 It is widely believed that dopamine (DA) mediates methamphetamine ({{A}}-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ')\n",
      "[1, 174]\n",
      "1\n",
      "0 190 {{A}}-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 174 ed toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance \n",
      "5 5 {{B}}\n",
      "3530 The aim of the study was to examine the influence of {{B}}, induced by {{A}} (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3531 The aim of the study was to examine the influence of {{B}}, induced by haloperidol ({{A}} on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3538 Although there was a discrepancy between the amount of cTnI and cTnT after {{A}}, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced {{B}} and possibly for cardioprotective experiments.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally ', u'ed ')\n",
      "[280, 3]\n",
      "3\n",
      "0 298 {{A}}, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 280 , probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3539 Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after {{A}} indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced {{B}} and possibly for cardioprotective experiments.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally ', u'ed ')\n",
      "[146, 3]\n",
      "3\n",
      "0 164 {{A}} indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 146  indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3552 Three patients who had experienced neuroleptic-induced {{B}} in the past reported that the symptoms of {{A}} akathisia were identical, although somewhat milder.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3553 Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of {{A}} {{B}} were identical, although somewhat milder.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3556 The authors suggest that fluoxetine-induced {{B}} may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic {{A}} \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3557 The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced {{B}} and tricyclic {{A}} \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3558 The authors suggest that {{A}} {{B}} may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3559 The authors suggest that {{A}} akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced {{B}} and tricyclic antidepressant-induced \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-', u'ed ')\n",
      "[142, 3]\n",
      "3\n",
      "0 160 {{A}} akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 142  akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3560 The authors suggest that fluoxetine-induced {{B}} may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of {{A}} akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3561 The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of {{A}} {{B}} and tricyclic antidepressant-induced \"jitteriness\" may be identical.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3562 This study investigated alleviation of streptomycin-induced {{B}} by {{A}} in guinea pigs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3566 The similarity between the histologic appearances of {{A}} {{B}} and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3567 The similarity between the histologic appearances of {{A}} cystitis and both radiation and cyclophosphamide-induced {{B}} is discussed and the world literature reviewed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' cystitis and both radiation and cyclophosphamide-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}} cystitis and both radiation and cyclophosphamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50  cystitis and both radiation and cyclophosphamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3570 In view of the known tendency of {{A}} to induce cellular atypia and {{B}} in other sites, periodic urinary cytology is suggested in patients on long-term therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to ', u'e cellular atypia and ')\n",
      "[4, 22]\n",
      "4\n",
      "0 41 {{A}} to induce cellular atypia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 4  to \n",
      "3 5 induc\n",
      "4 22 e cellular atypia and \n",
      "5 5 {{B}}\n",
      "3571 Attenuation of the lithium-induced {{B}} by {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3576 In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily {{A}} (300 mg/kg, orally) partially reversed AZT-induced {{B}} and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (300 mg/kg, orally) partially reversed AZT-', u'ed ')\n",
      "[44, 3]\n",
      "3\n",
      "0 62 {{A}} (300 mg/kg, orally) partially reversed AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 44  (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3577 In mice rendered {{B}} by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily {{A}} (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3578 In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily {{A}} (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}} (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (300 mg/kg, orally) partially reversed AZT-', u'ed anemia and ')\n",
      "[44, 14]\n",
      "14\n",
      "0 73 {{A}} (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 44  (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "3579 In mice rendered anemic and leukopenic by the administration of {{A}} for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced {{B}} and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-', u'ed ')\n",
      "[138, 3]\n",
      "3\n",
      "0 156 {{A}} for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 138  for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3580 In mice rendered {{B}} by the administration of {{A}} for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3581 In mice rendered anemic and leukopenic by the administration of {{A}} for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}} (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-', u'ed anemia and ')\n",
      "[138, 14]\n",
      "14\n",
      "0 167 {{A}} for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 138  for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "3582 In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of {{A}} plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced {{B}} and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' plus daily BAU (300 mg/kg, orally) partially reversed AZT-', u'ed ')\n",
      "[59, 3]\n",
      "3\n",
      "0 77 {{A}} plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 59  plus daily BAU (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3583 In mice rendered {{B}} by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of {{A}} plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3584 In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of {{A}} plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}} (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' plus daily BAU (300 mg/kg, orally) partially reversed AZT-', u'ed anemia and ')\n",
      "[59, 14]\n",
      "14\n",
      "0 88 {{A}} plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 59  plus daily BAU (300 mg/kg, orally) partially reversed AZT-\n",
      "3 5 induc\n",
      "4 14 ed anemia and \n",
      "5 5 {{B}}\n",
      "3591 In behavioral studies, pre-treatment of mice with BD1018, {{A}}, or LR132 significantly attenuated cocaine-induced {{B}} and lethality.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', or LR132 significantly attenuated cocaine-', u'ed ')\n",
      "[44, 3]\n",
      "3\n",
      "0 62 {{A}}, or LR132 significantly attenuated cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 44 , or LR132 significantly attenuated cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3592 The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced {{B}}, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of {{A}} depend on mitochondria protection.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3596 We used an in vitro model of chemotherapy induced {{B}} that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to {{A}} and cisplatin, two widely used and highly effective chemotherapeutic drugs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3597 We used an in vitro model of chemotherapy induced {{B}} that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and {{A}}, two widely used and highly effective chemotherapeutic drugs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3607 Our results demonstrate that both cisplatin and {{A}} cause early {{B}} with loss of membrane potential and induction of autophagic vacuoles in neurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3608 Our results demonstrate that both {{A}} and paclitaxel cause early {{B}} with loss of membrane potential and induction of autophagic vacuoles in neurons.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3611 {{A}} exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial {{B}} and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exerts neuroprotective effects against chemotherapy ', u'ed neurotoxicity in sensory neurons: it rescues the mitochondrial ')\n",
      "[53, 66]\n",
      "53\n",
      "0 134 {{A}} exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial {{B}}\n",
      "1 5 {{A}}\n",
      "2 53  exerts neuroprotective effects against chemotherapy \n",
      "3 5 induc\n",
      "4 66 ed neurotoxicity in sensory neurons: it rescues the mitochondrial \n",
      "5 5 {{B}}\n",
      "3612 {{A}} exerts neuroprotective effects against chemotherapy induced {{B}} in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exerts neuroprotective effects against chemotherapy ', u'ed ')\n",
      "[53, 3]\n",
      "3\n",
      "0 71 {{A}} exerts neuroprotective effects against chemotherapy induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 53  exerts neuroprotective effects against chemotherapy \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3613 In conclusion mitochondrial {{B}} is an early common event both in {{A}} and cisplatin induced neurotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3614 In conclusion mitochondrial toxicity is an early common event both in {{A}} and cisplatin induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and cisplatin ', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} and cisplatin induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  and cisplatin \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3615 In conclusion mitochondrial {{B}} is an early common event both in paclitaxel and {{A}} induced neurotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3616 In conclusion mitochondrial toxicity is an early common event both in paclitaxel and {{A}} induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3629 Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, {{A}} receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-', u'ed ')\n",
      "[150, 3]\n",
      "3\n",
      "0 168 {{A}} receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 150  receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3631 Effects of pallidal {{A}} on haloperidol-induced {{B}}: behavioral and electrophysiological studies.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on haloperidol-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} on haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  on haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3633 The present study aimed to investigate the effects of pallidal {{A}} on haloperidol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on haloperidol-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} on haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  on haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3646 This study was performed to determine cross-reactivity between {{A}} and isoflurane with the {{B}} induced by halothane.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3647 This study was performed to determine cross-reactivity between enflurane and isoflurane with the {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3648 This study was performed to determine cross-reactivity between enflurane and {{A}} with the {{B}} induced by halothane.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3650 MAIN OUTCOME MEASURE(S): Central {{B}} after ovulation induction with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3652 In our experience and according to the literature, FK506 does not seem to cross-react with {{A}} (CyA), an immuno-suppressive drug already known to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CyA), an immuno-suppressive drug already known to ', u'e ')\n",
      "[52, 2]\n",
      "2\n",
      "0 69 {{A}} (CyA), an immuno-suppressive drug already known to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 52  (CyA), an immuno-suppressive drug already known to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "3653 In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A ({{A}}, an immuno-suppressive drug already known to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', an immuno-suppressive drug already known to ', u'e ')\n",
      "[46, 2]\n",
      "2\n",
      "0 63 {{A}}, an immuno-suppressive drug already known to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 46 , an immuno-suppressive drug already known to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "3654 In our experience and according to the literature, {{A}} does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to ', u'e ')\n",
      "[100, 2]\n",
      "2\n",
      "0 117 {{A}} does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 100  does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "3661 In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced {{B}} in rats, but appears to escape from the regulation by {{A}} after day 3.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3679 Few cases of drug-induced {{B}} have been reported related to {{A}} antimicrobials.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3682 Upon rechallenge with either cephalosporin, the {{B}} was reproduced in most dogs tested; {{A}} (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3683 Upon rechallenge with either {{A}}, the {{B}} was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3684 Upon rechallenge with either cephalosporin, the {{B}} was reproduced in most dogs tested; cefonicid (but not {{A}}-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3702 To this end, persistent {{B}} was induced by administration of {{A}} in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3704 The minimum effective plasma concentrations of (+)-{{A}} for digitalis- and adrenaline-induced {{B}} were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for digitalis- and adrenaline-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} for digitalis- and adrenaline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  for digitalis- and adrenaline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3706 {{A}} pretreatment reverses alfentanil-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' pretreatment reverses alfentanil-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} pretreatment reverses alfentanil-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  pretreatment reverses alfentanil-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3754 {{A}} on either day induced {{B}}; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on either day ', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} on either day induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  on either day \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3755 {{A}} on either day induced status epilepticus; {{B}} at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on either day ', u'ed status epilepticus; ')\n",
      "[15, 23]\n",
      "15\n",
      "0 53 {{A}} on either day induced status epilepticus; {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  on either day \n",
      "3 5 induc\n",
      "4 23 ed status epilepticus; \n",
      "5 5 {{B}}\n",
      "3756 {{A}} on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous {{B}}, whereas P20 rats had no cell loss or spontaneous seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on either day ', u'ed status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous ')\n",
      "[15, 91]\n",
      "15\n",
      "0 121 {{A}} on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  on either day \n",
      "3 5 induc\n",
      "4 91 ed status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous \n",
      "5 5 {{B}}\n",
      "3757 {{A}} on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on either day ', u'ed status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous ')\n",
      "[15, 150]\n",
      "15\n",
      "0 180 {{A}} on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  on either day \n",
      "3 5 induc\n",
      "4 150 ed status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous \n",
      "5 5 {{B}}\n",
      "3777 Conversely, prostaglandin E2-induced {{B}} was blocked by {{A}} (greater than or equal to 500 ng) but not by the substance P antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3793 Erythropoietin restores the anemia-induced reduction in {{A}} cytotoxicity in rat {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3794 Erythropoietin restores the anemia-induced reduction in {{A}} {{B}} in rat tumors.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3796 These results suggest that chemotherapy-induced {{B}} reduces cytotoxicity of {{A}} in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3797 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of {{A}} in tumors, whereas correction of {{B}} by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3798 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of {{A}} in {{B}}, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3799 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of {{A}} in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to {{B}} tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3800 These results suggest that chemotherapy-induced anemia reduces {{B}} of {{A}} in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3801 These results suggest that chemotherapy-induced {{B}} reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved {{A}} supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3802 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of {{B}} by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved {{A}} supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3803 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in {{B}}, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved {{A}} supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3804 These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved {{A}} supply to {{B}} tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3805 These results suggest that chemotherapy-induced anemia reduces {{B}} of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved {{A}} supply to tumor tissue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3806 {{A}}, as well as propranolol and biperiden, inhibited the haloperidol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', as well as propranolol and biperiden, inhibited the haloperidol-', u'ed ')\n",
      "[66, 3]\n",
      "3\n",
      "0 84 {{A}}, as well as propranolol and biperiden, inhibited the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 66 , as well as propranolol and biperiden, inhibited the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3808 Carteolol, as well as propranolol and {{A}}, inhibited the haloperidol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', inhibited the haloperidol-', u'ed ')\n",
      "[28, 3]\n",
      "3\n",
      "0 46 {{A}}, inhibited the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 28 , inhibited the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3809 Carteolol, as well as {{A}} and biperiden, inhibited the haloperidol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and biperiden, inhibited the haloperidol-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} and biperiden, inhibited the haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  and biperiden, inhibited the haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3815 Components of lemon essential oil attenuate {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3825 In all the experiments, the attenuation of the lithium-induced {{B}} by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma {{A}} level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3826 In all the experiments, the attenuation of the lithium-induced {{B}} by {{A}} was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3828 In all the experiments, the attenuation of the lithium-induced {{B}} by amiloride was accompanied by a reduction of the ratio between the {{A}} concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3839 Methimazole-induced {{B}} was diagnosed, and {{A}} therapy was resumed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3858 Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to {{A}} {{B}} (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3859 Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to {{A}} acute renal failure ({{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3860 Because rats with streptozotocin-induced {{B}} (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to {{A}} acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3861 Because rats with streptozotocin-induced diabetes mellitus ({{B}} have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to {{A}} acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3862 Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis ({{B}} of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to {{A}} acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3863 Because rats with {{A}} diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced {{B}} (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-', u'ed ')\n",
      "[174, 3]\n",
      "3\n",
      "0 192 {{A}} diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 174  diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3864 Because rats with {{A}} diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure ({{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-', u'ed acute renal failure (')\n",
      "[174, 24]\n",
      "24\n",
      "0 213 {{A}} diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure ({{B}}\n",
      "1 5 {{A}}\n",
      "2 174  diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-\n",
      "3 5 induc\n",
      "4 24 ed acute renal failure (\n",
      "5 5 {{B}}\n",
      "3865 Because rats with {{A}} {{B}} (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3866 Because rats with {{A}} diabetes mellitus ({{B}} have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3867 Because rats with {{A}} diabetes mellitus (DM) have a high solute diuresis ({{B}} of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3870 We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening {{B}} following a standard dose of intravenous {{A}} for induction of anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3871 We report an undiagnosed case of {{B}} in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous {{A}} for induction of anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3882 The effects of the adjunctive {{A}} on male {{B}} induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3883 The effects of the adjunctive bupropion on male {{B}} induced by a selective {{A}} reuptake inhibitor: a double-blind placebo-controlled and randomized study.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3884 The rats treated with {{A}} showed severe typical OP-induced {{B}} signs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' showed severe typical OP-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} showed severe typical OP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  showed severe typical OP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3902 To our knowledge, this has not previously been reported as a side effect of preoperative {{A}} therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy, although dipyridamole-', u'ed myocardial ischemia has been demonstrated to occur in animals and humans with ')\n",
      "[32, 81]\n",
      "32\n",
      "0 128 {{A}} therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  therapy, although dipyridamole-\n",
      "3 5 induc\n",
      "4 81 ed myocardial ischemia has been demonstrated to occur in animals and humans with \n",
      "5 5 {{B}}\n",
      "3903 To our knowledge, this has not previously been reported as a side effect of preoperative {{A}} therapy, although dipyridamole-induced {{B}} has been demonstrated to occur in animals and humans with coronary artery disease.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy, although dipyridamole-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} therapy, although dipyridamole-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  therapy, although dipyridamole-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3947 {{A}} affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-', u'ed ')\n",
      "[91, 3]\n",
      "3\n",
      "0 109 {{A}} affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3950 A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced {{B}}, whereas 5 mg/kg i.v. was needed to suppress {{A}} arrhythmias.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3951 A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3952 A lower dose of 1 mg/kg i.v. of (-)-{{A}} suppressed the digitalis-induced {{B}}, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' suppressed the digitalis-', u'ed ')\n",
      "[26, 3]\n",
      "3\n",
      "0 44 {{A}} suppressed the digitalis-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  suppressed the digitalis-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3953 A lower dose of 1 mg/kg i.v. of (-)-{{A}} suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-', u'ed ')\n",
      "[101, 3]\n",
      "3\n",
      "0 119 {{A}} suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 101  suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "3964 A randomized, placebo-controlled, crossover study of {{A}} for SSRI-induced female {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for SSRI-', u'ed female ')\n",
      "[10, 10]\n",
      "10\n",
      "0 35 {{A}} for SSRI-induced female {{B}}\n",
      "1 5 {{A}}\n",
      "2 10  for SSRI-\n",
      "3 5 induc\n",
      "4 10 ed female \n",
      "5 5 {{B}}\n",
      "3979 Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced {{A}} {{B}} is also confounded by drug effects on body temperature.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "3981 Here we show that the recently reported ability of {{A}} to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA {{B}} is also confounded by drug effects on body temperature.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to reverse the protective effect of alpha-methyl-para-tyrosine on METH-', u'ed DA ')\n",
      "[72, 6]\n",
      "6\n",
      "0 93 {{A}} to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA {{B}}\n",
      "1 5 {{A}}\n",
      "2 72  to reverse the protective effect of alpha-methyl-para-tyrosine on METH-\n",
      "3 5 induc\n",
      "4 6 ed DA \n",
      "5 5 {{B}}\n",
      "4025 L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in {{B}} (PD) patients after a prolonged treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4026 L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease ({{B}} patients after a prolonged treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4027 L-DOPA-induced {{B}} (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4028 L-DOPA-induced dyskinesia ({{B}} is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4049 We recently showed elevated reactive {{A}} species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-', u'ed ')\n",
      "[152, 3]\n",
      "3\n",
      "0 170 {{A}} species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 152  species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4053 {{A}} synthase expression in the course of lead-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' synthase expression in the course of lead-', u'ed ')\n",
      "[43, 3]\n",
      "3\n",
      "0 61 {{A}} synthase expression in the course of lead-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 43  synthase expression in the course of lead-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4055 Differential effects of systemically administered ketamine and {{A}} on dynamic and static {{B}} induced by intradermal capsaicin in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4056 Differential effects of systemically administered {{A}} and lidocaine on dynamic and static {{B}} induced by intradermal capsaicin in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4057 Differential effects of systemically administered ketamine and lidocaine on dynamic and static {{B}} induced by intradermal {{A}} in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4071 VPU was more potent than {{A}}, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced {{B}} whereas the corresponding value for VPA was 322 mg/kg.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-', u'ed ')\n",
      "[99, 3]\n",
      "3\n",
      "0 117 {{A}}, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 99 , exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4072 VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced {{B}} whereas the corresponding value for {{A}} was 322 mg/kg.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4074 {{A}} was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced {{B}} whereas the corresponding value for VPA was 322 mg/kg.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-', u'ed ')\n",
      "[124, 3]\n",
      "3\n",
      "0 142 {{A}} was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 124  was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4078 Our results provide evidence that the AAP-induced {{B}} and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4079 Our results provide evidence that the AAP-induced {{B}} and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by {{A}} or by dietary depletion of the enzyme's substrate NAD.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4080 Our results provide evidence that the AAP-induced {{B}} and its exacerbation by {{A}} can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4101 Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat {{B}} after {{A}} treatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4103 To clarify the effects of {{A}} on {{B}} cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4104 To clarify the effects of {{A}} on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat {{B}} cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-', u'ed rat ')\n",
      "[122, 7]\n",
      "7\n",
      "0 144 {{A}} on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat {{B}}\n",
      "1 5 {{A}}\n",
      "2 122  on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-\n",
      "3 5 induc\n",
      "4 7 ed rat \n",
      "5 5 {{B}}\n",
      "4105 To clarify the effects of bromocriptine on {{B}} cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of {{A}} (3 mg/kg of body weight).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4106 To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat {{B}} cells 1 h and 6 h after injection of {{A}} (3 mg/kg of body weight).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4122 {{A}} prevented and reversed dexamethasone-induced {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevented and reversed dexamethasone-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} prevented and reversed dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  prevented and reversed dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4127 {{A}} 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-', u'ed ')\n",
      "[86, 3]\n",
      "3\n",
      "0 104 {{A}} 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 86  0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4128 Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of {{A}}- or diazepam-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- or diazepam-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}}- or diazepam-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 - or diazepam-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4135 {{A}}, an effective treatment for acromegaly, induces {{B}} in 13-60% of patients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', an effective treatment for acromegaly, ', u'es ')\n",
      "[41, 3]\n",
      "3\n",
      "0 59 {{A}}, an effective treatment for acromegaly, induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 41 , an effective treatment for acromegaly, \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "4136 {{A}}, an effective treatment for {{B}}, induces gall bladder stones in 13-60% of patients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4145 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4146 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[333, 44]\n",
      "44\n",
      "0 392 {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 333  or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4147 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4148 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4149 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4150 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by {{A}} or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4151 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4152 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[316, 44]\n",
      "44\n",
      "0 375 {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 316  administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4153 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4154 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4155 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4156 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or {{A}} administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4157 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4158 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[104, 44]\n",
      "44\n",
      "0 163 {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 104  injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4159 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4160 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4161 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4162 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by {{A}} injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4163 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4164 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[1105, 44]\n",
      "44\n",
      "0 1164 {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 1105  (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4165 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to ')\n",
      "[424, 142]\n",
      "142\n",
      "0 581 {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}}\n",
      "1 5 {{A}}\n",
      "2 424  (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 142 ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to \n",
      "5 5 {{B}}\n",
      "4166 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4167 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term ')\n",
      "[424, 14]\n",
      "14\n",
      "0 453 {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}}\n",
      "1 5 {{A}}\n",
      "2 424  (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 14 ed short-term \n",
      "5 5 {{B}}\n",
      "4168 The effect of {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against ')\n",
      "[424, 84]\n",
      "84\n",
      "0 523 {{A}} (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}}\n",
      "1 5 {{A}}\n",
      "2 424  (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 84 ed short-term amnesia for a passive avoidance task; (3) complete protection against \n",
      "5 5 {{B}}\n",
      "4169 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4170 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[1093, 44]\n",
      "44\n",
      "0 1152 {{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 1093 , 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4171 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to ')\n",
      "[412, 142]\n",
      "142\n",
      "0 569 {{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}}\n",
      "1 5 {{A}}\n",
      "2 412 , 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 142 ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to \n",
      "5 5 {{B}}\n",
      "4172 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4173 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term ')\n",
      "[412, 14]\n",
      "14\n",
      "0 441 {{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}}\n",
      "1 5 {{A}}\n",
      "2 412 , 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 14 ed short-term \n",
      "5 5 {{B}}\n",
      "4174 The effect of aniracetam ({{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against ')\n",
      "[412, 84]\n",
      "84\n",
      "0 511 {{A}}, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}}\n",
      "1 5 {{A}}\n",
      "2 412 , 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 84 ed short-term amnesia for a passive avoidance task; (3) complete protection against \n",
      "5 5 {{B}}\n",
      "4175 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4176 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[1065, 44]\n",
      "44\n",
      "0 1124 {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 1065  was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4177 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to ')\n",
      "[384, 142]\n",
      "142\n",
      "0 541 {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}}\n",
      "1 5 {{A}}\n",
      "2 384  was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 142 ed short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to \n",
      "5 5 {{B}}\n",
      "4178 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4179 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term ')\n",
      "[384, 14]\n",
      "14\n",
      "0 413 {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term {{B}}\n",
      "1 5 {{A}}\n",
      "2 384  was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 14 ed short-term \n",
      "5 5 {{B}}\n",
      "4180 The effect of aniracetam (Ro 13-5057, {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-', u'ed short-term amnesia for a passive avoidance task; (3) complete protection against ')\n",
      "[384, 84]\n",
      "84\n",
      "0 483 {{A}} was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against {{B}}\n",
      "1 5 {{A}}\n",
      "2 384  was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-\n",
      "3 5 induc\n",
      "4 84 ed short-term amnesia for a passive avoidance task; (3) complete protection against \n",
      "5 5 {{B}}\n",
      "4181 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal {{B}} immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4182 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}} applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task ', u'ed in mice by subconvulsant electroshock or ')\n",
      "[674, 44]\n",
      "44\n",
      "0 733 {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or {{B}}\n",
      "1 5 {{A}}\n",
      "2 674  short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task \n",
      "3 5 induc\n",
      "4 44 ed in mice by subconvulsant electroshock or \n",
      "5 5 {{B}}\n",
      "4183 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to {{B}} immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4184 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally {{B}} (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4185 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term {{B}} for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4186 The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the {{A}} short-term amnesia for a passive avoidance task; (3) complete protection against {{B}} for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4220 The present studies were designed to clarify the role of {{A}} and pineal idolamines on ketamine-induced {{B}} in the intact, pinealectomized or hypophysectomized chick and rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and pineal idolamines on ketamine-', u'ed ')\n",
      "[35, 3]\n",
      "3\n",
      "0 53 {{A}} and pineal idolamines on ketamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  and pineal idolamines on ketamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4224 Iatrogenically induced intractable atrioventricular reentrant tachycardia after {{A}} and catheter ablation in a patient with Wolff-Parkinson-White syndrome and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4225 Iatrogenically induced intractable {{B}} after {{A}} and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4226 Iatrogenically induced intractable atrioventricular reentrant tachycardia after {{A}} and catheter ablation in a patient with {{B}} and idiopathic dilated cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4227 The co-administration of aspirin with {{A}} (FANFT) to rats resulted in a reduced incidence of FANFT-induced {{B}} but a concomitant induction of forestomach tumors.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (FANFT) to rats resulted in a reduced incidence of FANFT-', u'ed ')\n",
      "[58, 3]\n",
      "3\n",
      "0 76 {{A}} (FANFT) to rats resulted in a reduced incidence of FANFT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 58  (FANFT) to rats resulted in a reduced incidence of FANFT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4228 The co-administration of aspirin with {{A}} (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant ', u'tion of ')\n",
      "[103, 8]\n",
      "8\n",
      "0 126 {{A}} (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}\n",
      "1 5 {{A}}\n",
      "2 103  (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant \n",
      "3 5 induc\n",
      "4 8 tion of \n",
      "5 5 {{B}}\n",
      "4229 The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ({{A}} to rats resulted in a reduced incidence of FANFT-induced {{B}} but a concomitant induction of forestomach tumors.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to rats resulted in a reduced incidence of FANFT-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}} to rats resulted in a reduced incidence of FANFT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50  to rats resulted in a reduced incidence of FANFT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4230 The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide ({{A}} to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant ', u'tion of ')\n",
      "[95, 8]\n",
      "8\n",
      "0 118 {{A}} to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}\n",
      "1 5 {{A}}\n",
      "2 95  to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant \n",
      "3 5 induc\n",
      "4 8 tion of \n",
      "5 5 {{B}}\n",
      "4231 The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of {{A}} {{B}} but a concomitant induction of forestomach tumors.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4232 The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of {{A}} bladder carcinomas but a concomitant induction of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' bladder carcinomas but a concomitant ', u'tion of ')\n",
      "[38, 8]\n",
      "8\n",
      "0 61 {{A}} bladder carcinomas but a concomitant induction of {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  bladder carcinomas but a concomitant \n",
      "3 5 induc\n",
      "4 8 tion of \n",
      "5 5 {{B}}\n",
      "4233 The co-administration of {{A}} with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced {{B}} but a concomitant induction of forestomach tumors.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-', u'ed ')\n",
      "[109, 3]\n",
      "3\n",
      "0 127 {{A}} with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 109  with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4234 The co-administration of {{A}} with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant ', u'tion of ')\n",
      "[154, 8]\n",
      "8\n",
      "0 177 {{A}} with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of {{B}}\n",
      "1 5 {{A}}\n",
      "2 154  with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant \n",
      "3 5 induc\n",
      "4 8 tion of \n",
      "5 5 {{B}}\n",
      "4259 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of {{B}} in a rat model of {{A}} (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4260 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of {{A}} (DOX)-induced {{B}}, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DOX)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4261 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of {{A}} (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of {{B}} monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DOX)-', u'ed cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of ')\n",
      "[7, 105]\n",
      "7\n",
      "0 127 {{A}} (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (DOX)-\n",
      "3 5 induc\n",
      "4 105 ed cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of \n",
      "5 5 {{B}}\n",
      "4262 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of {{B}} in a rat model of doxorubicin ({{A}}-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4263 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ({{A}}-induced {{B}}, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4264 We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ({{A}}-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of {{B}} monitored by echocardiography and histological examinations in this model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of ')\n",
      "[1, 105]\n",
      "1\n",
      "0 121 {{A}}-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 105 ed cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of \n",
      "5 5 {{B}}\n",
      "4301 The effects of REM sleep deprivation (REMD) on apomorphine-induced {{B}} and {{A}} head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4302 The effects of {{B}} (REMD) on apomorphine-induced aggressiveness and {{A}} head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4303 The effects of REM sleep deprivation ({{B}} on apomorphine-induced aggressiveness and {{A}} head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4304 The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and {{A}} {{B}} in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4305 The effects of REM sleep deprivation (REMD) on {{A}} {{B}} and quipazine-induced head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4306 The effects of {{B}} (REMD) on {{A}} aggressiveness and quipazine-induced head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4307 The effects of REM sleep deprivation ({{B}} on {{A}} aggressiveness and quipazine-induced head twitches in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4308 The effects of REM sleep deprivation (REMD) on {{A}} aggressiveness and quipazine-induced {{B}} in rats were determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' aggressiveness and quipazine-', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} aggressiveness and quipazine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  aggressiveness and quipazine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4309 Forty-eight hr of REMD increased apomorphine-induced {{B}}, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) {{A}} head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4310 Forty-eight hr of {{B}} increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) {{A}} head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4311 Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of {{B}} or increased (96 hr after completing of REMD) {{A}} head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4312 Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of {{B}} {{A}} head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4313 Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4314 Forty-eight hr of REMD increased {{A}} {{B}}, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4315 Forty-eight hr of {{B}} increased {{A}} aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4316 Forty-eight hr of REMD increased {{A}} aggressiveness, and reduced (immediately after completing of {{B}} or increased (96 hr after completing of REMD) quipazine-induced head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4317 Forty-eight hr of REMD increased {{A}} aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of {{B}} quipazine-induced head twitches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4318 Forty-eight hr of REMD increased {{A}} aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-', u'ed ')\n",
      "[124, 3]\n",
      "3\n",
      "0 142 {{A}} aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 124  aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4333 Cardioprotective effect of {{A}} on isoproterenol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on isoproterenol-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} on isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  on isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4334 Preclinical toxicologic investigation suggested that a new calcium channel blocker, {{A}}, induced {{B}} in rat fetuses exposed to this agent during organogenesis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', ', u'ed ')\n",
      "[2, 3]\n",
      "2\n",
      "0 20 {{A}}, induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 2 , \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4335 Preclinical toxicologic investigation suggested that a new {{A}} channel blocker, Ro 40-5967, induced {{B}} in rat fetuses exposed to this agent during organogenesis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blocker, Ro 40-5967, ', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} channel blocker, Ro 40-5967, induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  channel blocker, Ro 40-5967, \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4345 The present study was designed to evaluate the cardioprotective potential of {{A}} on isoproterenol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on isoproterenol-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} on isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  on isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4346 Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced {{B}} and climbing behavior, and stress-induced plasma {{A}} level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4347 Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, {{A}} {{B}} and climbing behavior, and stress-induced plasma corticosterone level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4348 Whatever was the dose, the central administration of {{A}} had no effect on body temperature, nociception, apomorphine-induced {{B}} and climbing behavior, and stress-induced plasma corticosterone level.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' had no effect on body temperature, nociception, apomorphine-', u'ed ')\n",
      "[61, 3]\n",
      "3\n",
      "0 79 {{A}} had no effect on body temperature, nociception, apomorphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  had no effect on body temperature, nociception, apomorphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4349 An {{B}} consisting of angioneurotic edema secondary to continuous infusion {{A}} occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4350 An allergic reaction consisting of angioneurotic edema secondary to continuous infusion {{A}} occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-', u'ed ')\n",
      "[93, 3]\n",
      "3\n",
      "0 111 {{A}} occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 93  occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4351 An allergic reaction consisting of angioneurotic edema secondary to continuous infusion {{A}} occurred in a patient with recurrent {{B}} of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4352 An allergic reaction consisting of {{B}} secondary to continuous infusion {{A}} occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4353 An allergic reaction consisting of angioneurotic edema secondary to continuous infusion {{A}} occurred in a patient with recurrent carcinoma of the oral cavity, {{B}}, and cisplatin-induced impaired renal function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4363 Administration of {{A}} for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and {{B}} and improved mitochondrial respiratory function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for a period of 8 days significantly attenuated isoproterenol-', u'ed cardiac dysfunction and ')\n",
      "[63, 27]\n",
      "27\n",
      "0 105 {{A}} for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and {{B}}\n",
      "1 5 {{A}}\n",
      "2 63  for a period of 8 days significantly attenuated isoproterenol-\n",
      "3 5 induc\n",
      "4 27 ed cardiac dysfunction and \n",
      "5 5 {{B}}\n",
      "4364 Administration of {{A}} for a period of 8 days significantly attenuated isoproterenol-induced {{B}} and myocardial injury and improved mitochondrial respiratory function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for a period of 8 days significantly attenuated isoproterenol-', u'ed ')\n",
      "[63, 3]\n",
      "3\n",
      "0 81 {{A}} for a period of 8 days significantly attenuated isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 63  for a period of 8 days significantly attenuated isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4367 The protective role of {{A}} against isoproterenol-induced {{B}} was further confirmed by histopathological examination.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' against isoproterenol-', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} against isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  against isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4372 The results of our study suggest that {{A}} possessing antioxidant activity has a significant protective effect against isoproterenol-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' possessing antioxidant activity has a significant protective effect against isoproterenol-', u'ed ')\n",
      "[91, 3]\n",
      "3\n",
      "0 109 {{A}} possessing antioxidant activity has a significant protective effect against isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  possessing antioxidant activity has a significant protective effect against isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4404 Recurrent acute {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4426 In contrast, {{A}} prevented alfentanil-induced {{B}} in a dose-dependent fashion.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevented alfentanil-', u'ed ')\n",
      "[22, 3]\n",
      "3\n",
      "0 40 {{A}} prevented alfentanil-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  prevented alfentanil-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4472 During HEM-induced {{B}} the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the {{A}} group.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4489 {{A}} 6 receptor gene is associated with methamphetamine-induced {{B}} in a Japanese population.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 6 receptor gene is associated with methamphetamine-', u'ed ')\n",
      "[52, 3]\n",
      "3\n",
      "0 70 {{A}} 6 receptor gene is associated with methamphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 52  6 receptor gene is associated with methamphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4493 The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as {{A}} and olanzapine, and d-amphetamine-induced {{B}} in rats is corrected with the use of a selective 5-HT6 receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and olanzapine, and d-amphetamine-', u'ed ')\n",
      "[35, 3]\n",
      "3\n",
      "0 53 {{A}} and olanzapine, and d-amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  and olanzapine, and d-amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4494 The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and {{A}}, and d-amphetamine-induced {{B}} in rats is corrected with the use of a selective 5-HT6 receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', and d-amphetamine-', u'ed ')\n",
      "[20, 3]\n",
      "3\n",
      "0 38 {{A}}, and d-amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 20 , and d-amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4495 The {{A}} 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced {{B}} in rats is corrected with the use of a selective 5-HT6 receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-', u'ed ')\n",
      "[145, 3]\n",
      "3\n",
      "0 163 {{A}} 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 145  6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4496 The serotonin 6 ({{A}}) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced {{B}} in rats is corrected with the use of a selective 5-HT6 receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u') receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-', u'ed ')\n",
      "[136, 3]\n",
      "3\n",
      "0 154 {{A}}) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 136 ) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4497 The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced {{B}} in rats is corrected with the use of a selective {{A}} receptor antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4501 Effect of green tea and {{A}} combination in isoproterenol induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' combination in isoproterenol ', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} combination in isoproterenol induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  combination in isoproterenol \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4502 Effect of green tea and vitamin E combination in {{A}} induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4503 Effect of {{A}} and vitamin E combination in isoproterenol induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and vitamin E combination in isoproterenol ', u'ed ')\n",
      "[44, 3]\n",
      "3\n",
      "0 62 {{A}} and vitamin E combination in isoproterenol induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 44  and vitamin E combination in isoproterenol \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4506 The present study was aimed to investigate the combined effects of green tea and {{A}} on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-', u'ed ')\n",
      "[147, 3]\n",
      "3\n",
      "0 165 {{A}} on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 147  on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4507 The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in {{A}} (ISO)-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (ISO)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (ISO)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (ISO)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4508 The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol ({{A}}-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4509 The present study was aimed to investigate the combined effects of {{A}} and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-', u'ed ')\n",
      "[161, 3]\n",
      "3\n",
      "0 179 {{A}} and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 161  and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4511 Therefore, we conducted an analysis of the association of the {{A}} gene (HTR6) with METH-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' gene (HTR6) with METH-', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} gene (HTR6) with METH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  gene (HTR6) with METH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4570 The alpha3 and beta4 nicotinic {{A}} receptor subunits are necessary for nicotine-induced {{B}} and hypolocomotion in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptor subunits are necessary for nicotine-', u'ed ')\n",
      "[46, 3]\n",
      "3\n",
      "0 64 {{A}} receptor subunits are necessary for nicotine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  receptor subunits are necessary for nicotine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4571 The alpha3 and beta4 nicotinic {{A}} receptor subunits are necessary for nicotine-induced seizures and {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptor subunits are necessary for nicotine-', u'ed seizures and ')\n",
      "[46, 16]\n",
      "16\n",
      "0 77 {{A}} receptor subunits are necessary for nicotine-induced seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  receptor subunits are necessary for nicotine-\n",
      "3 5 induc\n",
      "4 16 ed seizures and \n",
      "5 5 {{B}}\n",
      "4584 beta4 -/- mice were less sensitive to the effects of {{A}} both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-', u'ed ')\n",
      "[127, 3]\n",
      "3\n",
      "0 145 {{A}} both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 127  both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4672 The drug effect studied was the antagonism by {{A}} of terbutaline-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' of terbutaline-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} of terbutaline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  of terbutaline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4681 In the absence of caffeine, {{A}} (up to 300 mg/kg) did not modify the {{B}} induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4682 In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the {{B}} induced by maximal electroshock and did not alter the convulsant dose of {{A}} in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4683 In the absence of {{A}}, acetaminophen (up to 300 mg/kg) did not modify the {{B}} induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4689 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and {{A}}, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', but was less likely to reproduce the levodopa-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}}, but was less likely to reproduce the levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48 , but was less likely to reproduce the levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4690 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced {{B}} as levodopa and {{A}}, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4691 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either {{A}} or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4692 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced {{B}} as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either {{A}} or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4693 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as {{A}} and LY-171555, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "induc\n",
      "(u' and LY-171555, but was less likely to reproduce the levodopa-', u'ed ')\n",
      "[62, 3]\n",
      "3\n",
      "0 80 {{A}} and LY-171555, but was less likely to reproduce the levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  and LY-171555, but was less likely to reproduce the levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4694 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced {{B}} as {{A}} and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4695 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the {{A}} {{B}} in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4696 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced {{B}} as levodopa and LY-171555, but was less likely to reproduce the {{A}} dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4697 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either LY-171555 or subsequent challenge of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4698 Acute administration of A-86929 was as efficacious in alleviating MPTP-induced {{B}} as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4699 Acute administration of A-86929 was as efficacious in alleviating {{A}} parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-', u'ed ')\n",
      "[87, 3]\n",
      "3\n",
      "0 105 {{A}} parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 87  parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4700 Acute administration of A-86929 was as efficacious in alleviating {{A}} {{B}} as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4701 Acute administration of {{A}} was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}} in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-', u'ed ')\n",
      "[134, 3]\n",
      "3\n",
      "0 152 {{A}} was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 134  was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4702 Acute administration of {{A}} was as efficacious in alleviating MPTP-induced {{B}} as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was as efficacious in alleviating MPTP-', u'ed ')\n",
      "[40, 3]\n",
      "3\n",
      "0 58 {{A}} was as efficacious in alleviating MPTP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  was as efficacious in alleviating MPTP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4714 The attenuating effect of {{A}}, a beta-adrenoceptor antagonist, on neuroleptic-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a beta-adrenoceptor antagonist, on neuroleptic-', u'ed ')\n",
      "[49, 3]\n",
      "3\n",
      "0 67 {{A}}, a beta-adrenoceptor antagonist, on neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 49 , a beta-adrenoceptor antagonist, on neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4731 From the present study it is concluded that {{A}} exerts a beneficial effect against ISPH-induced {{B}} due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exerts a beneficial effect against ISPH-', u'ed ')\n",
      "[41, 3]\n",
      "3\n",
      "0 59 {{A}} exerts a beneficial effect against ISPH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 41  exerts a beneficial effect against ISPH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4732 From the present study it is concluded that {{A}} exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exerts a beneficial effect against ISPH-', u'ed MI due to its antioxidant potential, which regulated the tissues defense system against ')\n",
      "[41, 91]\n",
      "41\n",
      "0 147 {{A}} exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against {{B}}\n",
      "1 5 {{A}}\n",
      "2 41  exerts a beneficial effect against ISPH-\n",
      "3 5 induc\n",
      "4 91 ed MI due to its antioxidant potential, which regulated the tissues defense system against \n",
      "5 5 {{B}}\n",
      "4795 Dual effects of {{A}} on barbiturate-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on barbiturate-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} on barbiturate-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  on barbiturate-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4796 Acute analgesic and antiinflammatory activities were ascertained using {{A}} induced writhing model (mice) and carrageenan-induced rat paw {{B}} model, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' induced writhing model (mice) and carrageenan-', u'ed rat paw ')\n",
      "[47, 11]\n",
      "11\n",
      "0 73 {{A}} induced writhing model (mice) and carrageenan-induced rat paw {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  induced writhing model (mice) and carrageenan-\n",
      "3 5 induc\n",
      "4 11 ed rat paw \n",
      "5 5 {{B}}\n",
      "4797 Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and {{A}} rat paw {{B}} model, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4798 The results indicated that concomitant treatment with gum Arabic and {{A}} significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[260, 12]\n",
      "12\n",
      "0 287 {{A}} significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 260  significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4799 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and {{A}}, and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[100, 12]\n",
      "12\n",
      "0 127 {{A}}, and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 100 , and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4800 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus {{A}} group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' group) The GM-', u'ed proximal ')\n",
      "[15, 12]\n",
      "12\n",
      "0 42 {{A}} group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4802 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given {{A}} together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4803 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given {{A}} and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4804 The results indicated that concomitant treatment with {{A}} and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[267, 12]\n",
      "12\n",
      "0 294 {{A}} and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 267  and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4805 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with {{A}} than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4806 The results indicated that concomitant treatment with gum Arabic and GM significantly increased {{A}} and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[225, 12]\n",
      "12\n",
      "0 252 {{A}} and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 225  and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4807 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and {{A}} by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[216, 12]\n",
      "12\n",
      "0 243 {{A}} by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 216  by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4808 The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical {{A}} by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}} appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' by 21% (compared to 27% in the cellulose plus GM group) The GM-', u'ed proximal ')\n",
      "[64, 12]\n",
      "12\n",
      "0 91 {{A}} by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal {{B}}\n",
      "1 5 {{A}}\n",
      "2 64  by 21% (compared to 27% in the cellulose plus GM group) The GM-\n",
      "3 5 induc\n",
      "4 12 ed proximal \n",
      "5 5 {{B}}\n",
      "4817 Kindled {{B}} were induced by daily administration of 60 mg/kg {{A}} for 5 days.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4832 Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced {{B}}, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous {{A}} infusion.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4833 Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a {{B}} state induced by continuous {{A}} infusion.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4849 Concomitant {{A}} administration prevented the {{B}} and decreased the increased oxidative stress induced by these antiepileptic drugs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4851 PURPOSE: This study was designed to establish a rat model of {{B}} (TAA) by {{A}} (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4852 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm ({{B}} by {{A}} (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4853 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by {{A}} (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in {{B}} formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CaCl(2))-', u'ed arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in ')\n",
      "[11, 176]\n",
      "11\n",
      "0 202 {{A}} (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  (CaCl(2))-\n",
      "3 5 induc\n",
      "4 176 ed arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in \n",
      "5 5 {{B}}\n",
      "4854 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by {{A}} (CaCl(2))-induced {{B}} and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CaCl(2))-', u'ed ')\n",
      "[11, 3]\n",
      "3\n",
      "0 29 {{A}} (CaCl(2))-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  (CaCl(2))-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4855 PURPOSE: This study was designed to establish a rat model of {{B}} (TAA) by calcium chloride ({{A}}-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4856 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm ({{B}} by calcium chloride ({{A}}-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4857 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride ({{A}}-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in {{B}} formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in ')\n",
      "[1, 176]\n",
      "1\n",
      "0 192 {{A}}-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 176 ed arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in \n",
      "5 5 {{B}}\n",
      "4858 PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride ({{A}}-induced {{B}} and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4860 CONCLUSIONS: {{B}} induced by contrast medium may be less likely to develop in high-risk patients when {{A}} is used rather than a low-osmolar, nonionic contrast medium.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4882 A randomized comparison of labetalol and {{A}} for induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for ', u'ed ')\n",
      "[5, 3]\n",
      "3\n",
      "0 23 {{A}} for induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  for \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4883 A randomized comparison of {{A}} and nitroprusside for induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and nitroprusside for ', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} and nitroprusside for induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  and nitroprusside for \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4885 Moreover, naloxazone significantly attenuated the {{A}} hypotension and {{B}}, whereas morphine-induced bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4886 Moreover, naloxazone significantly attenuated the {{A}} {{B}} and respiratory depression, whereas morphine-induced bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4887 Moreover, naloxazone significantly attenuated the {{A}} hypotension and respiratory depression, whereas morphine-induced {{B}} was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' hypotension and respiratory depression, whereas morphine-', u'ed ')\n",
      "[58, 3]\n",
      "3\n",
      "0 76 {{A}} hypotension and respiratory depression, whereas morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 58  hypotension and respiratory depression, whereas morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4888 Moreover, naloxazone significantly attenuated the morphine-induced hypotension and {{B}}, whereas {{A}} bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4889 Moreover, naloxazone significantly attenuated the morphine-induced {{B}} and respiratory depression, whereas {{A}} bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4890 Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas {{A}} {{B}} was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4891 Moreover, {{A}} significantly attenuated the morphine-induced hypotension and {{B}}, whereas morphine-induced bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly attenuated the morphine-', u'ed hypotension and ')\n",
      "[39, 19]\n",
      "19\n",
      "0 73 {{A}} significantly attenuated the morphine-induced hypotension and {{B}}\n",
      "1 5 {{A}}\n",
      "2 39  significantly attenuated the morphine-\n",
      "3 5 induc\n",
      "4 19 ed hypotension and \n",
      "5 5 {{B}}\n",
      "4892 Moreover, {{A}} significantly attenuated the morphine-induced {{B}} and respiratory depression, whereas morphine-induced bradycardia was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly attenuated the morphine-', u'ed ')\n",
      "[39, 3]\n",
      "3\n",
      "0 57 {{A}} significantly attenuated the morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 39  significantly attenuated the morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4893 Moreover, {{A}} significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced {{B}} was less affected.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-', u'ed ')\n",
      "[104, 3]\n",
      "3\n",
      "0 122 {{A}} significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 104  significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4913 The frequency of sound-induced {{B}} after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4914 The frequency of sound-induced {{B}} after 12.5 or 25 mg/kg {{A}} was reduced from 50 to 5% by acetaminophen.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4920 Reversible {{B}} induced by {{A}} in a pediatric heart transplant recipient: case report.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4929 Herein we describe transient {{B}} induced by {{A}} after heart transplantation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4931 Thus, we conclude that {{A}} induces reversible {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es reversible ')\n",
      "[1, 14]\n",
      "1\n",
      "0 30 {{A}} induces reversible {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 14 es reversible \n",
      "5 5 {{B}}\n",
      "4932 Prenatal exposure to {{A}} induces {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "4936 {{A}} but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' but not ephedrine reduces frontal lobe oxygenation following anesthesia-', u'ed ')\n",
      "[73, 3]\n",
      "3\n",
      "0 91 {{A}} but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  but not ephedrine reduces frontal lobe oxygenation following anesthesia-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4937 Phenylephrine but not {{A}} reduces frontal lobe oxygenation following anesthesia-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' reduces frontal lobe oxygenation following anesthesia-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} reduces frontal lobe oxygenation following anesthesia-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  reduces frontal lobe oxygenation following anesthesia-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4939 BACKGROUND: The mechanisms underlying {{B}} induced by {{A}} are very complicated and still unclear.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4973 {{A}} did not, however, alter the {{B}} induced by 8-bromo cyclic adenosine monophosphate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4974 Morphine did not, however, alter the {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4987 The present study was undertaken to assess lithium-induced {{B}} in mice deficient in microsomal {{A}} synthase-1 (mPGES-1).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4995 We conclude that the administration of high doses of {{A}} or cefazedone to dogs can induce {{B}} similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or cefazedone to dogs can ', u'e ')\n",
      "[27, 2]\n",
      "2\n",
      "0 44 {{A}} or cefazedone to dogs can induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  or cefazedone to dogs can \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "4996 We conclude that the administration of high doses of {{A}} or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced {{B}} described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-', u'ed ')\n",
      "[78, 3]\n",
      "3\n",
      "0 96 {{A}} or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 78  or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "4997 We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce {{B}} similar to the {{A}} blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4998 We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the {{A}} {{B}} described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "4999 We conclude that the administration of high doses of cefonicid or {{A}} to dogs can induce {{B}} similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to dogs can ', u'e ')\n",
      "[13, 2]\n",
      "2\n",
      "0 30 {{A}} to dogs can induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 13  to dogs can \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "5000 We conclude that the administration of high doses of cefonicid or {{A}} to dogs can induce hematotoxicity similar to the cephalosporin-induced {{B}} described in man and thus provides a useful model for studying the mechanisms of these disorders.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to dogs can induce hematotoxicity similar to the cephalosporin-', u'ed ')\n",
      "[64, 3]\n",
      "3\n",
      "0 82 {{A}} to dogs can induce hematotoxicity similar to the cephalosporin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 64  to dogs can induce hematotoxicity similar to the cephalosporin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5006 In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced {{B}} and a urine concentrating defect, accompanied by nearly complete blockade of high urine {{A}} and cAMP output.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5010 The aim of this study was to investigate whether autophagy was involved in the progression of {{B}} induced by {{A}}, so that we can develop a novel treatment strategy for heart failure.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5011 The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by {{A}}, so that we can develop a novel treatment strategy for {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5018 We conclude that mPGES-1-derived {{A}} mediates lithium-induced {{B}} likely via inhibition of AQP2 and NKCC2 expression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' mediates lithium-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} mediates lithium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  mediates lithium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5033 In vitro, {{A}} induced {{B}} in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5034 In vitro, fluoxetine induced {{B}} in fetal, but not adult, animals (P < 0.01) and reduced {{A}} contraction at both ages (P < 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5052 Due to the risk of this {{B}} inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the {{A}} studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5053 Due to the risk of this tachycardia inducing {{B}}, we would not recommend the use in elderly patients of any of the {{A}} studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5124 METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a {{B}} model of rats induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5125 METHODS: {{A}} (3MA), a specific inhibitor on autophagy was used in a {{B}} model of rats induced by adriamycin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5126 METHODS: 3-methyladenine ({{A}}, a specific inhibitor on autophagy was used in a {{B}} model of rats induced by adriamycin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5128 The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the {{B}} induced by the {{A}} receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5129 The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the {{B}} induced by the dopamine receptor blocker {{A}} administered systemically (1 or 0.5 mg/kg) in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5130 The present study examined the influence of excitatory {{A}} mechanisms in the IC on the {{B}} induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5131 Haloperidol-induced {{B}} was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, {{A}} (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5135 The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as {{A}} (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}} in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA ', u'ed ')\n",
      "[141, 3]\n",
      "3\n",
      "0 159 {{A}} (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 141  (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5136 The combined administration of CSA and various chemotherapeutic drugs with a {{B}} potential, such as {{A}} (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5137 The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), {{A}} and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}} in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA ', u'ed ')\n",
      "[101, 3]\n",
      "3\n",
      "0 119 {{A}} and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 101  and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5138 The combined administration of CSA and various chemotherapeutic drugs with a {{B}} potential, such as gentamicin (at therapeutic doses), {{A}} and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5139 The combined administration of {{A}} and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}} in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA ', u'ed ')\n",
      "[225, 3]\n",
      "3\n",
      "0 243 {{A}} and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 225  and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5140 The combined administration of {{A}} and various chemotherapeutic drugs with a {{B}} potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5141 The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the {{A}} induced {{B}} in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5142 The combined administration of CSA and various chemotherapeutic drugs with a {{B}} potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the {{A}} induced toxicity in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5143 The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and {{A}}, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}} in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', which are frequently used in immunosuppressed patients, did not aggravate the CSA ', u'ed ')\n",
      "[84, 3]\n",
      "3\n",
      "0 102 {{A}}, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 84 , which are frequently used in immunosuppressed patients, did not aggravate the CSA \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5144 The combined administration of CSA and various chemotherapeutic drugs with a {{B}} potential, such as gentamicin (at therapeutic doses), amphothericin B and {{A}}, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5157 Enhanced {{B}} induced by beta-adrenoceptor antagonists in rats pretreated with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5169 The symptoms of {{A}} (METH)-induced psychosis are similar to those of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (METH)-', u'ed psychosis are similar to those of ')\n",
      "[8, 37]\n",
      "8\n",
      "0 60 {{A}} (METH)-induced psychosis are similar to those of {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (METH)-\n",
      "3 5 induc\n",
      "4 37 ed psychosis are similar to those of \n",
      "5 5 {{B}}\n",
      "5170 The symptoms of {{A}} (METH)-induced {{B}} are similar to those of paranoid type schizophrenia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (METH)-', u'ed ')\n",
      "[8, 3]\n",
      "3\n",
      "0 26 {{A}} (METH)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (METH)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5171 The symptoms of methamphetamine ({{A}}-induced psychosis are similar to those of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed psychosis are similar to those of ')\n",
      "[1, 37]\n",
      "1\n",
      "0 53 {{A}}-induced psychosis are similar to those of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 37 ed psychosis are similar to those of \n",
      "5 5 {{B}}\n",
      "5172 The symptoms of methamphetamine ({{A}}-induced {{B}} are similar to those of paranoid type schizophrenia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5198 The administration of several benzodiazepines, chemically related to {{A}}, did not interfere with recovery and did not induce any relapse of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', did not interfere with recovery and did not ', u'e any relapse of ')\n",
      "[46, 17]\n",
      "17\n",
      "0 78 {{A}}, did not interfere with recovery and did not induce any relapse of {{B}}\n",
      "1 5 {{A}}\n",
      "2 46 , did not interfere with recovery and did not \n",
      "3 5 induc\n",
      "4 17 e any relapse of \n",
      "5 5 {{B}}\n",
      "5199 The administration of several {{A}}, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', chemically related to clotiazepam, did not interfere with recovery and did not ', u'e any relapse of ')\n",
      "[81, 17]\n",
      "17\n",
      "0 113 {{A}}, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of {{B}}\n",
      "1 5 {{A}}\n",
      "2 81 , chemically related to clotiazepam, did not interfere with recovery and did not \n",
      "3 5 induc\n",
      "4 17 e any relapse of \n",
      "5 5 {{B}}\n",
      "5200 This observation shows that {{A}} can induce acute {{B}} and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' can ', u'e acute ')\n",
      "[5, 8]\n",
      "5\n",
      "0 28 {{A}} can induce acute {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  can \n",
      "3 5 induc\n",
      "4 8 e acute \n",
      "5 5 {{B}}\n",
      "5201 This observation shows that {{A}} can induce acute hepatitis and suggests that there is no cross {{B}} between clotiazepam and several benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' can ', u'e acute hepatitis and suggests that there is no cross ')\n",
      "[5, 54]\n",
      "5\n",
      "0 74 {{A}} can induce acute hepatitis and suggests that there is no cross {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  can \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3 5 induc\n",
      "4 54 e acute hepatitis and suggests that there is no cross \n",
      "5 5 {{B}}\n",
      "5202 This observation shows that clotiazepam can induce acute {{B}} and suggests that there is no cross hepatotoxicity between {{A}} and several benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5203 This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross {{B}} between {{A}} and several benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5204 This observation shows that clotiazepam can induce acute {{B}} and suggests that there is no cross hepatotoxicity between clotiazepam and several {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5205 This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross {{B}} between clotiazepam and several {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5218 However, the head-up tilt induced {{B}} in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with {{A}} (less than +2% MAP, n = 6).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5219 However, the head-up tilt induced {{B}} in the SHR treated with {{A}} (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5221 The effects of {{A}} on lidocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on lidocaine-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} on lidocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  on lidocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5224 The influence of {{A}} on lidocaine-induced {{B}} was studied in cats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on lidocaine-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} on lidocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  on lidocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5226 Our findings show that microinjection of {{A}} into the CA1 region of the hippocampus improves the scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' into the CA1 region of the hippocampus improves the scopolamine-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} into the CA1 region of the hippocampus improves the scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  into the CA1 region of the hippocampus improves the scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5229 {{B}} induced by combined {{A}} treatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5230 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from {{A}} (AAP)-{{B}}, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5231 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from {{A}} (AAP)-hepatitis, suggesting that the AAP-induced {{B}} involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AAP)-hepatitis, suggesting that the AAP-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} (AAP)-hepatitis, suggesting that the AAP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  (AAP)-hepatitis, suggesting that the AAP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5232 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen ({{A}}-{{B}}, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5233 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen ({{A}}-hepatitis, suggesting that the AAP-induced {{B}} involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-hepatitis, suggesting that the AAP-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}}-hepatitis, suggesting that the AAP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36 -hepatitis, suggesting that the AAP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5236 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of {{A}} polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-{{B}}, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5237 Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of {{A}} polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced {{B}} involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-', u'ed ')\n",
      "[110, 3]\n",
      "3\n",
      "0 128 {{A}} polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 110  polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5238 Recently, we demonstrated the hepatoprotective effects of {{A}}, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-{{B}}, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5239 Recently, we demonstrated the hepatoprotective effects of {{A}}, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced {{B}} involves a step which depends on adenoribosylation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-', u'ed ')\n",
      "[153, 3]\n",
      "3\n",
      "0 171 {{A}}, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 153 , a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5261 Because of the extreme {{B}} of {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5262 Because of the extreme toxicity of {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent {{B}} and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5263 Because of the extreme toxicity of {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce {{B}}, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that ', u'e ')\n",
      "[121, 2]\n",
      "2\n",
      "0 138 {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 121  in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "5264 Because of the extreme toxicity of {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent {{B}} when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that ', u'e milk fever, we concluded that vitamin D3 cannot be used practically to prevent ')\n",
      "[121, 81]\n",
      "81\n",
      "0 217 {{A}} in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent {{B}}\n",
      "1 5 {{A}}\n",
      "2 121  in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that \n",
      "3 5 induc\n",
      "4 81 e milk fever, we concluded that vitamin D3 cannot be used practically to prevent \n",
      "5 5 {{B}}\n",
      "5265 Because of the extreme {{B}} of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of {{A}} that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5266 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of {{A}} that prevent {{B}} and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5267 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of {{A}} that prevent milk fever and doses that induce {{B}}, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' that prevent milk fever and doses that ', u'e ')\n",
      "[40, 2]\n",
      "2\n",
      "0 57 {{A}} that prevent milk fever and doses that induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  that prevent milk fever and doses that \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "5268 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of {{A}} that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent {{B}} when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' that prevent milk fever and doses that ', u'e milk fever, we concluded that vitamin D3 cannot be used practically to prevent ')\n",
      "[40, 81]\n",
      "40\n",
      "0 136 {{A}} that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  that prevent milk fever and doses that \n",
      "3 5 induc\n",
      "4 81 e milk fever, we concluded that vitamin D3 cannot be used practically to prevent \n",
      "5 5 {{B}}\n",
      "5269 Because of the extreme {{B}} of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that {{A}} cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5270 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent {{B}} and doses that induce milk fever, we concluded that {{A}} cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5271 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce {{B}}, we concluded that {{A}} cannot be used practically to prevent milk fever when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5272 Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that {{A}} cannot be used practically to prevent {{B}} when injected several weeks prepartum.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5273 Noradrenergic involvement in {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5274 Continuous subcutaneous administration of {{A}} to prevent ifosfamide-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to prevent ifosfamide-', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} to prevent ifosfamide-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  to prevent ifosfamide-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5292 Effects of {{A}} on cholinesterase and scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on cholinesterase and scopolamine-', u'ed ')\n",
      "[35, 3]\n",
      "3\n",
      "0 53 {{A}} on cholinesterase and scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  on cholinesterase and scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5294 {{A}} was the most frequent agent in drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was the most frequent agent in drug-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} was the most frequent agent in drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  was the most frequent agent in drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5302 The effects of {{A}} on cholinesterase, scopolamine-induced {{B}} and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on cholinesterase, scopolamine-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} on cholinesterase, scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  on cholinesterase, scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5303 The effects of NIK-247 on cholinesterase, scopolamine-induced {{B}} and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5304 The effects of NIK-247 on cholinesterase, scopolamine-induced {{B}} and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors {{A}} and E-2020.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5308 DISCUSSION: Drug-induced symptoms of {{B}} are often associated with the use of substituted {{A}} drugs, but the underlying mechanism is unknown.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5313 Epidural blood flow during {{A}} or trimethaphan induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or trimethaphan ', u'ed ')\n",
      "[17, 3]\n",
      "3\n",
      "0 35 {{A}} or trimethaphan induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  or trimethaphan \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5314 Epidural blood flow during prostaglandin E1 or {{A}} induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5317 To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced {{B}} on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under {{A}} anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5318 To evaluate the effect of {{A}} (PGE1) or trimethaphan (TMP) induced {{B}} on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PGE1) or trimethaphan (TMP) ', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}} (PGE1) or trimethaphan (TMP) induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30  (PGE1) or trimethaphan (TMP) \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5319 To evaluate the effect of prostaglandin E1 ({{A}} or trimethaphan (TMP) induced {{B}} on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or trimethaphan (TMP) ', u'ed ')\n",
      "[23, 3]\n",
      "3\n",
      "0 41 {{A}} or trimethaphan (TMP) induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 23  or trimethaphan (TMP) \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5320 To evaluate the effect of prostaglandin E1 (PGE1) or {{A}} (TMP) induced {{B}} on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (TMP) ', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (TMP) induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (TMP) \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5321 To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan ({{A}} induced {{B}} on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5339 The appearance of impaired cardiac adrenergic neuron activity in the presence of slight {{B}} (scattered or focal vacuolar degeneration) indicates that {{A}} scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5340 The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that {{A}} scintigraphy may be a useful method for detection of adriamycin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' scintigraphy may be a useful method for detection of adriamycin-', u'ed ')\n",
      "[65, 3]\n",
      "3\n",
      "0 83 {{A}} scintigraphy may be a useful method for detection of adriamycin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 65  scintigraphy may be a useful method for detection of adriamycin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5341 The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal {{B}} indicates that {{A}} scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5362 The present study was done to investigate the protective effect of {{A}} on experimentally induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on experimentally ', u'ed ')\n",
      "[19, 3]\n",
      "3\n",
      "0 37 {{A}} on experimentally induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  on experimentally \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5363 All compounds at 0.1-1 mg/kg p.o. significantly improved the {{B}} induced by {{A}} (0.5 mg/kg s.c.) in rats performing a passive avoidance task.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5369 Cardioprotective effect of {{A}} on isoproterenol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on isoproterenol-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} on isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  on isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5377 These findings suggest that {{A}} at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced {{B}} but does not affect spontaneous movement.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5383 This suggests that {{A}} and DFO ameliorate the MA-induced {{B}} by decreasing the level of oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and DFO ameliorate the MA-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}} and DFO ameliorate the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  and DFO ameliorate the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5384 This suggests that alpha-TC and {{A}} ameliorate the MA-induced {{B}} by decreasing the level of oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ameliorate the MA-', u'ed ')\n",
      "[19, 3]\n",
      "3\n",
      "0 37 {{A}} ameliorate the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  ameliorate the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5399 BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of {{B}} (AF) and decreases L-type {{A}}2+) current.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5400 BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation ({{B}} and decreases L-type {{A}}2+) current.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5418 RESULTS: {{A}} caused {{B}} promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5419 RESULTS: {{A}} caused AF promotion in six dogs, increasing mean duration of {{B}} induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5434 We tested the hypothesis that nimodipine (NIMO) administered at the onset of {{A}} (NTG)-induced {{B}} would preserve long-term associative memory.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (NTG)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (NTG)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (NTG)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5435 We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin ({{A}}-induced {{B}} would preserve long-term associative memory.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5436 We tested the hypothesis that {{A}} (NIMO) administered at the onset of nitroglycerin (NTG)-induced {{B}} would preserve long-term associative memory.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (NIMO) administered at the onset of nitroglycerin (NTG)-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} (NIMO) administered at the onset of nitroglycerin (NTG)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  (NIMO) administered at the onset of nitroglycerin (NTG)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5437 We tested the hypothesis that nimodipine ({{A}} administered at the onset of nitroglycerin (NTG)-induced {{B}} would preserve long-term associative memory.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administered at the onset of nitroglycerin (NTG)-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}} administered at the onset of nitroglycerin (NTG)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50  administered at the onset of nitroglycerin (NTG)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5450 Effect of {{A}} and deferoxamine on methamphetamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and deferoxamine on methamphetamine-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} and deferoxamine on methamphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  and deferoxamine on methamphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5451 Effect of alpha-tocopherol and {{A}} on methamphetamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on methamphetamine-', u'ed ')\n",
      "[20, 3]\n",
      "3\n",
      "0 38 {{A}} on methamphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 20  on methamphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5454 This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and {{A}} (DFO), an iron chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DFO), an iron chelator, on the MA-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}} (DFO), an iron chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  (DFO), an iron chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5455 This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine ({{A}}, an iron chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', an iron chelator, on the MA-', u'ed ')\n",
      "[30, 3]\n",
      "3\n",
      "0 48 {{A}}, an iron chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 30 , an iron chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5456 This study examined the effect of {{A}} (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-', u'ed ')\n",
      "[105, 3]\n",
      "3\n",
      "0 123 {{A}} (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 105  (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5457 This study examined the effect of alpha-tocopherol ({{A}}, a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-', u'ed ')\n",
      "[94, 3]\n",
      "3\n",
      "0 112 {{A}}, a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 94 , a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5458 This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive {{A}} species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species, and deferoxamine (DFO), an iron chelator, on the MA-', u'ed ')\n",
      "[62, 3]\n",
      "3\n",
      "0 80 {{A}} species, and deferoxamine (DFO), an iron chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  species, and deferoxamine (DFO), an iron chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5459 This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an {{A}} chelator, on the MA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' chelator, on the MA-', u'ed ')\n",
      "[21, 3]\n",
      "3\n",
      "0 39 {{A}} chelator, on the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 21  chelator, on the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5468 {{A}} and DFO attenuated the MA-induced {{B}} as well as the alterations in the locomotor activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and DFO attenuated the MA-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}} and DFO attenuated the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  and DFO attenuated the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5469 alpha-TC and {{A}} attenuated the MA-induced {{B}} as well as the alterations in the locomotor activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' attenuated the MA-', u'ed ')\n",
      "[19, 3]\n",
      "3\n",
      "0 37 {{A}} attenuated the MA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  attenuated the MA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5473 RESULTS: Bilateral infusions of {{A}} into the globus pallidus reversed haloperidol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' into the globus pallidus reversed haloperidol-', u'ed ')\n",
      "[47, 3]\n",
      "3\n",
      "0 65 {{A}} into the globus pallidus reversed haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  into the globus pallidus reversed haloperidol-\n",
      "3 5 induc\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5483 The third patient had acute amphetamine-induced {{B}} after prolonged {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5485 The {{A}} achieves little palliative benefit and induces severe {{B}} at a fairly high rate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' achieves little palliative benefit and ', u'es severe ')\n",
      "[40, 10]\n",
      "10\n",
      "0 65 {{A}} achieves little palliative benefit and induces severe {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  achieves little palliative benefit and \n",
      "3 5 induc\n",
      "4 10 es severe \n",
      "5 5 {{B}}\n",
      "5543 {{A}} prevents the development of puromycin aminonucleoside-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevents the development of puromycin aminonucleoside-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} prevents the development of puromycin aminonucleoside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  prevents the development of puromycin aminonucleoside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5544 Short-term use of {{A}} is very effective in ATRA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is very effective in ATRA-', u'ed ')\n",
      "[27, 3]\n",
      "3\n",
      "0 45 {{A}} is very effective in ATRA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 27  is very effective in ATRA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5571 Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with {{A}} induced {{B}} who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5572 Ancrod has been used successfully for prophylaxis against development of {{B}} in patients with {{A}} induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5573 Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with {{A}} induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the {{B}} is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the ')\n",
      "[1, 116]\n",
      "1\n",
      "0 132 {{A}} induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 116 ed platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the \n",
      "5 5 {{B}}\n",
      "5574 Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced {{B}} who require brief reexposure to {{A}}, but its success in patients who have developed the thrombosis syndrome is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5575 Ancrod has been used successfully for prophylaxis against development of {{B}} in patients with heparin induced platelet aggregation who require brief reexposure to {{A}}, but its success in patients who have developed the thrombosis syndrome is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5576 Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to {{A}}, but its success in patients who have developed the {{B}} is not well defined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5590 CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of {{B}} in rats induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5597 Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing {{A}} and cholesterol to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and cholesterol to ', u'e ')\n",
      "[20, 2]\n",
      "2\n",
      "0 37 {{A}} and cholesterol to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 20  and cholesterol to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "5598 Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and {{A}} to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to ', u'e ')\n",
      "[4, 2]\n",
      "2\n",
      "0 21 {{A}} to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 4  to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "5601 We have examined the effect of systemic administration of ketamine and {{A}} on brush-evoked (dynamic) {{B}} and punctate-evoked (static) hyperalgesia induced by capsaicin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5602 We have examined the effect of systemic administration of ketamine and {{A}} on brush-evoked (dynamic) pain and punctate-evoked (static) {{B}} induced by capsaicin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5603 We have examined the effect of systemic administration of {{A}} and lidocaine on brush-evoked (dynamic) {{B}} and punctate-evoked (static) hyperalgesia induced by capsaicin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5604 We have examined the effect of systemic administration of {{A}} and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) {{B}} induced by capsaicin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5605 We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) {{B}} and punctate-evoked (static) hyperalgesia induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5606 We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5615 Effects of active constituents of Crocus sativus L., {{A}} on streptozocin-induced model of sporadic {{B}} in male rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on streptozocin-', u'ed model of sporadic ')\n",
      "[17, 21]\n",
      "17\n",
      "0 53 {{A}} on streptozocin-induced model of sporadic {{B}}\n",
      "1 5 {{A}}\n",
      "2 17  on streptozocin-\n",
      "3 5 induc\n",
      "4 21 ed model of sporadic \n",
      "5 5 {{B}}\n",
      "5621 In the present study, the effect of {{A}} on sporadic {{B}} induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5622 In the present study, the effect of crocins on sporadic {{B}} induced by intracerebroventricular (icv) {{A}} (STZ) in male rats was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5623 In the present study, the effect of crocins on sporadic {{B}} induced by intracerebroventricular (icv) streptozocin ({{A}} in male rats was investigated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5641 Reduction of {{A}} anionic sites in the glomerular basement membrane of rats with streptozotocin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' anionic sites in the glomerular basement membrane of rats with streptozotocin-', u'ed ')\n",
      "[79, 3]\n",
      "3\n",
      "0 97 {{A}} anionic sites in the glomerular basement membrane of rats with streptozotocin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 79  anionic sites in the glomerular basement membrane of rats with streptozotocin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5645 The mechanism of this {{B}} is uncertain but may involve the induction by {{A}} of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5652 Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of {{B}} by {{A}} and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5653 Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of {{B}} by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5654 {{A}} anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of {{B}} by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' anionic sites in the glomerular basement membrane were studied in rats 8 months after ', u'tion of ')\n",
      "[87, 8]\n",
      "8\n",
      "0 110 {{A}} anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of {{B}}\n",
      "1 5 {{A}}\n",
      "2 87  anionic sites in the glomerular basement membrane were studied in rats 8 months after \n",
      "3 5 induc\n",
      "4 8 tion of \n",
      "5 5 {{B}}\n",
      "5659 Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine {{B}}, antiarrhythmic effects of {{A}} were examined and the minimum effective plasma concentration for each arrhythmia model was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5660 Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of {{A}} were examined and the minimum effective plasma concentration for each {{B}} model was determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5661 Cibenzoline suppressed all the {{B}}, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and {{A}} were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5662 Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for {{B}} induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and {{A}} were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5663 {{A}} suppressed all the {{B}}, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5664 {{A}} suppressed all the arrhythmias, and the minimum effective plasma concentrations for {{B}} induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5670 Treatment of risperidone-induced {{B}} with a {{A}} agonist in children.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5681 VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after {{A}} (CYP)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (CYP)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (CYP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (CYP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5682 VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ({{A}}-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5692 Protective effect of {{A}} against streptomycin-induced {{B}} in the guinea pig.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' against streptomycin-', u'ed ')\n",
      "[22, 3]\n",
      "3\n",
      "0 40 {{A}} against streptomycin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  against streptomycin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5704 The pharmacological challenge data suggest that tolerance may occur to {{B}} activity induced by PTZ and PTX 24 h after {{A}}, since the response to only these two seizure-inducing agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5705 The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after {{A}}, since the response to only these two {{B}} agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5706 The pharmacological challenge data suggest that tolerance may occur to {{B}} activity induced by PTZ and {{A}} 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5707 The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and {{A}} 24 h after gamma-HCH, since the response to only these two {{B}} agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5708 The pharmacological challenge data suggest that tolerance may occur to {{B}} activity induced by {{A}} and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5709 The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by {{A}} and PTX 24 h after gamma-HCH, since the response to only these two {{B}} agents is decreased.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5710 After 2 individuals with {{B}} developed a capillary leak syndrome following treatment with oral {{A}} lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5711 After 2 individuals with psoriasis developed a {{B}} following treatment with oral {{A}} lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5712 Subsequently 20 {{B}} patients, who developed an early onset attack with frontotemporal {{A}}, received the drug in a second induction test at other body areas.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5755 {{A}} torsade de pointes may be related to serum magnesium levels and {{B}} may synergistically induce torsade.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5756 {{A}} {{B}} may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5757 Pentamidine-induced torsade de pointes may be related to serum {{A}} levels and {{B}} may synergistically induce torsade.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5758 Pentamidine-induced {{B}} may be related to serum {{A}} levels and hypomagnesemia may synergistically induce torsade.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5764 Acute effects of N-(2-propylpentanoyl)urea on hippocampal {{A}} neurotransmitters in pilocarpine-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' neurotransmitters in pilocarpine-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}} neurotransmitters in pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34  neurotransmitters in pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5766 Acute effects of {{A}} on hippocampal amino acid neurotransmitters in pilocarpine-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on hippocampal amino acid neurotransmitters in pilocarpine-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} on hippocampal amino acid neurotransmitters in pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  on hippocampal amino acid neurotransmitters in pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5778 We conclude that the systemic {{B}} of {{A}} is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5779 We conclude that the systemic toxicity of {{A}} is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}} appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-', u'ed ')\n",
      "[117, 3]\n",
      "3\n",
      "0 135 {{A}} is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 117  is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5780 We conclude that the systemic {{B}} of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5781 We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}} appears to be more susceptible to treatment than that induced by bupivacaine or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5782 We conclude that the systemic {{B}} of levobupivacaine is intermediate between that of {{A}} and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5783 We conclude that the systemic toxicity of levobupivacaine is intermediate between that of {{A}} and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}} appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and bupivacaine when administered at the same rate and that ropivacaine-', u'ed ')\n",
      "[73, 3]\n",
      "3\n",
      "0 91 {{A}} and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  and bupivacaine when administered at the same rate and that ropivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5784 We conclude that the systemic {{B}} of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that {{A}} cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5785 We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that {{A}} {{B}} appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5786 We conclude that the systemic {{B}} of levobupivacaine is intermediate between that of ropivacaine and {{A}} when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5787 We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and {{A}} when administered at the same rate and that ropivacaine-induced {{B}} appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' when administered at the same rate and that ropivacaine-', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} when administered at the same rate and that ropivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  when administered at the same rate and that ropivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5788 We conclude that the systemic {{B}} of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by {{A}} or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5789 We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced {{B}} appears to be more susceptible to treatment than that induced by {{A}} or levobupivacaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5835 Ten years previously he had been diagnosed to have lithium-induced {{B}}, and {{A}} therapy had been discontinued.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5844 Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5848 {{A}} is an {{B}} agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5851 Protection against amphetamine-induced {{B}} toward striatal {{A}} neurons in rodents by LY274614, an excitatory amino acid antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5852 Protection against amphetamine-induced {{B}} toward striatal dopamine neurons in rodents by {{A}}, an excitatory amino acid antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5854 Protection against amphetamine-induced {{B}} toward striatal dopamine neurons in rodents by LY274614, an excitatory {{A}} antagonist.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5897 Effect of {{A}} synthetase inhibitors on experimentally induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' synthetase inhibitors on experimentally ', u'ed ')\n",
      "[41, 3]\n",
      "3\n",
      "0 59 {{A}} synthetase inhibitors on experimentally induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 41  synthetase inhibitors on experimentally \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5899 {{B}} in pregnancy associated with {{A}} for ovulation induction: a case report.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5902 Effect of methanolic extract of {{A}} (100-300 mg/kg) was studied on reserpine-induced orofacial {{B}} and neurochemical alterations.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (100-300 mg/kg) was studied on reserpine-', u'ed orofacial ')\n",
      "[42, 13]\n",
      "13\n",
      "0 70 {{A}} (100-300 mg/kg) was studied on reserpine-induced orofacial {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  (100-300 mg/kg) was studied on reserpine-\n",
      "3 5 induc\n",
      "4 13 ed orofacial \n",
      "5 5 {{B}}\n",
      "5904 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no {{B}} and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5905 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable {{B}} induced by hydralazine or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5906 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no {{B}} and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by {{A}} or nitroglycerin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5907 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable {{B}} induced by {{A}} or nitroglycerin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5908 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no {{B}} and no augmentation of the {{A}} release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5909 Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the {{A}} release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable {{B}} induced by hydralazine or nitroglycerin.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5913 {{B}} is a rare but life-threatening complication that has been reported after ovulation induction with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5920 CASE: A 33-year-old woman with a 5-week gestation had recently received {{A}} for ovulation induction and presented with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for ovulation ', u'tion and presented with ')\n",
      "[15, 24]\n",
      "15\n",
      "0 54 {{A}} for ovulation induction and presented with {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  for ovulation \n",
      "3 5 induc\n",
      "4 24 tion and presented with \n",
      "5 5 {{B}}\n",
      "5921 The results of the present study suggested that {{A}} had a protective role against reserpine-induced orofacial {{B}} and oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' had a protective role against reserpine-', u'ed orofacial ')\n",
      "[41, 13]\n",
      "13\n",
      "0 69 {{A}} had a protective role against reserpine-induced orofacial {{B}}\n",
      "1 5 {{A}}\n",
      "2 41  had a protective role against reserpine-\n",
      "3 5 induc\n",
      "4 13 ed orofacial \n",
      "5 5 {{B}}\n",
      "5928 {{A}} in the treatment of D-penicillamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in the treatment of D-penicillamine-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} in the treatment of D-penicillamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  in the treatment of D-penicillamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5944 {{A}} and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced {{B}} in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-', u'ed ')\n",
      "[100, 3]\n",
      "3\n",
      "0 118 {{A}} and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 100  and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5945 Vitamin B12 and folinic acid supplementation of {{A}} therapy does not seem useful in preventing or reducing ZDV-induced {{B}} in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' therapy does not seem useful in preventing or reducing ZDV-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} therapy does not seem useful in preventing or reducing ZDV-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  therapy does not seem useful in preventing or reducing ZDV-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5947 Vitamin B12 and {{A}} supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced {{B}} in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-', u'ed ')\n",
      "[83, 3]\n",
      "3\n",
      "0 101 {{A}} supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 83  supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5962 Although low concentrations (less than or equal to 50 ppm) of {{A}} had beneficial effects on TOTP-induced {{B}}, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' had beneficial effects on TOTP-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} had beneficial effects on TOTP-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  had beneficial effects on TOTP-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5963 Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced {{B}}, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5965 Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced {{B}}, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either {{A}} or DFP.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5970 Reactive oxygen species have been implicated in the pathogenesis of acute {{A}} (PAN)-induced {{B}}, with antioxidants significantly reducing the proteinuria.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PAN)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (PAN)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (PAN)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5971 Reactive oxygen species have been implicated in the pathogenesis of acute {{A}} (PAN)-induced nephropathy, with antioxidants significantly reducing the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PAN)-', u'ed nephropathy, with antioxidants significantly reducing the ')\n",
      "[7, 61]\n",
      "7\n",
      "0 83 {{A}} (PAN)-induced nephropathy, with antioxidants significantly reducing the {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (PAN)-\n",
      "3 5 induc\n",
      "4 61 ed nephropathy, with antioxidants significantly reducing the \n",
      "5 5 {{B}}\n",
      "5972 Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ({{A}}-induced {{B}}, with antioxidants significantly reducing the proteinuria.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5973 Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ({{A}}-induced nephropathy, with antioxidants significantly reducing the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed nephropathy, with antioxidants significantly reducing the ')\n",
      "[1, 61]\n",
      "1\n",
      "0 77 {{A}}-induced nephropathy, with antioxidants significantly reducing the {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 61 ed nephropathy, with antioxidants significantly reducing the \n",
      "5 5 {{B}}\n",
      "5974 Reactive {{A}} species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced {{B}}, with antioxidants significantly reducing the proteinuria.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-', u'ed ')\n",
      "[91, 3]\n",
      "3\n",
      "0 109 {{A}} species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5975 Reactive {{A}} species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-', u'ed nephropathy, with antioxidants significantly reducing the ')\n",
      "[91, 61]\n",
      "61\n",
      "0 167 {{A}} species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-\n",
      "3 5 induc\n",
      "4 61 ed nephropathy, with antioxidants significantly reducing the \n",
      "5 5 {{B}}\n",
      "5986 The expression of {{A}} (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced {{B}}, using in situ hybridization histochemistry and radioimmunoassay.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-', u'ed ')\n",
      "[112, 3]\n",
      "3\n",
      "0 130 {{A}} (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 112  (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5987 The expression of arginine vasopressin ({{A}} gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced {{B}}, using in situ hybridization histochemistry and radioimmunoassay.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-', u'ed ')\n",
      "[106, 3]\n",
      "3\n",
      "0 124 {{A}} gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 106  gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5988 The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with {{A}} (Li)-induced {{B}}, using in situ hybridization histochemistry and radioimmunoassay.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (Li)-', u'ed ')\n",
      "[6, 3]\n",
      "3\n",
      "0 24 {{A}} (Li)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 6  (Li)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5989 The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium ({{A}}-induced {{B}}, using in situ hybridization histochemistry and radioimmunoassay.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "5997 Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in {{A}} outflow and inhibition of {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5998 Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic {{B}} is associated with a decrease in {{A}} outflow and inhibition of hyperthermia in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "5999 Neuroprotective action of {{A}}, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a selective mGluR5 antagonist, in methamphetamine-', u'ed dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of ')\n",
      "[52, 98]\n",
      "52\n",
      "0 165 {{A}}, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of {{B}}\n",
      "1 5 {{A}}\n",
      "2 52 , a selective mGluR5 antagonist, in methamphetamine-\n",
      "3 5 induc\n",
      "4 98 ed dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of \n",
      "5 5 {{B}}\n",
      "6000 Neuroprotective action of {{A}}, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic {{B}} is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a selective mGluR5 antagonist, in methamphetamine-', u'ed dopaminergic ')\n",
      "[52, 16]\n",
      "16\n",
      "0 83 {{A}}, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic {{B}}\n",
      "1 5 {{A}}\n",
      "2 52 , a selective mGluR5 antagonist, in methamphetamine-\n",
      "3 5 induc\n",
      "4 16 ed dopaminergic \n",
      "5 5 {{B}}\n",
      "6016 Chronic oral {{A}} inhibited the development of both lidocaine- and cocaine-induced {{B}}, but had little effect on the fully developed local anesthetic seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' inhibited the development of both lidocaine- and cocaine-', u'ed ')\n",
      "[58, 3]\n",
      "3\n",
      "0 76 {{A}} inhibited the development of both lidocaine- and cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 58  inhibited the development of both lidocaine- and cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6017 Chronic oral {{A}} inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' inhibited the development of both lidocaine- and cocaine-', u'ed seizures, but had little effect on the fully developed local anesthetic ')\n",
      "[58, 75]\n",
      "58\n",
      "0 148 {{A}} inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic {{B}}\n",
      "1 5 {{A}}\n",
      "2 58  inhibited the development of both lidocaine- and cocaine-\n",
      "3 5 induc\n",
      "4 75 ed seizures, but had little effect on the fully developed local anesthetic \n",
      "5 5 {{B}}\n",
      "6018 Chronic oral CBZ inhibited the development of both {{A}}- and cocaine-induced {{B}}, but had little effect on the fully developed local anesthetic seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and cocaine-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}}- and cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 - and cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6019 Chronic oral CBZ inhibited the development of both {{A}}- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and cocaine-', u'ed seizures, but had little effect on the fully developed local anesthetic ')\n",
      "[14, 75]\n",
      "14\n",
      "0 104 {{A}}- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic {{B}}\n",
      "1 5 {{A}}\n",
      "2 14 - and cocaine-\n",
      "3 5 induc\n",
      "4 75 ed seizures, but had little effect on the fully developed local anesthetic \n",
      "5 5 {{B}}\n",
      "6029 Acute {{A}} over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-', u'ed ')\n",
      "[99, 3]\n",
      "3\n",
      "0 117 {{A}} over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 99  over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "5 5 {{B}}\n",
      "6030 Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed {{A}} or acute cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' or acute cocaine-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}} or acute cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  or acute cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6033 In a randomized study, labetalol-induced {{B}} and {{A}} hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6034 In a randomized study, labetalol-induced hypotension and {{A}} {{B}} were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6035 In a randomized study, {{A}} {{B}} and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6036 In a randomized study, {{A}} hypotension and nitroprusside-induced {{B}} were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' hypotension and nitroprusside-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} hypotension and nitroprusside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  hypotension and nitroprusside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6037 Activated peripheral blood T cells from patients with {{B}} tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6043 Furthermore, the {{B}} that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic {{A}} treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6047 Pretreatment with type-2 {{A}} antagonists may be clinically useful in attenuating opiate-induced {{B}}, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' antagonists may be clinically useful in attenuating opiate-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} antagonists may be clinically useful in attenuating opiate-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  antagonists may be clinically useful in attenuating opiate-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6048 Pretreatment with type-2 {{A}} antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' antagonists may be clinically useful in attenuating opiate-', u'ed rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and ')\n",
      "[60, 128]\n",
      "60\n",
      "0 203 {{A}} antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  antagonists may be clinically useful in attenuating opiate-\n",
      "3 5 induc\n",
      "4 128 ed rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and \n",
      "5 5 {{B}}\n",
      "6053 Phlorizin-induced glycosuria does not prevent {{A}} {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6054 Phlorizin-induced {{B}} does not prevent {{A}} nephrotoxicity in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6061 The protection from {{A}} {{B}} was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6062 The protection from {{A}} nephrotoxicity was studied in {{B}} rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6063 The protection from gentamicin {{B}} was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with {{A}} (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6064 The protection from gentamicin nephrotoxicity was studied in {{B}} rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with {{A}} (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6065 The protection from gentamicin {{B}} was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6066 The protection from gentamicin nephrotoxicity was studied in {{B}} rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6067 The protection from gentamicin {{B}} was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular {{A}} reabsorption with phlorizin (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6068 The protection from gentamicin nephrotoxicity was studied in {{B}} rats with chronic solute diuresis induced by blockage of tubular {{A}} reabsorption with phlorizin (P).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6102 In Group I, {{A}} induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage ({{B}} score [maximum 4], zero).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (')\n",
      "[1, 195]\n",
      "1\n",
      "0 211 {{A}} induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage ({{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 195 ed a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (\n",
      "5 5 {{B}}\n",
      "6103 In Group I, {{A}} induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of {{B}} (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of ')\n",
      "[1, 106]\n",
      "1\n",
      "0 122 {{A}} induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 106 ed a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of \n",
      "5 5 {{B}}\n",
      "6104 In Group I, {{A}} induced a moderate and stable {{B}} (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed a moderate and stable ')\n",
      "[1, 25]\n",
      "1\n",
      "0 41 {{A}} induced a moderate and stable {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 25 ed a moderate and stable \n",
      "5 5 {{B}}\n",
      "6129 Hippocampal {{A}} also was measured during testing for handling-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also was measured during testing for handling-', u'ed ')\n",
      "[47, 3]\n",
      "3\n",
      "0 65 {{A}} also was measured during testing for handling-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  also was measured during testing for handling-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6142 When hippocampal {{A}} was measured during testing for handling-induced {{B}}, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was measured during testing for handling-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} was measured during testing for handling-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  was measured during testing for handling-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6143 When hippocampal ACh was measured during testing for handling-induced {{B}}, extracellular {{A}} was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6147 The present study was designed to investigate the hypothesis that {{A}} channel blockers in general induce cardiovascular {{B}} indicating a pharmacologic class effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blockers in general ', u'e cardiovascular ')\n",
      "[29, 17]\n",
      "17\n",
      "0 61 {{A}} channel blockers in general induce cardiovascular {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  channel blockers in general \n",
      "3 5 induc\n",
      "4 17 e cardiovascular \n",
      "5 5 {{B}}\n",
      "6148 RESULTS: Sensitivity to several {{B}} endpoints induced by {{A}}, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6149 RESULTS: Sensitivity to several {{B}} endpoints induced by nicotine, {{A}}, and neostigmine were significantly greater in WSR versus WSP mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6150 RESULTS: Sensitivity to several {{B}} endpoints induced by nicotine, carbachol, and {{A}} were significantly greater in WSR versus WSP mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6155 We report a case of variant ventricular tachycardia induced by {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6156 We report a case of variant {{B}} induced by {{A}} toxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6182 METHOD: {{B}} was induced by {{A}} administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6183 METHOD: {{B}} was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg {{A}} subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6184 METHOD: {{B}} was induced by prostigmine-morphine administration (0.5 mg {{A}} intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6213 Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of {{A}}, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', we need to assess the use of NO inhibitors for the prevention of aminoglycoside-', u'ed ')\n",
      "[82, 3]\n",
      "3\n",
      "0 100 {{A}}, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 82 , we need to assess the use of NO inhibitors for the prevention of aminoglycoside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6214 Their {{B}} is a serious health problem and, as their ototoxic mechanism involves the production of {{A}}, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6215 Their ototoxicity is a serious health problem and, as their {{B}} mechanism involves the production of {{A}}, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6216 Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of {{A}} for the prevention of aminoglycoside-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for the prevention of aminoglycoside-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} for the prevention of aminoglycoside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  for the prevention of aminoglycoside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6217 Their {{B}} is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of {{A}} for the prevention of aminoglycoside-induced sensorineural hearing loss.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6218 Their ototoxicity is a serious health problem and, as their {{B}} mechanism involves the production of NO, we need to assess the use of {{A}} for the prevention of aminoglycoside-induced sensorineural hearing loss.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6221 Acute {{B}}, autoimmune hemolytic anemia, and erythroblastocytopenia induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6222 Acute hepatitis, {{B}}, and erythroblastocytopenia induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6231 Ginsenoside Rg1 restores the {{B}} induced by chronic {{A}} administration in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6232 {{A}} restores the {{B}} induced by chronic morphine administration in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6235 {{A}} induces activation changes in healthy subjects similar to those observed in patients with {{B}}, particularly in frontal and temporal brain regions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es activation changes in healthy subjects similar to those observed in patients with ')\n",
      "[1, 85]\n",
      "1\n",
      "0 101 {{A}} induces activation changes in healthy subjects similar to those observed in patients with {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 85 es activation changes in healthy subjects similar to those observed in patients with \n",
      "5 5 {{B}}\n",
      "6316 OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected {{A}} patient with {{B}} (21%).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6317 OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced {{B}} had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected {{A}} patient with psoriasis (21%).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6356 Catecholamine-induced {{B}} due to chronic excess of endogenous {{A}} has been recognized for decades as a clinical phenomenon.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6359 This, together with our previous findings that {{A}} failed to prevent adrenocorticotrophic hormone induced {{B}}, suggests that XO activity is not a major determinant of GC-HT in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' failed to prevent adrenocorticotrophic hormone ', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}} failed to prevent adrenocorticotrophic hormone induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  failed to prevent adrenocorticotrophic hormone \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6360 This, together with our previous findings that {{A}} failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' failed to prevent adrenocorticotrophic hormone ', u'ed hypertension, suggests that XO activity is not a major determinant of ')\n",
      "[48, 73]\n",
      "48\n",
      "0 136 {{A}} failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  failed to prevent adrenocorticotrophic hormone \n",
      "3 5 induc\n",
      "4 73 ed hypertension, suggests that XO activity is not a major determinant of \n",
      "5 5 {{B}}\n",
      "6377 {{A}}- and haloperidol-induced {{B}} are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and haloperidol-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}}- and haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6378 {{A}}- and haloperidol-induced orofacial dyskinesia are putative animal models of {{B}} (TD) whose pathophysiology has been related to free radical generation and oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and haloperidol-', u'ed orofacial dyskinesia are putative animal models of ')\n",
      "[18, 54]\n",
      "18\n",
      "0 87 {{A}}- and haloperidol-induced orofacial dyskinesia are putative animal models of {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and haloperidol-\n",
      "3 5 induc\n",
      "4 54 ed orofacial dyskinesia are putative animal models of \n",
      "5 5 {{B}}\n",
      "6379 {{A}}- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia ({{B}} whose pathophysiology has been related to free radical generation and oxidative stress.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and haloperidol-', u'ed orofacial dyskinesia are putative animal models of tardive dyskinesia (')\n",
      "[18, 74]\n",
      "18\n",
      "0 107 {{A}}- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia ({{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and haloperidol-\n",
      "3 5 induc\n",
      "4 74 ed orofacial dyskinesia are putative animal models of tardive dyskinesia (\n",
      "5 5 {{B}}\n",
      "6380 In the present study, the authors induced {{B}} by acute reserpine and subchronic {{A}} administration to rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6381 In the present study, the authors induced {{B}} by acute {{A}} and subchronic haloperidol administration to rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6394 {{A}} involvement in naloxone induced reversal of {{B}} produced by thiopental.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' involvement in naloxone ', u'ed reversal of ')\n",
      "[25, 15]\n",
      "15\n",
      "0 55 {{A}} involvement in naloxone induced reversal of {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  involvement in naloxone \n",
      "3 5 induc\n",
      "4 15 ed reversal of \n",
      "5 5 {{B}}\n",
      "6395 GABA involvement in naloxone induced reversal of {{B}} produced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6396 GABA involvement in {{A}} induced reversal of {{B}} produced by thiopental.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed reversal of ')\n",
      "[1, 15]\n",
      "1\n",
      "0 31 {{A}} induced reversal of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 15 ed reversal of \n",
      "5 5 {{B}}\n",
      "6400 In this study naloxone reversed {{B}} induced by {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6401 In this study {{A}} reversed {{B}} induced by thiopental in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6436 In the mouse passive-avoidance test, {{A}} (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented {{B}} induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6437 In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented {{B}} induced by both the non selective antimuscarinic drug {{A}} and the M1-selective antagonist S-(-)-ET-126.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6438 In the same experimental conditions, {{A}} (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced {{B}}, demonstrating a central localization of the activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-', u'ed ')\n",
      "[72, 3]\n",
      "3\n",
      "0 90 {{A}} (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 72  (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6439 Based on the finding that VPU and {{A}} could protect the animals against pilocarpine-induced {{B}} it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' could protect the animals against pilocarpine-', u'ed ')\n",
      "[47, 3]\n",
      "3\n",
      "0 65 {{A}} could protect the animals against pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  could protect the animals against pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6440 Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced {{B}} it is suggested that the reduction of inhibitory {{A}} neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6442 Based on the finding that {{A}} and VPA could protect the animals against pilocarpine-induced {{B}} it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and VPA could protect the animals against pilocarpine-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} and VPA could protect the animals against pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  and VPA could protect the animals against pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6459 Therefore, like {{A}}, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}} in experimental animals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-', u'ed ')\n",
      "[194, 3]\n",
      "3\n",
      "0 212 {{A}}, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 194 , the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6460 Therefore, like VPA, the finding that VPU could drastically reduce {{A}} increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}} in experimental animals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-', u'ed ')\n",
      "[127, 3]\n",
      "3\n",
      "0 145 {{A}} increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 127  increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6461 Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in {{A}} {{B}} in experimental animals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6462 Therefore, like VPA, the finding that {{A}} could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}} in experimental animals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-', u'ed ')\n",
      "[172, 3]\n",
      "3\n",
      "0 190 {{A}} could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 172  could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6485 Effects of deliberate {{B}} induced by labetalol with {{A}} on neuropsychological function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6486 Effects of deliberate {{B}} induced by {{A}} with isoflurane on neuropsychological function.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6501 CONCLUSIONS: {{A}} induces or aggravates pre-existing {{B}} in an unpredictable subset of renal allograft recipients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es or aggravates pre-existing ')\n",
      "[1, 30]\n",
      "1\n",
      "0 46 {{A}} induces or aggravates pre-existing {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 30 es or aggravates pre-existing \n",
      "5 5 {{B}}\n",
      "6512 OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced {{B}} (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high {{A}} concentration.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6513 OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia ({{B}} antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high {{A}} concentration.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6514 OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with {{B}}; the assay utilizes reaction inhibition characteristics of a high {{A}} concentration.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6515 We report the successful treatment of risperidone-induced {{B}} with {{A}} in youth.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6522 We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and {{A}} {{B}} after i.p. injections.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6523 We measured {{A}} anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced {{B}} after i.p. injections.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-', u'ed ')\n",
      "[145, 3]\n",
      "3\n",
      "0 163 {{A}} anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 145  anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6524 We measured diazepam-induced anxiolysis with the elevated plus-maze test, {{A}} sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced {{B}} after i.p. injections.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-', u'ed ')\n",
      "[83, 3]\n",
      "3\n",
      "0 101 {{A}} sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 83  sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6525 We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and {{A}}- and pentylenetetrazol-induced {{B}} after i.p. injections.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and pentylenetetrazol-', u'ed ')\n",
      "[24, 3]\n",
      "3\n",
      "0 42 {{A}}- and pentylenetetrazol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 24 - and pentylenetetrazol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6527 Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to {{B}} induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the {{A}}A) receptor benzodiazepine site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6528 Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to {{B}} induced by a single i.p. injection of {{A}} (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6529 Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to {{B}} induced by a single i.p. injection of methyl beta-carboline-3-carboxylate ({{A}}, an inverse agonist of the GABA(A) receptor benzodiazepine site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6530 Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to {{B}} induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor {{A}} site.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6531 {{A}} has induced a {{B}} in AIDS patients on long term AZT therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' has ', u'ed a ')\n",
      "[5, 5]\n",
      "5\n",
      "0 25 {{A}} has induced a {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  has \n",
      "3 5 induc\n",
      "4 5 ed a \n",
      "5 5 {{B}}\n",
      "6532 {{A}} has induced a macrocytic anemia in {{B}} patients on long term AZT therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' has ', u'ed a macrocytic anemia in ')\n",
      "[5, 26]\n",
      "5\n",
      "0 46 {{A}} has induced a macrocytic anemia in {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  has \n",
      "3 5 induc\n",
      "4 26 ed a macrocytic anemia in \n",
      "5 5 {{B}}\n",
      "6533 AZT has induced a {{B}} in AIDS patients on long term {{A}} therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6534 AZT has induced a macrocytic anemia in {{B}} patients on long term {{A}} therapy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6549 Two mouse lines selected for differential sensitivities to beta-carboline-induced {{B}} are also differentially sensitive to various pharmacological effects of other {{A}}A) receptor ligands.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6551 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of {{B}} patients on {{A}} medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6552 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on {{A}} medication, the first one without L-dopa induced {{B}} (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' medication, the first one without L-dopa ', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}} medication, the first one without L-dopa induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  medication, the first one without L-dopa \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6553 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on {{A}} medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose {{B}} (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' medication, the first one without L-dopa ', u'ed dyskinesia (n = 23) and the other with moderate peak-dose ')\n",
      "[42, 61]\n",
      "42\n",
      "0 118 {{A}} medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose {{B}}\n",
      "1 5 {{A}}\n",
      "2 42  medication, the first one without L-dopa \n",
      "3 5 induc\n",
      "4 61 ed dyskinesia (n = 23) and the other with moderate peak-dose \n",
      "5 5 {{B}}\n",
      "6554 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of {{B}} patients on L-dopa medication, the first one without {{A}} induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6555 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without {{A}} induced {{B}} (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6556 We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without {{A}} induced dyskinesia (n = 23) and the other with moderate peak-dose {{B}} (n = 15), and of a group of 14 normal subjects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed dyskinesia (n = 23) and the other with moderate peak-dose ')\n",
      "[1, 61]\n",
      "1\n",
      "0 77 {{A}} induced dyskinesia (n = 23) and the other with moderate peak-dose {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 61 ed dyskinesia (n = 23) and the other with moderate peak-dose \n",
      "5 5 {{B}}\n",
      "6559 We have studied the role of NO and its association with apoptosis in an experimental model of {{B}} induced by a single injection of {{A}} (ADR).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6560 We have studied the role of NO and its association with apoptosis in an experimental model of {{B}} induced by a single injection of adriamycin ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6561 We have studied the role of {{A}} and its association with apoptosis in an experimental model of {{B}} induced by a single injection of adriamycin (ADR).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6562 {{B}} was induced using a single dose of {{A}} (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6566 Chronic {{B}} induced by the {{A}} antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6567 Chronic {{B}} induced by the dopamine antagonist {{A}} caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6568 Chronic {{B}} induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6569 Plasma and urinary lipids and lipoproteins during the development of {{B}} induced in the rat by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6603 Suppression of irCRF secretion in response to nitroprusside-induced {{B}} is observed and occurs at a plasma {{A}} level between 8-12 micrograms/dl.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6607 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of {{B}} (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose {{A}} on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6608 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ({{B}} associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose {{A}} on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6609 OBJECTIVES: Given its preclinical success for treating {{B}} and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose {{A}} on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6610 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of {{B}} (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) {{A}} (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6611 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ({{B}} associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) {{A}} (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6612 OBJECTIVES: Given its preclinical success for treating {{B}} and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) {{A}} (DA).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6613 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of {{B}} (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6614 OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ({{B}} associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6615 OBJECTIVES: Given its preclinical success for treating {{B}} and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6638 Moreover, test conditions can impact upon other physiological responses to {{A}} such as drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' such as drug-', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} such as drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  such as drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6639 The extension of {{B}} is variable with erythrocyte samples, but 12.5 microM {{A}} induces total hemolysis of all tested suspensions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6640 The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM {{A}} induces total {{B}} of all tested suspensions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es total ')\n",
      "[1, 9]\n",
      "1\n",
      "0 25 {{A}} induces total {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 9 es total \n",
      "5 5 {{B}}\n",
      "6641 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, {{B}}, or headaches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during midtrimester-', u'ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, ')\n",
      "[36, 248]\n",
      "36\n",
      "0 299 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration during midtrimester-\n",
      "3 5 induc\n",
      "4 248 ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, \n",
      "5 5 {{B}}\n",
      "6642 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of {{B}} and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during midtrimester-', u'ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of ')\n",
      "[36, 135]\n",
      "36\n",
      "0 186 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration during midtrimester-\n",
      "3 5 induc\n",
      "4 135 ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of \n",
      "5 5 {{B}}\n",
      "6643 {{A}} administration during midtrimester-induced {{B}} is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during midtrimester-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}} administration during midtrimester-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration during midtrimester-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6644 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during midtrimester-', u'ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or ')\n",
      "[36, 274]\n",
      "36\n",
      "0 325 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration during midtrimester-\n",
      "3 5 induc\n",
      "4 274 ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or \n",
      "5 5 {{B}}\n",
      "6645 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as {{B}}, muscular irritability, or headaches.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration during midtrimester-', u'ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as ')\n",
      "[36, 238]\n",
      "36\n",
      "0 289 {{A}} administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration during midtrimester-\n",
      "3 5 induc\n",
      "4 238 ed abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as \n",
      "5 5 {{B}}\n",
      "6646 {{B}} was induced by a single injection of {{A}} (PAN).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6647 {{B}} was induced by a single injection of puromycin amino-nucleoside ({{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6657 This was further evidenced by absence of {{A}} consumption and hemoglobin oxidation both determined in parallel with TAM-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' consumption and hemoglobin oxidation both determined in parallel with TAM-', u'ed ')\n",
      "[75, 3]\n",
      "3\n",
      "0 93 {{A}} consumption and hemoglobin oxidation both determined in parallel with TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 75  consumption and hemoglobin oxidation both determined in parallel with TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6660 {{B}} of human erythrocytes induced by {{A}} is related to disruption of membrane structure.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6662 {{A}} induces {{B}} of erythrocytes as a function of concentration.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "6667 However, the mechanisms of {{B}} induced by {{A}} were significantly different from those of exercise.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6671 Apomorphine, a nonselective {{A}}, was selected due to its biphasic behavioral effects, its ability to induce {{B}}, and to produce distinct changes to dopamine turnover in the rodent brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', was selected due to its biphasic behavioral effects, its ability to ', u'e ')\n",
      "[70, 2]\n",
      "2\n",
      "0 87 {{A}}, was selected due to its biphasic behavioral effects, its ability to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 70 , was selected due to its biphasic behavioral effects, its ability to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "6672 Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce {{B}}, and to produce distinct changes to {{A}} turnover in the rodent brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6673 {{A}}, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce {{B}}, and to produce distinct changes to dopamine turnover in the rodent brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to ', u'e ')\n",
      "[103, 2]\n",
      "2\n",
      "0 120 {{A}}, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 103 , a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "6676 {{A}} (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, ', u'es changes in normal discoid shape of erythrocytes and ')\n",
      "[93, 55]\n",
      "55\n",
      "0 163 {{A}} (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and {{B}}\n",
      "1 5 {{A}}\n",
      "2 93  (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, \n",
      "3 5 induc\n",
      "4 55 es changes in normal discoid shape of erythrocytes and \n",
      "5 5 {{B}}\n",
      "6677 {{A}} (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of {{B}}, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6678 Tamoxifen ({{A}}, the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, ', u'es changes in normal discoid shape of erythrocytes and ')\n",
      "[87, 55]\n",
      "55\n",
      "0 157 {{A}}, the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and {{B}}\n",
      "1 5 {{A}}\n",
      "2 87 , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, \n",
      "3 5 induc\n",
      "4 55 es changes in normal discoid shape of erythrocytes and \n",
      "5 5 {{B}}\n",
      "6679 Tamoxifen ({{A}}, the antiestrogenic drug most widely prescribed in the chemotherapy of {{B}}, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6680 This work evaluates the effects of {{A}} on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced {{B}} and the involvement of biomembranes in its cytostatic action mechanisms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-', u'ed ')\n",
      "[89, 3]\n",
      "3\n",
      "0 107 {{A}} on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 89  on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6682 The hemolytic effect of {{A}} is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-', u'ed ')\n",
      "[161, 3]\n",
      "3\n",
      "0 179 {{A}} is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 161  is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6684 The hemolytic effect of TAM is prevented by low concentrations of {{A}} (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-', u'ed ')\n",
      "[106, 3]\n",
      "3\n",
      "0 124 {{A}} (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 106  (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6685 The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol ({{A}} and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-', u'ed ')\n",
      "[96, 3]\n",
      "3\n",
      "0 114 {{A}} and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 96  and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6686 The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and {{A}} (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-', u'ed ')\n",
      "[67, 3]\n",
      "3\n",
      "0 85 {{A}} (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 67  (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6687 The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate ({{A}} (inactivated functional hydroxyl) indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (inactivated functional hydroxyl) indicating that TAM-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} (inactivated functional hydroxyl) indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  (inactivated functional hydroxyl) indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6688 The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional {{A}} indicating that TAM-induced {{B}} is not related to oxidative membrane damage.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' indicating that TAM-', u'ed ')\n",
      "[21, 3]\n",
      "3\n",
      "0 39 {{A}} indicating that TAM-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 21  indicating that TAM-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6690 Acute {{B}} induced by {{A}} is a well known adverse drug reaction in patients with renal impairment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6691 Acute confusion induced by {{A}} is a well known adverse drug reaction in patients with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6694 Daily administration of desipramine increased the incidence of appearance of lidocaine-induced {{B}} and decreased that of {{A}} convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6695 Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6696 Daily administration of desipramine increased the incidence of appearance of {{A}} {{B}} and decreased that of cocaine-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6697 Daily administration of desipramine increased the incidence of appearance of {{A}} convulsions and decreased that of cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' convulsions and decreased that of cocaine-', u'ed ')\n",
      "[43, 3]\n",
      "3\n",
      "0 61 {{A}} convulsions and decreased that of cocaine-induced {{B}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1 5 {{A}}\n",
      "2 43  convulsions and decreased that of cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6698 Daily administration of {{A}} increased the incidence of appearance of lidocaine-induced {{B}} and decreased that of cocaine-induced convulsions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' increased the incidence of appearance of lidocaine-', u'ed ')\n",
      "[52, 3]\n",
      "3\n",
      "0 70 {{A}} increased the incidence of appearance of lidocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 52  increased the incidence of appearance of lidocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6699 Daily administration of {{A}} increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-', u'ed ')\n",
      "[102, 3]\n",
      "3\n",
      "0 120 {{A}} increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 102  increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6701 Co-administration of lidocaine with desipramine reversed the changes of {{B}} activity of lidocaine and {{A}} induced by repeated administration of desipramine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6702 Co-administration of {{A}} with desipramine reversed the changes of {{B}} activity of lidocaine and cocaine induced by repeated administration of desipramine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6703 Co-administration of lidocaine with desipramine reversed the changes of {{B}} activity of {{A}} and cocaine induced by repeated administration of desipramine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6704 Co-administration of lidocaine with {{A}} reversed the changes of {{B}} activity of lidocaine and cocaine induced by repeated administration of desipramine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6705 Co-administration of lidocaine with desipramine reversed the changes of {{B}} activity of lidocaine and cocaine induced by repeated administration of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6711 CONCLUSION: In a PA retention paradigm, the injection of {{A}} immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced {{B}} had no effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed ', u'ed ')\n",
      "[119, 3]\n",
      "3\n",
      "0 137 {{A}} immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 119  immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6717 Desipramine-induced sensitization of lidocaine {{B}} may have a mechanism distinct from kindling resulting from repeated administration of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6718 Desipramine-induced sensitization of {{A}} {{B}} may have a mechanism distinct from kindling resulting from repeated administration of cocaine.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6742 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, {{A}} hepatotoxicity and VPA-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' hepatotoxicity and VPA-', u'ed ')\n",
      "[24, 3]\n",
      "3\n",
      "0 42 {{A}} hepatotoxicity and VPA-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  hepatotoxicity and VPA-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6743 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, {{B}}, {{A}} hepatotoxicity and VPA-induced encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6744 Rare serious complications may occur in some patients, including {{B}}, bone marrow suppression, {{A}} hepatotoxicity and VPA-induced encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6745 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, {{A}} {{B}} and VPA-induced encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6746 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6747 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, {{B}}, VPA-induced hepatotoxicity and {{A}} encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6748 Rare serious complications may occur in some patients, including {{B}}, bone marrow suppression, VPA-induced hepatotoxicity and {{A}} encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6749 Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced {{B}} and {{A}} encephalopathy.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6752 Preservation of renal blood flow during {{B}} induced with {{A}} in dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6769 Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to {{B}} induce by {{A}} and local anesthetics were studied in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6770 Alterations of {{A}} transporter (NET) function by chronic inhibition of NET in relation to sensitization to {{B}} induce by cocaine and local anesthetics were studied in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6781 In male animals, repeated {{A}} treatment induced a gradual development of {{B}} as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment ', u'ed a gradual development of ')\n",
      "[11, 28]\n",
      "11\n",
      "0 54 {{A}} treatment induced a gradual development of {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment \n",
      "3 5 induc\n",
      "4 28 ed a gradual development of \n",
      "5 5 {{B}}\n",
      "6782 In male animals, repeated {{A}} treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of {{B}} and shortened latency before the first attack toward the opponent.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment ', u'ed a gradual development of aggressive behavior as evidenced by the increased intensity of ')\n",
      "[11, 91]\n",
      "11\n",
      "0 117 {{A}} treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of {{B}}\n",
      "1 5 {{A}}\n",
      "2 11  treatment \n",
      "3 5 induc\n",
      "4 91 ed a gradual development of aggressive behavior as evidenced by the increased intensity of \n",
      "5 5 {{B}}\n",
      "6784 Because the CNS damage caused by METH and MPTP is highly selective for the {{A}} neuronal system in mouse models of {{B}}, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6785 Because the CNS damage caused by METH and MPTP is highly selective for the {{A}} neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}} and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-', u'ed ')\n",
      "[104, 3]\n",
      "3\n",
      "0 122 {{A}} neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 104  neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6786 Because the CNS damage caused by METH and {{A}} is highly selective for the DA neuronal system in mouse models of {{B}}, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6787 Because the CNS damage caused by METH and {{A}} is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}} and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-', u'ed ')\n",
      "[135, 3]\n",
      "3\n",
      "0 153 {{A}} is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 135  is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6788 Because the CNS damage caused by {{A}} and MPTP is highly selective for the DA neuronal system in mouse models of {{B}}, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6789 Because the CNS damage caused by {{A}} and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}} and microglial activation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-', u'ed ')\n",
      "[144, 3]\n",
      "3\n",
      "0 162 {{A}} and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 144  and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6793 {{A}} and benztropine in neuroleptic-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and benztropine in neuroleptic-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} and benztropine in neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  and benztropine in neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6794 Ethopropazine and {{A}} in neuroleptic-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in neuroleptic-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} in neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  in neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6795 {{A}} potentiates initiation induced by {{B}} in rat liver.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' potentiates initiation ', u'ed by ')\n",
      "[24, 6]\n",
      "6\n",
      "0 45 {{A}} potentiates initiation induced by {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  potentiates initiation \n",
      "3 5 induc\n",
      "4 6 ed by \n",
      "5 5 {{B}}\n",
      "6803 {{A}} activates choline acetyltransferase from MC-IXC cells and improves drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' activates choline acetyltransferase from MC-IXC cells and improves drug-', u'ed ')\n",
      "[73, 3]\n",
      "3\n",
      "0 91 {{A}} activates choline acetyltransferase from MC-IXC cells and improves drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  activates choline acetyltransferase from MC-IXC cells and improves drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6804 Daidzein activates {{A}} acetyltransferase from MC-IXC cells and improves drug-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' acetyltransferase from MC-IXC cells and improves drug-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} acetyltransferase from MC-IXC cells and improves drug-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  acetyltransferase from MC-IXC cells and improves drug-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6826 Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced {{A}} efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6827 Neuroprotection rendered by {{A}} may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may be associated with the reduction of the methamphetamine-', u'ed dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in ')\n",
      "[61, 103]\n",
      "61\n",
      "0 179 {{A}} may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  may be associated with the reduction of the methamphetamine-\n",
      "3 5 induc\n",
      "4 103 ed dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in \n",
      "5 5 {{B}}\n",
      "6831 Moreover, it transiently diminished the {{A}} (10 mg/kg sc)-induced {{B}} and reduced basal body temperature.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (10 mg/kg sc)-', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} (10 mg/kg sc)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  (10 mg/kg sc)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6856 The results of this study suggest that the blockade of mGluR5 by {{A}} may protect dopaminergic neurones against methamphetamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may protect dopaminergic neurones against methamphetamine-', u'ed ')\n",
      "[59, 3]\n",
      "3\n",
      "0 77 {{A}} may protect dopaminergic neurones against methamphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 59  may protect dopaminergic neurones against methamphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6864 The present study was carried out to test the effects of {{A}} (L-alpha-GFC) on {{B}} induced by scopolamine in man.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6865 The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine ({{A}} on {{B}} induced by scopolamine in man.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6866 The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on {{B}} induced by {{A}} in man.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6870 The findings of this study indicate that the drug is able to antagonize {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6875 BACKGROUND: Heparin-induced {{B}} presents 5 to 12 days after {{A}} exposure, with or without arterial or venous thromboemboli.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6876 BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after {{A}} exposure, with or without arterial or {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6879 The purpose of this study was to investigate the influence of {{A}} channel blockers on bupivacaine-induced acute {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blockers on bupivacaine-', u'ed acute ')\n",
      "[33, 9]\n",
      "9\n",
      "0 57 {{A}} channel blockers on bupivacaine-induced acute {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  channel blockers on bupivacaine-\n",
      "3 5 induc\n",
      "4 9 ed acute \n",
      "5 5 {{B}}\n",
      "6890 The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced {{B}}; this effect was less pronounced with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6891 The convulsant activity of {{A}} was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced {{B}}; this effect was less pronounced with bepridil.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-', u'ed ')\n",
      "[113, 3]\n",
      "3\n",
      "0 131 {{A}} was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 113  was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6893 The convulsant activity of bupivacaine was not significantly modified but {{A}} channel blockers decreased the time of latency to obtain bupivacaine-induced {{B}}; this effect was less pronounced with bepridil.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' channel blockers decreased the time of latency to obtain bupivacaine-', u'ed ')\n",
      "[70, 3]\n",
      "3\n",
      "0 88 {{A}} channel blockers decreased the time of latency to obtain bupivacaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 70  channel blockers decreased the time of latency to obtain bupivacaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6894 Both, {{A}} (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed {{B}} induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6895 Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed {{B}} induced by {{A}} and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6896 Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and {{A}} (10 mg/kg, p.o., respectively) reversed {{B}} induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6908 High-dose intravenous {{A}} is an effective treatment for the induction of remission after meningeal relapse in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is an effective treatment for the ', u'tion of remission after meningeal relapse in ')\n",
      "[35, 45]\n",
      "35\n",
      "0 95 {{A}} is an effective treatment for the induction of remission after meningeal relapse in {{B}}\n",
      "1 5 {{A}}\n",
      "2 35  is an effective treatment for the \n",
      "3 5 induc\n",
      "4 45 tion of remission after meningeal relapse in \n",
      "5 5 {{B}}\n",
      "6917 {{B}} induced by {{A}} (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6918 Seizures induced by {{A}} (HFDE) were also found to be a more sensitive measure of protection by CBZ than {{B}} induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6919 {{B}} induced by hexafluorodiethyl ether ({{A}} were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6920 Seizures induced by hexafluorodiethyl ether ({{A}} were also found to be a more sensitive measure of protection by CBZ than {{B}} induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6921 {{B}} induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by {{A}} than seizures induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6922 Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by {{A}} than {{B}} induced by maximal electroshock (MES).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6931 METHODS: {{A}} (PAN) was administered to Sprague Dawley rats to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (PAN) was administered to Sprague Dawley rats to ', u'e ')\n",
      "[50, 2]\n",
      "2\n",
      "0 67 {{A}} (PAN) was administered to Sprague Dawley rats to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 50  (PAN) was administered to Sprague Dawley rats to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "6932 METHODS: Puromycin aminonucleoside ({{A}} was administered to Sprague Dawley rats to induce {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was administered to Sprague Dawley rats to ', u'e ')\n",
      "[44, 2]\n",
      "2\n",
      "0 61 {{A}} was administered to Sprague Dawley rats to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 44  was administered to Sprague Dawley rats to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "6936 Oral administration of {{A}} as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by {{B}} over 8 weeks of treatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-', u'ed seizures and was minimally toxic as measured by ')\n",
      "[100, 51]\n",
      "51\n",
      "0 166 {{A}} as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by {{B}}\n",
      "1 5 {{A}}\n",
      "2 100  as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-\n",
      "3 5 induc\n",
      "4 51 ed seizures and was minimally toxic as measured by \n",
      "5 5 {{B}}\n",
      "6937 Oral administration of {{A}} as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced {{B}} and was minimally toxic as measured by weight gain over 8 weeks of treatment.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-', u'ed ')\n",
      "[100, 3]\n",
      "3\n",
      "0 118 {{A}} as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 100  as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6942 Prednisolone-induced {{B}} is caused more by atrophy than by altered {{A}} receptor expression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6943 Prednisolone-induced muscle dysfunction is caused more by {{B}} than by altered {{A}} receptor expression.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6961 In the vitro human {{B}} induced by the agonists used in tests, TET and {{A}} showed the inhibitions dose dependently.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6962 In the vitro human {{B}} induced by the agonists used in tests, {{A}} and FAN showed the inhibitions dose dependently.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6963 The present study was undertaken to investigate the effects of TET and {{A}} on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and {{B}} in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on the experimental thrombosis ', u'ed by collagen plus epinephrine (EP) in mice, and platelet aggregation and ')\n",
      "[32, 75]\n",
      "32\n",
      "0 122 {{A}} on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  on the experimental thrombosis \n",
      "3 5 induc\n",
      "4 75 ed by collagen plus epinephrine (EP) in mice, and platelet aggregation and \n",
      "5 5 {{B}}\n",
      "6964 The present study was undertaken to investigate the effects of TET and {{A}} on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and {{B}} and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on the experimental thrombosis ', u'ed by collagen plus epinephrine (EP) in mice, and ')\n",
      "[32, 50]\n",
      "32\n",
      "0 97 {{A}} on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  on the experimental thrombosis \n",
      "3 5 induc\n",
      "4 50 ed by collagen plus epinephrine (EP) in mice, and \n",
      "5 5 {{B}}\n",
      "6965 The present study was undertaken to investigate the effects of TET and {{A}} on the experimental {{B}} induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6966 The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus {{A}} (EP) in mice, and platelet aggregation and {{B}} in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6967 The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus {{A}} (EP) in mice, and {{B}} and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6968 The present study was undertaken to investigate the effects of TET and FAN on the experimental {{B}} induced by collagen plus {{A}} (EP) in mice, and platelet aggregation and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6969 The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ({{A}} in mice, and platelet aggregation and {{B}} in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6970 The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ({{A}} in mice, and {{B}} and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6971 The present study was undertaken to investigate the effects of TET and FAN on the experimental {{B}} induced by collagen plus epinephrine ({{A}} in mice, and platelet aggregation and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6972 The present study was undertaken to investigate the effects of {{A}} and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and {{B}} in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and FAN on the experimental thrombosis ', u'ed by collagen plus epinephrine (EP) in mice, and platelet aggregation and ')\n",
      "[40, 75]\n",
      "40\n",
      "0 130 {{A}} and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  and FAN on the experimental thrombosis \n",
      "3 5 induc\n",
      "4 75 ed by collagen plus epinephrine (EP) in mice, and platelet aggregation and \n",
      "5 5 {{B}}\n",
      "6973 The present study was undertaken to investigate the effects of {{A}} and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and {{B}} and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and FAN on the experimental thrombosis ', u'ed by collagen plus epinephrine (EP) in mice, and ')\n",
      "[40, 50]\n",
      "40\n",
      "0 105 {{A}} and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  and FAN on the experimental thrombosis \n",
      "3 5 induc\n",
      "4 50 ed by collagen plus epinephrine (EP) in mice, and \n",
      "5 5 {{B}}\n",
      "6974 The present study was undertaken to investigate the effects of {{A}} and FAN on the experimental {{B}} induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6975 Flumazenil is a {{A}} receptor antagonist used to reverse sedation and {{B}} induced by benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6976 Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6977 {{A}} is a benzodiazepine receptor antagonist used to reverse sedation and {{B}} induced by benzodiazepines.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "6998 CONCLUSIONS: As of March 24, 2005, this is the first reported case of {{A}}- and tiapride-induced {{B}} crisis in a patient with pheochromocytoma.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and tiapride-', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}}- and tiapride-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15 - and tiapride-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "6999 CONCLUSIONS: As of March 24, 2005, this is the first reported case of {{A}}- and tiapride-induced hypertensive crisis in a patient with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and tiapride-', u'ed hypertensive crisis in a patient with ')\n",
      "[15, 41]\n",
      "15\n",
      "0 71 {{A}}- and tiapride-induced hypertensive crisis in a patient with {{B}}\n",
      "1 5 {{A}}\n",
      "2 15 - and tiapride-\n",
      "3 5 induc\n",
      "4 41 ed hypertensive crisis in a patient with \n",
      "5 5 {{B}}\n",
      "7009 Neuroactive {{A}} protect against pilocarpine- and kainic acid-induced limbic seizures and {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' protect against pilocarpine- and kainic acid-', u'ed limbic seizures and ')\n",
      "[46, 23]\n",
      "23\n",
      "0 84 {{A}} protect against pilocarpine- and kainic acid-induced limbic seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  protect against pilocarpine- and kainic acid-\n",
      "3 5 induc\n",
      "4 23 ed limbic seizures and \n",
      "5 5 {{B}}\n",
      "7010 Neuroactive {{A}} protect against pilocarpine- and kainic acid-induced limbic {{B}} and status epilepticus in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' protect against pilocarpine- and kainic acid-', u'ed limbic ')\n",
      "[46, 10]\n",
      "10\n",
      "0 71 {{A}} protect against pilocarpine- and kainic acid-induced limbic {{B}}\n",
      "1 5 {{A}}\n",
      "2 46  protect against pilocarpine- and kainic acid-\n",
      "3 5 induc\n",
      "4 10 ed limbic \n",
      "5 5 {{B}}\n",
      "7011 Neuroactive steroids protect against {{A}}- and kainic acid-induced limbic seizures and {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and kainic acid-', u'ed limbic seizures and ')\n",
      "[18, 23]\n",
      "18\n",
      "0 56 {{A}}- and kainic acid-induced limbic seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and kainic acid-\n",
      "3 5 induc\n",
      "4 23 ed limbic seizures and \n",
      "5 5 {{B}}\n",
      "7012 Neuroactive steroids protect against {{A}}- and kainic acid-induced limbic {{B}} and status epilepticus in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and kainic acid-', u'ed limbic ')\n",
      "[18, 10]\n",
      "10\n",
      "0 43 {{A}}- and kainic acid-induced limbic {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and kainic acid-\n",
      "3 5 induc\n",
      "4 10 ed limbic \n",
      "5 5 {{B}}\n",
      "7018 Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, {{A}}- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[34, 3]\n",
      "3\n",
      "0 52 {{A}}- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 34 - and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7019 Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and {{A}} (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[175, 3]\n",
      "3\n",
      "0 193 {{A}} (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 175  (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7020 Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone ({{A}} and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[132, 3]\n",
      "3\n",
      "0 150 {{A}} and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 132  and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7021 Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against {{A}}-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-, kainic acid- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}}-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48 -, kainic acid- and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7022 Several structurally related metabolites of {{A}} (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[234, 3]\n",
      "3\n",
      "0 252 {{A}} (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 234  (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7023 Several structurally related metabolites of progesterone ({{A}} and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-', u'ed ')\n",
      "[199, 3]\n",
      "3\n",
      "0 217 {{A}} and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 199  and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7026 The effectiveness of administration of {{A}} 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent {{B}} and bradycardia following repeated doses of suxamethonium in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the ', u'tion of anaesthesia, to prevent ')\n",
      "[93, 32]\n",
      "32\n",
      "0 140 {{A}} 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent {{B}}\n",
      "1 5 {{A}}\n",
      "2 93  5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the \n",
      "3 5 induc\n",
      "4 32 tion of anaesthesia, to prevent \n",
      "5 5 {{B}}\n",
      "7027 The effectiveness of administration of {{A}} 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and {{B}} following repeated doses of suxamethonium in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the ', u'tion of anaesthesia, to prevent arrhythmia and ')\n",
      "[93, 47]\n",
      "47\n",
      "0 155 {{A}} 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 93  5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the \n",
      "3 5 induc\n",
      "4 47 tion of anaesthesia, to prevent arrhythmia and \n",
      "5 5 {{B}}\n",
      "7028 The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent {{B}} and bradycardia following repeated doses of {{A}} in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7029 The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and {{B}} following repeated doses of {{A}} in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7030 The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and {{A}} 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent {{B}} and bradycardia following repeated doses of suxamethonium in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 10 and 20 micrograms kg-1 i.v. immediately before the ', u'tion of anaesthesia, to prevent ')\n",
      "[55, 32]\n",
      "32\n",
      "0 102 {{A}} 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  10 and 20 micrograms kg-1 i.v. immediately before the \n",
      "3 5 induc\n",
      "4 32 tion of anaesthesia, to prevent \n",
      "5 5 {{B}}\n",
      "7031 The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and {{A}} 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and {{B}} following repeated doses of suxamethonium in children, was studied.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 10 and 20 micrograms kg-1 i.v. immediately before the ', u'tion of anaesthesia, to prevent arrhythmia and ')\n",
      "[55, 47]\n",
      "47\n",
      "0 117 {{A}} 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  10 and 20 micrograms kg-1 i.v. immediately before the \n",
      "3 5 induc\n",
      "4 47 tion of anaesthesia, to prevent arrhythmia and \n",
      "5 5 {{B}}\n",
      "7036 {{A}} with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and {{B}} (ED50 values, 7.0-18.7 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-', u'ed limbic motor seizures and ')\n",
      "[167, 29]\n",
      "29\n",
      "0 211 {{A}} with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 167  with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-\n",
      "3 5 induc\n",
      "4 29 ed limbic motor seizures and \n",
      "5 5 {{B}}\n",
      "7037 {{A}} with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor {{B}} and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-', u'ed limbic motor ')\n",
      "[167, 16]\n",
      "16\n",
      "0 198 {{A}} with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor {{B}}\n",
      "1 5 {{A}}\n",
      "2 167  with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-\n",
      "3 5 induc\n",
      "4 16 ed limbic motor \n",
      "5 5 {{B}}\n",
      "7038 Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against {{A}} (416 mg/kg, s.c.)-induced limbic motor seizures and {{B}} (ED50 values, 7.0-18.7 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (416 mg/kg, s.c.)-', u'ed limbic motor seizures and ')\n",
      "[19, 29]\n",
      "19\n",
      "0 63 {{A}} (416 mg/kg, s.c.)-induced limbic motor seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  (416 mg/kg, s.c.)-\n",
      "3 5 induc\n",
      "4 29 ed limbic motor seizures and \n",
      "5 5 {{B}}\n",
      "7039 Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against {{A}} (416 mg/kg, s.c.)-induced limbic motor {{B}} and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (416 mg/kg, s.c.)-', u'ed limbic motor ')\n",
      "[19, 16]\n",
      "16\n",
      "0 50 {{A}} (416 mg/kg, s.c.)-induced limbic motor {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  (416 mg/kg, s.c.)-\n",
      "3 5 induc\n",
      "4 16 ed limbic motor \n",
      "5 5 {{B}}\n",
      "7046 CONCLUSION: Pretreatment with {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, {{B}}, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 1 microg/kg reduced myoclonus after etomidate ', u'tion without side effects such as sedation, apnea, ')\n",
      "[47, 51]\n",
      "47\n",
      "0 113 {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  1 microg/kg reduced myoclonus after etomidate \n",
      "3 5 induc\n",
      "4 51 tion without side effects such as sedation, apnea, \n",
      "5 5 {{B}}\n",
      "7047 CONCLUSION: Pretreatment with {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 1 microg/kg reduced myoclonus after etomidate ', u'tion without side effects such as sedation, apnea, nausea, or ')\n",
      "[47, 62]\n",
      "47\n",
      "0 124 {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or {{B}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1 5 {{A}}\n",
      "2 47  1 microg/kg reduced myoclonus after etomidate \n",
      "3 5 induc\n",
      "4 62 tion without side effects such as sedation, apnea, nausea, or \n",
      "5 5 {{B}}\n",
      "7048 CONCLUSION: Pretreatment with {{A}} 1 microg/kg reduced {{B}} after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7049 CONCLUSION: Pretreatment with {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, {{B}}, nausea, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 1 microg/kg reduced myoclonus after etomidate ', u'tion without side effects such as sedation, ')\n",
      "[47, 44]\n",
      "44\n",
      "0 106 {{A}} 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, {{B}}\n",
      "1 5 {{A}}\n",
      "2 47  1 microg/kg reduced myoclonus after etomidate \n",
      "3 5 induc\n",
      "4 44 tion without side effects such as sedation, \n",
      "5 5 {{B}}\n",
      "7050 CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after {{A}} induction without side effects such as sedation, apnea, {{B}}, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'tion without side effects such as sedation, apnea, ')\n",
      "[1, 51]\n",
      "1\n",
      "0 67 {{A}} induction without side effects such as sedation, apnea, {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 51 tion without side effects such as sedation, apnea, \n",
      "5 5 {{B}}\n",
      "7051 CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after {{A}} induction without side effects such as sedation, apnea, nausea, or {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'tion without side effects such as sedation, apnea, nausea, or ')\n",
      "[1, 62]\n",
      "1\n",
      "0 78 {{A}} induction without side effects such as sedation, apnea, nausea, or {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 62 tion without side effects such as sedation, apnea, nausea, or \n",
      "5 5 {{B}}\n",
      "7052 CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced {{B}} after {{A}} induction without side effects such as sedation, apnea, nausea, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7053 CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after {{A}} induction without side effects such as sedation, {{B}}, nausea, or pruritus.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'tion without side effects such as sedation, ')\n",
      "[1, 44]\n",
      "1\n",
      "0 60 {{A}} induction without side effects such as sedation, {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 44 tion without side effects such as sedation, \n",
      "5 5 {{B}}\n",
      "7070 {{B}} induced by combinations of ketamine and {{A}}: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7071 {{B}} induced by combinations of {{A}} and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7072 Previous studies demonstrated that both ketamine and {{A}} induced {{B}} and catalepsy in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7073 Previous studies demonstrated that both ketamine and {{A}} induced analgesia and {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed analgesia and ')\n",
      "[1, 17]\n",
      "1\n",
      "0 33 {{A}} induced analgesia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 17 ed analgesia and \n",
      "5 5 {{B}}\n",
      "7074 Previous studies demonstrated that both {{A}} and morphine induced {{B}} and catalepsy in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and morphine ', u'ed ')\n",
      "[14, 3]\n",
      "3\n",
      "0 32 {{A}} and morphine induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  and morphine \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7075 Previous studies demonstrated that both {{A}} and morphine induced analgesia and {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and morphine ', u'ed analgesia and ')\n",
      "[14, 17]\n",
      "14\n",
      "0 46 {{A}} and morphine induced analgesia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 14  and morphine \n",
      "3 5 induc\n",
      "4 17 ed analgesia and \n",
      "5 5 {{B}}\n",
      "7082 Pre-treatment with ketamine produced cross-tolerance to {{A}}, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the {{B}} response; this augmentation was attributed to residual morphine in the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', whereas pretreatment with morphine did not ', u'e cross-tolerance to ketamine but rather augmented the ')\n",
      "[45, 55]\n",
      "45\n",
      "0 115 {{A}}, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the {{B}}\n",
      "1 5 {{A}}\n",
      "2 45 , whereas pretreatment with morphine did not \n",
      "3 5 induc\n",
      "4 55 e cross-tolerance to ketamine but rather augmented the \n",
      "5 5 {{B}}\n",
      "7083 Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with {{A}} did not induce cross-tolerance to ketamine but rather augmented the {{B}} response; this augmentation was attributed to residual morphine in the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' did not ', u'e cross-tolerance to ketamine but rather augmented the ')\n",
      "[9, 55]\n",
      "9\n",
      "0 79 {{A}} did not induce cross-tolerance to ketamine but rather augmented the {{B}}\n",
      "1 5 {{A}}\n",
      "2 9  did not \n",
      "3 5 induc\n",
      "4 55 e cross-tolerance to ketamine but rather augmented the \n",
      "5 5 {{B}}\n",
      "7084 Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the {{B}} response; this augmentation was attributed to residual {{A}} in the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7085 Pre-treatment with {{A}} produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the {{B}} response; this augmentation was attributed to residual morphine in the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' produced cross-tolerance to morphine, whereas pretreatment with morphine did not ', u'e cross-tolerance to ketamine but rather augmented the ')\n",
      "[82, 55]\n",
      "55\n",
      "0 152 {{A}} produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the {{B}}\n",
      "1 5 {{A}}\n",
      "2 82  produced cross-tolerance to morphine, whereas pretreatment with morphine did not \n",
      "3 5 induc\n",
      "4 55 e cross-tolerance to ketamine but rather augmented the \n",
      "5 5 {{B}}\n",
      "7086 Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to {{A}} but rather augmented the {{B}} response; this augmentation was attributed to residual morphine in the brain.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7087 Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic {{B}} induced by {{A}} (32 mg/kg, s.c.), but did not completely protect against the seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7088 Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by {{A}} (32 mg/kg, s.c.), but did not completely protect against the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7089 {{A}} with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic {{B}} induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7090 {{A}} with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures ', u'ed by kainic acid (32 mg/kg, s.c.), but did not completely protect against the ')\n",
      "[129, 79]\n",
      "79\n",
      "0 223 {{A}} with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the {{B}}\n",
      "1 5 {{A}}\n",
      "2 129  with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures \n",
      "3 5 induc\n",
      "4 79 ed by kainic acid (32 mg/kg, s.c.), but did not completely protect against the \n",
      "5 5 {{B}}\n",
      "7095 {{A}} inhibited the induced {{B}} effects.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' inhibited the ', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} inhibited the induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  inhibited the \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7100 However, when a second dose of the {{A}} was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and {{B}} was obtained.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was administered 1 hr after the first dose, complete protection from the kainic acid-', u'ed limbic seizures and ')\n",
      "[86, 23]\n",
      "23\n",
      "0 124 {{A}} was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 86  was administered 1 hr after the first dose, complete protection from the kainic acid-\n",
      "3 5 induc\n",
      "4 23 ed limbic seizures and \n",
      "5 5 {{B}}\n",
      "7101 However, when a second dose of the {{A}} was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic {{B}} and status epilepticus was obtained.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' was administered 1 hr after the first dose, complete protection from the kainic acid-', u'ed limbic ')\n",
      "[86, 10]\n",
      "10\n",
      "0 111 {{A}} was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic {{B}}\n",
      "1 5 {{A}}\n",
      "2 86  was administered 1 hr after the first dose, complete protection from the kainic acid-\n",
      "3 5 induc\n",
      "4 10 ed limbic \n",
      "5 5 {{B}}\n",
      "7108 OBJECTIVE: To determine the safety and efficacy of adjunctive {{A}} sustained-release (SR) on male {{B}} (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7109 OBJECTIVE: To determine the safety and efficacy of adjunctive {{A}} sustained-release (SR) on male sexual dysfunction ({{B}} induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7110 OBJECTIVE: To determine the safety and efficacy of adjunctive {{A}} sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as {{B}} is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' sustained-release (SR) on male sexual dysfunction (SD) ', u'ed by a selective serotonin reuptake inhibitor (SSRI), as ')\n",
      "[56, 58]\n",
      "56\n",
      "0 129 {{A}} sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as {{B}}\n",
      "1 5 {{A}}\n",
      "2 56  sustained-release (SR) on male sexual dysfunction (SD) \n",
      "3 5 induc\n",
      "4 58 ed by a selective serotonin reuptake inhibitor (SSRI), as \n",
      "5 5 {{B}}\n",
      "7111 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male {{B}} (SD) induced by a selective serotonin reuptake inhibitor ({{A}}, as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7112 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction ({{B}} induced by a selective serotonin reuptake inhibitor ({{A}}, as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7113 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor ({{A}}, as {{B}} is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7114 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male {{B}} (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of {{A}} and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7115 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction ({{B}} induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of {{A}} and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7116 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as {{B}} is a common side-effect of {{A}} and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7117 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male {{B}} (SD) induced by a selective {{A}} reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7118 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction ({{B}} induced by a selective {{A}} reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7119 OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective {{A}} reuptake inhibitor (SSRI), as {{B}} is a common side-effect of SSRIs and the most effective treatments have yet to be determined.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7125 {{B}}, which is suppressed by Ca channel blockers, was induced by {{A}} infusion in halothane-anesthetized dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7126 {{B}}, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in {{A}} dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7127 {{B}}, which is suppressed by {{A}} channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7134 The minimum effective plasma concentrations of (-)-{{A}} for digitalis- and adrenaline-induced {{B}} were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' for digitalis- and adrenaline-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} for digitalis- and adrenaline-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  for digitalis- and adrenaline-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7137 The {{A}} also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA {{B}} or lethality.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-', u'ed lethality, but did not completely protect against NMDA ')\n",
      "[62, 58]\n",
      "58\n",
      "0 135 {{A}} also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-\n",
      "3 5 induc\n",
      "4 58 ed lethality, but did not completely protect against NMDA \n",
      "5 5 {{B}}\n",
      "7144 We conclude that neuroactive {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and {{B}} in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' are highly effective in protecting against pilocarpine- and kainic acid-', u'ed seizures and ')\n",
      "[73, 16]\n",
      "16\n",
      "0 104 {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  are highly effective in protecting against pilocarpine- and kainic acid-\n",
      "3 5 induc\n",
      "4 16 ed seizures and \n",
      "5 5 {{B}}\n",
      "7145 We conclude that neuroactive {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of {{B}} in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' are highly effective in protecting against pilocarpine- and kainic acid-', u'ed seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of ')\n",
      "[73, 100]\n",
      "73\n",
      "0 188 {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  are highly effective in protecting against pilocarpine- and kainic acid-\n",
      "3 5 induc\n",
      "4 100 ed seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of \n",
      "5 5 {{B}}\n",
      "7146 We conclude that neuroactive {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced {{B}} and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' are highly effective in protecting against pilocarpine- and kainic acid-', u'ed ')\n",
      "[73, 3]\n",
      "3\n",
      "0 91 {{A}} are highly effective in protecting against pilocarpine- and kainic acid-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  are highly effective in protecting against pilocarpine- and kainic acid-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7147 We conclude that neuroactive steroids are highly effective in protecting against {{A}}- and kainic acid-induced seizures and {{B}} in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and kainic acid-', u'ed seizures and ')\n",
      "[18, 16]\n",
      "16\n",
      "0 49 {{A}}- and kainic acid-induced seizures and {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and kainic acid-\n",
      "3 5 induc\n",
      "4 16 ed seizures and \n",
      "5 5 {{B}}\n",
      "7148 We conclude that neuroactive steroids are highly effective in protecting against {{A}}- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of {{B}} in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and kainic acid-', u'ed seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of ')\n",
      "[18, 100]\n",
      "18\n",
      "0 133 {{A}}- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and kainic acid-\n",
      "3 5 induc\n",
      "4 100 ed seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of \n",
      "5 5 {{B}}\n",
      "7149 We conclude that neuroactive steroids are highly effective in protecting against {{A}}- and kainic acid-induced {{B}} and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'- and kainic acid-', u'ed ')\n",
      "[18, 3]\n",
      "3\n",
      "0 36 {{A}}- and kainic acid-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 18 - and kainic acid-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7155 CONCLUSIONS: {{A}} may be useful for the treatment of risperidone-induced {{B}} in youth; however, further research is needed.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may be useful for the treatment of risperidone-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}} may be useful for the treatment of risperidone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  may be useful for the treatment of risperidone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7173 To avoid disastrous outcomes, physicians must consider heparin-induced {{B}} whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not {{A}}, should be initiated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7174 To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with {{B}}; therapy with alternative anticoagulants, not {{A}}, should be initiated.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7199 In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the {{A}} retention associated with PAN-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' retention associated with PAN-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} retention associated with PAN-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  retention associated with PAN-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7207 The novel anxiolytic drug, {{A}}, reverses {{B}} induced by haloperidol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7208 The novel anxiolytic drug, buspirone, reverses {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7209 A series of aryl-piperazine analogues of buspirone and other {{A}} were tested for their ability to reverse haloperidol induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' were tested for their ability to reverse haloperidol ', u'ed ')\n",
      "[54, 3]\n",
      "3\n",
      "0 72 {{A}} were tested for their ability to reverse haloperidol induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 54  were tested for their ability to reverse haloperidol \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7210 A series of aryl-piperazine analogues of {{A}} and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol ', u'ed ')\n",
      "[97, 3]\n",
      "3\n",
      "0 115 {{A}} and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 97  and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7211 A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse {{A}} induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7241 These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7242 Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the {{A}}, was sufficient to minimize early, edrophonium-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', was sufficient to minimize early, edrophonium-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}}, was sufficient to minimize early, edrophonium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48 , was sufficient to minimize early, edrophonium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7244 Use of {{A}} 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-', u'ed ')\n",
      "[148, 3]\n",
      "3\n",
      "0 166 {{A}} 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 148  5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7271 {{A}} also has a potential for inducing {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' also has a potential for ', u'ing ')\n",
      "[26, 4]\n",
      "4\n",
      "0 45 {{A}} also has a potential for inducing {{B}}\n",
      "1 5 {{A}}\n",
      "2 26  also has a potential for \n",
      "3 5 induc\n",
      "4 4 ing \n",
      "5 5 {{B}}\n",
      "7288 Thus, the absence of D2R lowers the threshold for {{B}} induced by both glutamate and {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7306 In patients premedicated with scopolamine + morphine (+5 mg {{A}} the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' the evening before surgery), the sleep-', u'ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ')\n",
      "[40, 207]\n",
      "40\n",
      "0 262 {{A}} the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}}\n",
      "1 5 {{A}}\n",
      "2 40  the evening before surgery), the sleep-\n",
      "3 5 induc\n",
      "4 207 ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although \n",
      "5 5 {{B}}\n",
      "7307 In patients premedicated with scopolamine + {{A}} (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (+5 mg nitrazepam the evening before surgery), the sleep-', u'ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ')\n",
      "[58, 207]\n",
      "58\n",
      "0 280 {{A}} (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}}\n",
      "1 5 {{A}}\n",
      "2 58  (+5 mg nitrazepam the evening before surgery), the sleep-\n",
      "3 5 induc\n",
      "4 207 ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although \n",
      "5 5 {{B}}\n",
      "7308 In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of {{A}} 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7309 In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the {{A}} group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7310 In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the {{A}} group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7311 In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of {{A}} 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7312 In patients premedicated with {{A}} + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}} occurred less often in the midazolam group it lasted longer.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' + morphine (+5 mg nitrazepam the evening before surgery), the sleep-', u'ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ')\n",
      "[69, 207]\n",
      "69\n",
      "0 291 {{A}} + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although {{B}}\n",
      "1 5 {{A}}\n",
      "2 69  + morphine (+5 mg nitrazepam the evening before surgery), the sleep-\n",
      "3 5 induc\n",
      "4 207 ing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although \n",
      "5 5 {{B}}\n",
      "7315 Cocaine-induced mood disorder: prevalence rates and {{B}} symptoms in an outpatient {{A}} sample.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7316 Cocaine-induced {{B}}: prevalence rates and psychiatric symptoms in an outpatient {{A}} sample.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7366 Role of {{A}} on biochemical alterations and antioxidant status in isoproterenol-induced {{B}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on biochemical alterations and antioxidant status in isoproterenol-', u'ed ')\n",
      "[68, 3]\n",
      "3\n",
      "0 86 {{A}} on biochemical alterations and antioxidant status in isoproterenol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 68  on biochemical alterations and antioxidant status in isoproterenol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7371 (Anacardiaceae), on {{A}} (ISPH)-induced {{B}} (MI) in rats through its antioxidative mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (ISPH)-', u'ed ')\n",
      "[8, 3]\n",
      "3\n",
      "0 26 {{A}} (ISPH)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (ISPH)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7372 (Anacardiaceae), on {{A}} (ISPH)-induced myocardial infarction ({{B}} in rats through its antioxidative mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (ISPH)-', u'ed myocardial infarction (')\n",
      "[8, 26]\n",
      "8\n",
      "0 49 {{A}} (ISPH)-induced myocardial infarction ({{B}}\n",
      "1 5 {{A}}\n",
      "2 8  (ISPH)-\n",
      "3 5 induc\n",
      "4 26 ed myocardial infarction (\n",
      "5 5 {{B}}\n",
      "7373 (Anacardiaceae), on isoproterenol ({{A}}-induced {{B}} (MI) in rats through its antioxidative mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7374 (Anacardiaceae), on isoproterenol ({{A}}-induced myocardial infarction ({{B}} in rats through its antioxidative mechanism.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed myocardial infarction (')\n",
      "[1, 26]\n",
      "1\n",
      "0 42 {{A}}-induced myocardial infarction ({{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 26 ed myocardial infarction (\n",
      "5 5 {{B}}\n",
      "7397 Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon {{A}} administration as compared to ISPH-induced {{B}} rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' administration as compared to ISPH-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}} administration as compared to ISPH-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36  administration as compared to ISPH-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7399 Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while {{A}} {{B}} was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7400 Exercise-induced {{B}} was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while {{A}} ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7401 The present study was designed to study the effect of {{A}} H(3)-receptor ligands on neuroleptic-induced {{B}}, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' H(3)-receptor ligands on neuroleptic-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} H(3)-receptor ligands on neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2 38  H(3)-receptor ligands on neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7402 The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced {{B}}, apomorphine-induced climbing behavior and {{A}} locomotor activities in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7403 The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced {{B}}, {{A}} climbing behavior and amphetamine-induced locomotor activities in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7405 {{B}} was induced by {{A}} (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7406 {{B}} was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and {{A}} (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7407 {{B}} was induced by haloperidol (2 mg/kg p.o.), while {{A}} (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7414 {{B}} induced by {{A}} in an elderly woman with preexisting complete left bundle branch block.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7415 Torsade de pointes induced by {{A}} in an elderly woman with preexisting complete {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7418 On amphetamine-induced {{B}}, {{A}} (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7423 {{A}} (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-', u'ed ')\n",
      "[124, 3]\n",
      "3\n",
      "0 142 {{A}} (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 124  (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7424 GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to {{A}}, dose-dependently attenuated the psychostimulant-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', dose-dependently attenuated the psychostimulant-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}}, dose-dependently attenuated the psychostimulant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50 , dose-dependently attenuated the psychostimulant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7427 THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced {{B}} and reducing {{A}} climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7428 THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced {{B}}, reducing amphetamine-induced hyperactivity and reducing {{A}} climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7429 THP exhibited an antipsychotic-like profile by potentiating {{A}} catalepsy, reducing amphetamine-induced {{B}} and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' catalepsy, reducing amphetamine-', u'ed ')\n",
      "[33, 3]\n",
      "3\n",
      "0 51 {{A}} catalepsy, reducing amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  catalepsy, reducing amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7430 THP exhibited an antipsychotic-like profile by potentiating {{A}} {{B}}, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7431 THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing {{A}} {{B}} and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7432 THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced {{B}}, reducing {{A}} hyperactivity and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7433 {{A}} exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced {{B}} and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-', u'ed ')\n",
      "[109, 3]\n",
      "3\n",
      "0 127 {{A}} exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 109  exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7434 {{A}} exhibited an antipsychotic-like profile by potentiating haloperidol-induced {{B}}, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exhibited an antipsychotic-like profile by potentiating haloperidol-', u'ed ')\n",
      "[69, 3]\n",
      "3\n",
      "0 87 {{A}} exhibited an antipsychotic-like profile by potentiating haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 69  exhibited an antipsychotic-like profile by potentiating haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7459 Additionally, in terms of management of EMB-induced {{B}}, it is important to properly manage {{A}} dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7460 Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage {{A}} dosing in patients with {{B}} and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7474 The combination inhibited intestinal transit similar to that produced by {{A}} regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-', u'ed ')\n",
      "[92, 3]\n",
      "3\n",
      "0 110 {{A}} regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 92  regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7476 The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that {{A}} did not potentiate morphine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' did not potentiate morphine-', u'ed ')\n",
      "[29, 3]\n",
      "3\n",
      "0 47 {{A}} did not potentiate morphine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 29  did not potentiate morphine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7477 METHODS: In this study, we evaluated the performance of {{A}} beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-', u'ed ')\n",
      "[173, 3]\n",
      "3\n",
      "0 191 {{A}} beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 173  beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7479 METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack {{A}} (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-', u'ed ')\n",
      "[105, 3]\n",
      "3\n",
      "0 123 {{A}} (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 105  (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7480 METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine ({{A}}, in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-', u'ed ')\n",
      "[100, 3]\n",
      "3\n",
      "0 118 {{A}}, in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 100 , in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7484 Rapid reversal of life-threatening diltiazem-induced {{B}} with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7503 Therefore, we studied the predictive effect of renal ACE activity for the severity of {{B}} induced by a single injection of {{A}} in rats.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7506 After 1 week of recovery, {{B}} was induced by {{A}} [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9].\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7521 The effect of amiloride on lithium-induced {{B}} and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7522 The effect of amiloride on lithium-induced polydipsia and {{B}} and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7523 The effect of {{A}} on lithium-induced {{B}} and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on lithium-', u'ed ')\n",
      "[12, 3]\n",
      "3\n",
      "0 30 {{A}} on lithium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  on lithium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7524 The effect of {{A}} on lithium-induced polydipsia and {{B}} and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on lithium-', u'ed polydipsia and ')\n",
      "[12, 18]\n",
      "12\n",
      "0 45 {{A}} on lithium-induced polydipsia and {{B}}\n",
      "1 5 {{A}}\n",
      "2 12  on lithium-\n",
      "3 5 induc\n",
      "4 18 ed polydipsia and \n",
      "5 5 {{B}}\n",
      "7527 The effect of amiloride on lithium-induced {{B}} and polyuria and on the {{A}} concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7528 The effect of amiloride on lithium-induced polydipsia and {{B}} and on the {{A}} concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7541 Sprague-Dawley rats were injected intraperitoneally with {{A}}, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-', u'ed ')\n",
      "[110, 3]\n",
      "3\n",
      "0 128 {{A}}, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 110 , and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7552 Controlled {{B}} to an average MAP of 50-55 mm Hg was induced by increasing the dose of {{A}}, and maintained at an inspired concentration of 2.2 +/- 0.2%.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7560 These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7561 These results suggest that down-regulation of hippocampal NET induced by chronic administration of {{A}} may be relevant to desipramine-induced sensitization of lidocaine {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may be relevant to desipramine-', u'ed sensitization of lidocaine ')\n",
      "[32, 30]\n",
      "30\n",
      "0 77 {{A}} may be relevant to desipramine-induced sensitization of lidocaine {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  may be relevant to desipramine-\n",
      "3 5 induc\n",
      "4 30 ed sensitization of lidocaine \n",
      "5 5 {{B}}\n",
      "7562 These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to {{A}} sensitization of lidocaine {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7563 These results strongly suggest that {{A}} improves haloperidol-induced {{B}} via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' improves haloperidol-', u'ed ')\n",
      "[22, 3]\n",
      "3\n",
      "0 40 {{A}} improves haloperidol-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  improves haloperidol-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7564 These results strongly suggest that {{A}} improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of {{B}} without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' improves haloperidol-', u'ed catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of ')\n",
      "[22, 113]\n",
      "22\n",
      "0 150 {{A}} improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of {{B}}\n",
      "1 5 {{A}}\n",
      "2 22  improves haloperidol-\n",
      "3 5 induc\n",
      "4 113 ed catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of \n",
      "5 5 {{B}}\n",
      "7565 These results strongly suggest that carteolol improves haloperidol-induced {{B}} via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic {{A}} receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7566 These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of {{B}} without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic {{A}} receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7567 These results strongly suggest that carteolol improves {{A}} {{B}} via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7568 These results strongly suggest that carteolol improves {{A}} catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of {{B}} without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7576 The appearance of {{B}} such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of {{A}} was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7577 The appearance of nephrotic syndromes such as proteinuria, {{B}}, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of {{A}} was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7578 The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, {{B}} and increase in blood nitrogen urea, induced in rats by injection of {{A}} was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7579 The appearance of nephrotic syndromes such as {{B}}, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of {{A}} was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7580 The appearance of {{B}} such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of {{A}} (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7581 The appearance of nephrotic syndromes such as proteinuria, {{B}}, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of {{A}} (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7582 The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, {{B}} and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of {{A}} (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7583 The appearance of nephrotic syndromes such as {{B}}, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of {{A}} (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7584 The appearance of {{B}} such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ({{A}}, a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7585 The appearance of nephrotic syndromes such as proteinuria, {{B}}, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ({{A}}, a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7586 The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, {{B}} and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ({{A}}, a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7587 The appearance of nephrotic syndromes such as {{B}}, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ({{A}}, a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7588 The appearance of {{B}} such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel {{A}} receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7589 The appearance of nephrotic syndromes such as proteinuria, {{B}}, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel {{A}} receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7590 The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, {{B}} and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel {{A}} receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7591 The appearance of nephrotic syndromes such as {{B}}, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel {{A}} receptor antagonist, at a dose of 1 or 2 mg/kg per day.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7592 We therefore conducted the present acute dose-response study in four {{A}} (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-', u'ed ')\n",
      "[62, 3]\n",
      "3\n",
      "0 80 {{A}} (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7593 We therefore conducted the present acute dose-response study in four {{A}} (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-', u'ed dyskinesias to evaluate the locomotor and ')\n",
      "[62, 45]\n",
      "45\n",
      "0 122 {{A}} (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}}\n",
      "1 5 {{A}}\n",
      "2 62  (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-\n",
      "3 5 induc\n",
      "4 45 ed dyskinesias to evaluate the locomotor and \n",
      "5 5 {{B}}\n",
      "7594 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ({{A}}-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-exposed cynomolgus monkeys primed to exhibit levodopa-', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}}-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55 -exposed cynomolgus monkeys primed to exhibit levodopa-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7595 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ({{A}}-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-exposed cynomolgus monkeys primed to exhibit levodopa-', u'ed dyskinesias to evaluate the locomotor and ')\n",
      "[55, 45]\n",
      "45\n",
      "0 115 {{A}}-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}}\n",
      "1 5 {{A}}\n",
      "2 55 -exposed cynomolgus monkeys primed to exhibit levodopa-\n",
      "3 5 induc\n",
      "4 45 ed dyskinesias to evaluate the locomotor and \n",
      "5 5 {{B}}\n",
      "7596 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]{{A}}, a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7597 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]{{A}}, a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7600 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full {{A}} D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7601 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full {{A}} D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7602 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5{{A}}-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7603 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5{{A}}-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7604 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced {{B}} to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of {{A}} ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7605 We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and {{B}} effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of {{A}} ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7606 The results suggest a possible involvement of the {{A}} system in the development of puromycin aminonucleoside-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' system in the development of puromycin aminonucleoside-', u'ed ')\n",
      "[56, 3]\n",
      "3\n",
      "0 74 {{A}} system in the development of puromycin aminonucleoside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 56  system in the development of puromycin aminonucleoside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7618 The objective of this study was to determine whether {{A}}, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-', u'ed ')\n",
      "[148, 3]\n",
      "3\n",
      "0 166 {{A}}, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 148 , an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7622 CONCLUSIONS: In contrast to the adult, {{A}} exposure in utero induces {{B}} in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' exposure in utero ', u'es ')\n",
      "[19, 3]\n",
      "3\n",
      "0 37 {{A}} exposure in utero induces {{B}}\n",
      "1 5 {{A}}\n",
      "2 19  exposure in utero \n",
      "3 5 induc\n",
      "4 3 es \n",
      "5 5 {{B}}\n",
      "7623 While the mechanisms underlying {{A}} rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states ', u'ed by cocaine, such as ')\n",
      "[115, 23]\n",
      "23\n",
      "0 153 {{A}} rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as {{B}}\n",
      "1 5 {{A}}\n",
      "2 115  rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states \n",
      "3 5 induc\n",
      "4 23 ed by cocaine, such as \n",
      "5 5 {{B}}\n",
      "7624 While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by {{A}}, such as {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7630 It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of {{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7631 It could be inferred that {{A}} treatment has induced a modest amelioration of some of the histological and biochemical indices of GM {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment has ', u'ed a modest amelioration of some of the histological and biochemical indices of GM ')\n",
      "[15, 83]\n",
      "15\n",
      "0 113 {{A}} treatment has induced a modest amelioration of some of the histological and biochemical indices of GM {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  treatment has \n",
      "3 5 induc\n",
      "4 83 ed a modest amelioration of some of the histological and biochemical indices of GM \n",
      "5 5 {{B}}\n",
      "7647 CONCLUSION: We suggest that interactions between {{A}} and apoptosis are important in the pathogenesis of the ADR-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and apoptosis are important in the pathogenesis of the ADR-', u'ed ')\n",
      "[60, 3]\n",
      "3\n",
      "0 78 {{A}} and apoptosis are important in the pathogenesis of the ADR-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 60  and apoptosis are important in the pathogenesis of the ADR-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7654 Cross-sectional echocardiographic screening of newborns exposed to {{A}} during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-', u'ed ')\n",
      "[108, 3]\n",
      "3\n",
      "0 126 {{A}} during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 108  during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7656 Thus, {{A}} prevented and reversed dexamethasone-induced {{B}} in the rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' prevented and reversed dexamethasone-', u'ed ')\n",
      "[38, 3]\n",
      "3\n",
      "0 56 {{A}} prevented and reversed dexamethasone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 38  prevented and reversed dexamethasone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7658 The antidiabetic drug {{A}} can diminish apoptosis induced by oxidative stress in endothelial cells and prevent {{B}} even in nondiabetic patients.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' can diminish apoptosis ', u'ed by oxidative stress in endothelial cells and prevent ')\n",
      "[24, 56]\n",
      "24\n",
      "0 95 {{A}} can diminish apoptosis induced by oxidative stress in endothelial cells and prevent {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  can diminish apoptosis \n",
      "3 5 induc\n",
      "4 56 ed by oxidative stress in endothelial cells and prevent \n",
      "5 5 {{B}}\n",
      "7673 Cocaine-induced {{B}} was also attenuated in Dbh +/- mice following administration of {{A}}, a dopamine beta-hydroxylase (DBH) inhibitor.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7675 Cocaine-induced {{B}} was also attenuated in Dbh +/- mice following administration of disulfiram, a {{A}} beta-hydroxylase (DBH) inhibitor.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7690 Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled {{A}} before and during phenylephrine-induced acute {{B}} in rats treated with vehicle and Hoe-140 (0.1 microM).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' before and during phenylephrine-', u'ed acute ')\n",
      "[33, 9]\n",
      "9\n",
      "0 57 {{A}} before and during phenylephrine-induced acute {{B}}\n",
      "1 5 {{A}}\n",
      "2 33  before and during phenylephrine-\n",
      "3 5 induc\n",
      "4 9 ed acute \n",
      "5 5 {{B}}\n",
      "7691 Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute {{B}} in rats treated with vehicle and {{A}} (0.1 microM).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7710 CONCLUSIONS: The epileptic pregnant patient's {{B}} (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of {{A}} triggered a cluster of seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7711 CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of {{A}} triggered a cluster of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7712 CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced {{B}} could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of {{A}} triggered a cluster of seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7713 CONCLUSIONS: The {{B}} pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of {{A}} triggered a cluster of seizures.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7714 Our findings show that long-term treatment with high doses of {{A}} may induce enzyme blockade leading to mineralocorticoid-related {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' may ', u'e enzyme blockade leading to mineralocorticoid-related ')\n",
      "[5, 55]\n",
      "5\n",
      "0 75 {{A}} may induce enzyme blockade leading to mineralocorticoid-related {{B}}\n",
      "1 5 {{A}}\n",
      "2 5  may \n",
      "3 5 induc\n",
      "4 55 e enzyme blockade leading to mineralocorticoid-related \n",
      "5 5 {{B}}\n",
      "7725 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, {{A}} lung toxicity and doxorubicin-induced {{B}} by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' lung toxicity and doxorubicin-', u'ed ')\n",
      "[31, 3]\n",
      "3\n",
      "0 49 {{A}} lung toxicity and doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 31  lung toxicity and doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7726 In vivo protection of dna damage associated apoptotic and {{B}} cell deaths during acetaminophen-induced nephrotoxicity, {{A}} lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7727 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced {{B}}, {{A}} lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7728 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, {{A}} {{B}} and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7729 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during {{A}} nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced {{B}} by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-', u'ed ')\n",
      "[66, 3]\n",
      "3\n",
      "0 84 {{A}} nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 66  nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7730 In vivo protection of dna damage associated apoptotic and {{B}} cell deaths during {{A}} nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7731 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during {{A}} {{B}}, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7732 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during {{A}} nephrotoxicity, amiodarone-induced {{B}} and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' nephrotoxicity, amiodarone-', u'ed ')\n",
      "[28, 3]\n",
      "3\n",
      "0 46 {{A}} nephrotoxicity, amiodarone-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 28  nephrotoxicity, amiodarone-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7733 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and {{A}} {{B}} by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7734 In vivo protection of dna damage associated apoptotic and {{B}} cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and {{A}} cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7735 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced {{B}}, amiodarone-induced lung toxicity and {{A}} cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7736 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced {{B}} and {{A}} cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7737 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced {{B}} by a novel {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7738 In vivo protection of dna damage associated apoptotic and {{B}} cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7739 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced {{B}}, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7740 In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced {{B}} and doxorubicin-induced cardiotoxicity by a novel {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7747 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, {{A}} (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AMI)-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[52, 3]\n",
      "3\n",
      "0 70 {{A}} (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 52  (AMI)-induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7748 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced {{B}}, {{A}} (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7749 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, {{A}} (AMI)-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AMI)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (AMI)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (AMI)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7750 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone ({{A}}-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[46, 3]\n",
      "3\n",
      "0 64 {{A}}-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 46 -induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7751 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced {{B}}, amiodarone ({{A}}-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7752 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone ({{A}}-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7753 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent {{A}} (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[93, 3]\n",
      "3\n",
      "0 111 {{A}} (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 93  (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7754 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent {{A}} (AAP)-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AAP)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (AAP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (AAP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7755 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent {{A}} (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (AAP)-induced nephrotoxicity, amiodarone (AMI)-', u'ed ')\n",
      "[48, 3]\n",
      "3\n",
      "0 66 {{A}} (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 48  (AAP)-induced nephrotoxicity, amiodarone (AMI)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7756 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen ({{A}}-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[87, 3]\n",
      "3\n",
      "0 105 {{A}}-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 87 -induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7757 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen ({{A}}-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7758 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen ({{A}}-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-induced nephrotoxicity, amiodarone (AMI)-', u'ed ')\n",
      "[42, 3]\n",
      "3\n",
      "0 60 {{A}}-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 42 -induced nephrotoxicity, amiodarone (AMI)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7759 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and {{A}} (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DOX)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7760 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and {{A}} (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7761 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and {{A}} (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7762 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin ({{A}}-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7763 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and doxorubicin ({{A}}-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7764 This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and doxorubicin ({{A}}-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7765 This study assessed the ability of {{A}} (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[125, 3]\n",
      "3\n",
      "0 143 {{A}} (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 125  (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7766 This study assessed the ability of {{A}} (GSPE) to prevent acetaminophen (AAP)-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (GSPE) to prevent acetaminophen (AAP)-', u'ed ')\n",
      "[39, 3]\n",
      "3\n",
      "0 57 {{A}} (GSPE) to prevent acetaminophen (AAP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 39  (GSPE) to prevent acetaminophen (AAP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7767 This study assessed the ability of {{A}} (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-', u'ed ')\n",
      "[80, 3]\n",
      "3\n",
      "0 98 {{A}} (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 80  (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7768 This study assessed the ability of IH636 grape seed proanthocyanidin extract ({{A}} to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}} in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-', u'ed ')\n",
      "[118, 3]\n",
      "3\n",
      "0 136 {{A}} to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 118  to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7769 This study assessed the ability of IH636 grape seed proanthocyanidin extract ({{A}} to prevent acetaminophen (AAP)-induced {{B}}, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to prevent acetaminophen (AAP)-', u'ed ')\n",
      "[32, 3]\n",
      "3\n",
      "0 50 {{A}} to prevent acetaminophen (AAP)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 32  to prevent acetaminophen (AAP)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7770 This study assessed the ability of IH636 grape seed proanthocyanidin extract ({{A}} to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}, and doxorubicin (DOX)-induced cardiotoxicity in mice.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-', u'ed ')\n",
      "[73, 3]\n",
      "3\n",
      "0 91 {{A}} to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 73  to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7792 BACKGROUND AND PURPOSE: The Intravenous {{A}} West European {{B}} Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7793 BACKGROUND AND PURPOSE: The Intravenous {{A}} West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' West European Stroke Trial (INWEST) found a correlation between nimodipine-', u'ed reduction in blood pressure (BP) and an unfavorable outcome in ')\n",
      "[76, 66]\n",
      "66\n",
      "0 157 {{A}} West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in {{B}}\n",
      "1 5 {{A}}\n",
      "2 76  West European Stroke Trial (INWEST) found a correlation between nimodipine-\n",
      "3 5 induc\n",
      "4 66 ed reduction in blood pressure (BP) and an unfavorable outcome in \n",
      "5 5 {{B}}\n",
      "7818 Different mechanisms have been suggested for {{A}} {{B}} including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7819 Different mechanisms have been suggested for cocaine {{B}} including an increase in oxidative stress but the association between oxidative status in the brain and {{A}} induced-behaviour is poorly understood.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7820 {{B}} induced by {{A}} - the influence of drug-drug interactions.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7844 PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced {{B}} due to {{A}} and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7845 PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced {{B}} due to warfarin and {{A}} interactions in patients living in the county of Osterg  tland, Sweden.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7856 These results indicate that noradrenergic neurons have an important role in the manifestation of {{B}} induced by {{A}}, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7857 These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by {{A}}, whereas dopaminergic neurons are important in {{B}} induced by haloperidol.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7858 These results indicate that noradrenergic neurons have an important role in the manifestation of {{B}} induced by THC, whereas dopaminergic neurons are important in catalepsy induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7859 These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in {{B}} induced by {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7862 Upregulation of the expression of {{A}} gene in the paraventricular and supraoptic nuclei of the lithium-induced {{B}} rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' gene in the paraventricular and supraoptic nuclei of the lithium-', u'ed ')\n",
      "[66, 3]\n",
      "3\n",
      "0 84 {{A}} gene in the paraventricular and supraoptic nuclei of the lithium-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 66  gene in the paraventricular and supraoptic nuclei of the lithium-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7864 {{A}} induced {{B}}19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7865 Valproic acid induced {{B}}19 new cases in Germany from 1994 to 2003--a side effect associated to {{A}} not only in young children.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7868 NO-induced {{B}} attack: strong increase in plasma {{A}} (CGRP) concentration and negative correlation with platelet serotonin release.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7869 NO-induced {{B}} attack: strong increase in plasma calcitonin gene-related peptide ({{A}} concentration and negative correlation with platelet serotonin release.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7870 NO-induced {{B}} attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet {{A}} release.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7874 We observed the {{B}} induced by {{A}} at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7885 These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma {{A}} and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced {{B}} rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and the upregulation of AVP gene expression in the PVN and the SON of the Li-', u'ed ')\n",
      "[78, 3]\n",
      "3\n",
      "0 96 {{A}} and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 78  and the upregulation of AVP gene expression in the PVN and the SON of the Li-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7886 These results suggest that {{B}} and/or the activation of visceral afferent inputs may contribute to the elevation of plasma {{A}} and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7887 These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of {{A}} gene expression in the PVN and the SON of the Li-induced {{B}} rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' gene expression in the PVN and the SON of the Li-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}} gene expression in the PVN and the SON of the Li-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50  gene expression in the PVN and the SON of the Li-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7888 These results suggest that {{B}} and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of {{A}} gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7894 Effects of acetylsalicylic acid, {{A}}, and hydrocortisone on epinephrine-induced {{B}} in dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', and hydrocortisone on epinephrine-', u'ed ')\n",
      "[36, 3]\n",
      "3\n",
      "0 54 {{A}}, and hydrocortisone on epinephrine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 36 , and hydrocortisone on epinephrine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7895 Effects of acetylsalicylic acid, dipyridamole, and {{A}} on epinephrine-induced {{B}} in dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on epinephrine-', u'ed ')\n",
      "[16, 3]\n",
      "3\n",
      "0 34 {{A}} on epinephrine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 16  on epinephrine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7896 Effects of {{A}}, dipyridamole, and hydrocortisone on epinephrine-induced {{B}} in dogs.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u', dipyridamole, and hydrocortisone on epinephrine-', u'ed ')\n",
      "[50, 3]\n",
      "3\n",
      "0 68 {{A}}, dipyridamole, and hydrocortisone on epinephrine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 50 , dipyridamole, and hydrocortisone on epinephrine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7901 (+/-)-{{A}} (10-40 mg kg-1 i.p.) was able to prevent {{B}} induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7902 (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent {{B}} induced by scopolamine (1 mg kg-1 i.p.) and {{A}} (2 mg kg-1 i.p.) in the mouse passive-avoidance test.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7903 (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent {{B}} induced by {{A}} (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7918 BACKGROUND: We report on the manifestation of a {{A}} (LEV)-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (LEV)-', u'ed ')\n",
      "[7, 3]\n",
      "3\n",
      "0 25 {{A}} (LEV)-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 7  (LEV)-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7919 BACKGROUND: We report on the manifestation of a levetiracetam ({{A}}-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}}-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7923 The present study was undertaken to examine the role of {{B}}, induced by {{A}} administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7940 OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using {{A}} single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7941 OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced {{B}}, using {{A}} single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "7966 Prolonged elevation of plasma {{A}} in a cardiac transplant patient with a suspected history of heparin-induced {{B}} with thrombosis.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in a cardiac transplant patient with a suspected history of heparin-', u'ed ')\n",
      "[69, 3]\n",
      "3\n",
      "0 87 {{A}} in a cardiac transplant patient with a suspected history of heparin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 69  in a cardiac transplant patient with a suspected history of heparin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "7967 Prolonged elevation of plasma {{A}} in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' in a cardiac transplant patient with a suspected history of heparin-', u'ed thrombocytopenia with ')\n",
      "[69, 25]\n",
      "25\n",
      "0 109 {{A}} in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with {{B}}\n",
      "1 5 {{A}}\n",
      "2 69  in a cardiac transplant patient with a suspected history of heparin-\n",
      "3 5 induc\n",
      "4 25 ed thrombocytopenia with \n",
      "5 5 {{B}}\n",
      "7969 In individuals with preexisting, high-grade coronary arterial narrowing, acute {{B}} may result from an increase in myocardial {{A}} demand associated with cocaine-induced increase in rate-pressure product.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8005 In the present work we assessed the effect of treatment of rats with gum Arabic on {{B}} induced by {{A}} (GM) nephrotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8006 In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by {{A}} (GM) {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8007 In the present work we assessed the effect of treatment of rats with gum Arabic on {{B}} induced by gentamicin ({{A}} nephrotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8008 In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ({{A}} {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8009 In the present work we assessed the effect of treatment of rats with {{A}} on {{B}} induced by gentamicin (GM) nephrotoxicity.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8010 In the present work we assessed the effect of treatment of rats with {{A}} on acute renal failure induced by gentamicin (GM) {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' on acute renal failure ', u'ed by gentamicin (GM) ')\n",
      "[24, 22]\n",
      "22\n",
      "0 61 {{A}} on acute renal failure induced by gentamicin (GM) {{B}}\n",
      "1 5 {{A}}\n",
      "2 24  on acute renal failure \n",
      "3 5 induc\n",
      "4 22 ed by gentamicin (GM) \n",
      "5 5 {{B}}\n",
      "8011 {{A}} (MA)-induced dopaminergic {{B}} is believed to be associated with the increased formation of free radicals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (MA)-', u'ed dopaminergic ')\n",
      "[6, 16]\n",
      "6\n",
      "0 37 {{A}} (MA)-induced dopaminergic {{B}}\n",
      "1 5 {{A}}\n",
      "2 6  (MA)-\n",
      "3 5 induc\n",
      "4 16 ed dopaminergic \n",
      "5 5 {{B}}\n",
      "8012 Methamphetamine ({{A}}-induced dopaminergic {{B}} is believed to be associated with the increased formation of free radicals.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u'-', u'ed dopaminergic ')\n",
      "[1, 16]\n",
      "1\n",
      "0 32 {{A}}-induced dopaminergic {{B}}\n",
      "1 5 {{A}}\n",
      "2 1 -\n",
      "3 5 induc\n",
      "4 16 ed dopaminergic \n",
      "5 5 {{B}}\n",
      "8017 The hypothesis that {{A}} could be used to induce {{B}} and preserve blood flow to the kidney was tested.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' could be used to ', u'e ')\n",
      "[18, 2]\n",
      "2\n",
      "0 35 {{A}} could be used to induce {{B}}\n",
      "1 5 {{A}}\n",
      "2 18  could be used to \n",
      "3 5 induc\n",
      "4 2 e \n",
      "5 5 {{B}}\n",
      "8030 In order to investigate the effects of {{A}} from Pueraria thunbergiana on scopolamine-induced {{B}}, we conducted a series of in vivo tests.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' from Pueraria thunbergiana on scopolamine-', u'ed ')\n",
      "[43, 3]\n",
      "3\n",
      "0 61 {{A}} from Pueraria thunbergiana on scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 43  from Pueraria thunbergiana on scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8032 Administration of {{A}} (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced {{B}}, according to the results of a Y-maze test.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-', u'ed ')\n",
      "[80, 3]\n",
      "3\n",
      "0 98 {{A}} (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 80  (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8041 These results indicate that {{A}} might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-', u'ed ')\n",
      "[111, 3]\n",
      "3\n",
      "0 129 {{A}} might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 111  might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8042 These results indicate that daidzein might play a role in {{A}} biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-', u'ed ')\n",
      "[76, 3]\n",
      "3\n",
      "0 94 {{A}} biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 76  biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8044 Renal blood flow (RBF) increased during fenoldopam-induced {{B}} 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium {{A}} hypotension (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8045 Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium {{A}} {{B}} (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8046 Renal blood flow (RBF) increased during {{A}} {{B}} 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8047 Renal blood flow (RBF) increased during {{A}} hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced {{B}} (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-', u'ed ')\n",
      "[91, 3]\n",
      "3\n",
      "0 109 {{A}} hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 91  hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8048 Renal blood flow (RBF) increased during fenoldopam-induced {{B}} 11 +/- 7 per cent and decreased 21 +/- 8 per cent during {{A}} nitroprusside-induced hypotension (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8049 Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during {{A}} nitroprusside-induced {{B}} (P less than 0.01).\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' nitroprusside-', u'ed ')\n",
      "[15, 3]\n",
      "3\n",
      "0 33 {{A}} nitroprusside-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 15  nitroprusside-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8055 {{A}} is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during ', u'ed ')\n",
      "[128, 3]\n",
      "3\n",
      "0 146 {{A}} is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 128  is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8057 Fenoldopam is a selective {{A}} (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during ', u'ed ')\n",
      "[147, 3]\n",
      "3\n",
      "0 165 {{A}} (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 147  (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8058 Fenoldopam is a selective dopamine-1 ({{A}} receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during ', u'ed ')\n",
      "[141, 3]\n",
      "3\n",
      "0 159 {{A}} receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 141  receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8059 Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with {{A}} receptors and preserves blood flow to the kidney during induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors and preserves blood flow to the kidney during ', u'ed ')\n",
      "[57, 3]\n",
      "3\n",
      "0 75 {{A}} receptors and preserves blood flow to the kidney during induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 57  receptors and preserves blood flow to the kidney during \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8072 These results suggest that {{A}} suppresses streptomycin-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' suppresses streptomycin-', u'ed ')\n",
      "[25, 3]\n",
      "3\n",
      "0 43 {{A}} suppresses streptomycin-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 25  suppresses streptomycin-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8087 {{A}} signaling through beta-adrenergic receptors is critical for expression of cocaine-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' signaling through beta-adrenergic receptors is critical for expression of cocaine-', u'ed ')\n",
      "[83, 3]\n",
      "3\n",
      "0 101 {{A}} signaling through beta-adrenergic receptors is critical for expression of cocaine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 83  signaling through beta-adrenergic receptors is critical for expression of cocaine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8132 {{A}} induces attacks of migraine without aura in sufferers of {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es attacks of migraine without aura in sufferers of ')\n",
      "[1, 52]\n",
      "1\n",
      "0 68 {{A}} induces attacks of migraine without aura in sufferers of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 52 es attacks of migraine without aura in sufferers of \n",
      "5 5 {{B}}\n",
      "8133 {{A}} induces attacks of {{B}} in sufferers of migraine with aura.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'es attacks of ')\n",
      "[1, 14]\n",
      "1\n",
      "0 30 {{A}} induces attacks of {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 14 es attacks of \n",
      "5 5 {{B}}\n",
      "8134 This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in {{B}} induced by {{A}} were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8135 This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by {{A}} were due to {{B}} per se, or, at least in part, to the aminonucleoside.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8136 This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in {{B}} induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8137 This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to {{B}} per se, or, at least in part, to the {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8178 Mature male and female mice from six inbred stains were tested for susceptibility to behavioral {{B}} induced by a single injection of {{A}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8185 Down-regulation of norepinephrine transporter function induced by chronic administration of {{A}} linking to the alteration of sensitivity of local-anesthetics-induced {{B}} and the counteraction by co-administration with local anesthetics.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' linking to the alteration of sensitivity of local-anesthetics-', u'ed ')\n",
      "[63, 3]\n",
      "3\n",
      "0 81 {{A}} linking to the alteration of sensitivity of local-anesthetics-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 63  linking to the alteration of sensitivity of local-anesthetics-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8186 Down-regulation of {{A}} transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced {{B}} and the counteraction by co-administration with local anesthetics.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-', u'ed ')\n",
      "[133, 3]\n",
      "3\n",
      "0 151 {{A}} transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 133  transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8196 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of {{B}} including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and {{A}} non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8197 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced {{B}}, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and {{A}} non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8198 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced {{B}}, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and {{A}} non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8199 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of {{B}} including mouse and rat models of {{A}} catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8200 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of {{A}} catalepsy, mouse model of reserpine-induced {{B}}, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' catalepsy, mouse model of reserpine-', u'ed ')\n",
      "[37, 3]\n",
      "3\n",
      "0 55 {{A}} catalepsy, mouse model of reserpine-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 37  catalepsy, mouse model of reserpine-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8201 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of {{A}} {{B}}, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8202 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of {{B}} including mouse and rat models of haloperidol-induced catalepsy, mouse model of {{A}} akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8203 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of {{A}} {{B}}, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8204 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced {{B}}, mouse model of {{A}} akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8205 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of {{B}} including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat {{A}} (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8206 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced {{B}}, rat {{A}} (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8207 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced {{B}}, mouse model of reserpine-induced akinesia, rat {{A}} (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8208 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of {{B}} including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine ({{A}} lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8209 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced {{B}}, rat 6-hydroxydopamine ({{A}} lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8210 Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced {{B}}, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine ({{A}} lesion model of drug-induced rotation, and MPTP-treated non-human primate model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8211 Our findings, showing no interaction between {{A}} treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical {{B}} through independent mechanisms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment and attentional modulation suggest that capsaicin-', u'ed secondary hyperalgesia and attention might affect mechanical ')\n",
      "[61, 64]\n",
      "61\n",
      "0 140 {{A}} treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  treatment and attentional modulation suggest that capsaicin-\n",
      "3 5 induc\n",
      "4 64 ed secondary hyperalgesia and attention might affect mechanical \n",
      "5 5 {{B}}\n",
      "8212 Our findings, showing no interaction between {{A}} treatment and attentional modulation suggest that capsaicin-induced secondary {{B}} and attention might affect mechanical pain through independent mechanisms.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' treatment and attentional modulation suggest that capsaicin-', u'ed secondary ')\n",
      "[61, 13]\n",
      "13\n",
      "0 89 {{A}} treatment and attentional modulation suggest that capsaicin-induced secondary {{B}}\n",
      "1 5 {{A}}\n",
      "2 61  treatment and attentional modulation suggest that capsaicin-\n",
      "3 5 induc\n",
      "4 13 ed secondary \n",
      "5 5 {{B}}\n",
      "8216 {{A}} induced {{B}}: case report and review of the literature.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8218 The typical {{A}} symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked {{B}} were indistinguishable from those of neuroleptic-induced akathisia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8219 The typical {{A}} symptoms of {{B}}, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8220 The typical {{A}} symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced {{B}}.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-', u'ed ')\n",
      "[156, 3]\n",
      "3\n",
      "0 174 {{A}} symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 156  symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-\n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8225 Bradykinin receptors antagonists and nitric oxide synthase inhibitors in {{A}} and streptozotocin induced hyperalgesia in chemotherapy and {{B}} rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and streptozotocin ', u'ed hyperalgesia in chemotherapy and ')\n",
      "[20, 36]\n",
      "20\n",
      "0 71 {{A}} and streptozotocin induced hyperalgesia in chemotherapy and {{B}}\n",
      "1 5 {{A}}\n",
      "2 20  and streptozotocin \n",
      "3 5 induc\n",
      "4 36 ed hyperalgesia in chemotherapy and \n",
      "5 5 {{B}}\n",
      "8226 Bradykinin receptors antagonists and nitric oxide synthase inhibitors in {{A}} and streptozotocin induced {{B}} in chemotherapy and diabetic neuropathy rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' and streptozotocin ', u'ed ')\n",
      "[20, 3]\n",
      "3\n",
      "0 38 {{A}} and streptozotocin induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 20  and streptozotocin \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8227 Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and {{A}} induced hyperalgesia in chemotherapy and {{B}} rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed hyperalgesia in chemotherapy and ')\n",
      "[1, 36]\n",
      "1\n",
      "0 52 {{A}} induced hyperalgesia in chemotherapy and {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 36 ed hyperalgesia in chemotherapy and \n",
      "5 5 {{B}}\n",
      "8228 Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and {{A}} induced {{B}} in chemotherapy and diabetic neuropathy rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' ', u'ed ')\n",
      "[1, 3]\n",
      "1\n",
      "0 19 {{A}} induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 1  \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8229 Bradykinin receptors antagonists and {{A}} synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and {{B}} rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' synthase inhibitors in vincristine and streptozotocin ', u'ed hyperalgesia in chemotherapy and ')\n",
      "[55, 36]\n",
      "36\n",
      "0 106 {{A}} synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  synthase inhibitors in vincristine and streptozotocin \n",
      "3 5 induc\n",
      "4 36 ed hyperalgesia in chemotherapy and \n",
      "5 5 {{B}}\n",
      "8230 Bradykinin receptors antagonists and {{A}} synthase inhibitors in vincristine and streptozotocin induced {{B}} in chemotherapy and diabetic neuropathy rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' synthase inhibitors in vincristine and streptozotocin ', u'ed ')\n",
      "[55, 3]\n",
      "3\n",
      "0 73 {{A}} synthase inhibitors in vincristine and streptozotocin induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 55  synthase inhibitors in vincristine and streptozotocin \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8231 {{A}} receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and {{B}} rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin ', u'ed hyperalgesia in chemotherapy and ')\n",
      "[94, 36]\n",
      "36\n",
      "0 145 {{A}} receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and {{B}}\n",
      "1 5 {{A}}\n",
      "2 94  receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin \n",
      "3 5 induc\n",
      "4 36 ed hyperalgesia in chemotherapy and \n",
      "5 5 {{B}}\n",
      "8232 {{A}} receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced {{B}} in chemotherapy and diabetic neuropathy rat model.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "induc\n",
      "(u' receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin ', u'ed ')\n",
      "[94, 3]\n",
      "3\n",
      "0 112 {{A}} receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced {{B}}\n",
      "1 5 {{A}}\n",
      "2 94  receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin \n",
      "3 5 induc\n",
      "4 3 ed \n",
      "5 5 {{B}}\n",
      "8249 In ICH induction using 0.014-unit collagenase, {{A}} enhanced the {{B}} volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8250 In ICH induction using 0.014-unit collagenase, {{A}} enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the {{B}} 7.6-fold.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8251 In {{B}} induction using 0.014-unit collagenase, {{A}} enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n",
      "8252 In ICH induction using 0.014-unit collagenase, {{A}} enhanced the hematoma volume 3.4-fold over that seen in control {{B}} animals and the bleeding 7.6-fold.\n",
      "({{A}})(.*)(induc)(.*)({{B}})\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "# def distanceCD_(c,l):\n",
    "#     dist = [0]\n",
    "#     for w in l:\n",
    "#         pattern = r'({{A}})(.*)('+w+r')(.*)({{B}})'\n",
    "#         print(pattern)\n",
    "#         matchObj = re.search(pattern, get_tagged_text(c), flags=re.I)\n",
    "#         if(matchObj):\n",
    "#             print(w)\n",
    "#             match_groups = matchObj.group(2,4)\n",
    "#             print(match_groups)\n",
    "#             print([len(mg) for mg in match_groups])\n",
    "#             print(min([len(mg) for mg in match_groups]))\n",
    "#             dist.append(min([len(mg) for mg in match_groups]))        \n",
    "#             print(0,len(matchObj.group(0)),matchObj.group(0))\n",
    "#             print(1,len(matchObj.group(1)),matchObj.group(1))\n",
    "#             print(2,len(matchObj.group(2)),matchObj.group(2))\n",
    "#             print(3,len(matchObj.group(3)),matchObj.group(3))\n",
    "#             print(4,len(matchObj.group(4)),matchObj.group(4))\n",
    "#             print(5,len(matchObj.group(5)),matchObj.group(5))\n",
    "#     return (1000-max(dist))/1000\n",
    "\n",
    "# dir(train_cands[0])\n",
    "# print(train_cands[0].get_parent())\n",
    "\n",
    "# print(get_tagged_text(train_cands[0]))\n",
    "# distanceCD_(train_cands[0],['induc'])\n",
    "\n",
    "# i =0;\n",
    "# for c in train_cands[0:]:\n",
    "#     i+=1\n",
    "#     if('induc' in get_tagged_text(c)):\n",
    "#         print(i,get_tagged_text(c))\n",
    "#         distanceCD_(c,['induc'])\n",
    "        \n",
    "        "
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
